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General Introduction
C h ap ter 1
1.1 Neurodegenerative conformational diseases
Neurodegeneration is an umbrella term for the progressive loss of structure or function 
and, eventually, death of cells in the central nervous system (CNS). In contrast to most 
cells in the periphery, cells in the CNS have only limited regenerative capacity. Thus, once 
a cell is lost, it can hardly be replaced. Depending on the cell type and area affected, loss 
of cells within the CNS ultimately leads to a diverse spectrum of neurological disorders, 
most commonly dementia or movement disorders. The cause of neurodegeneration 
can be of various origins and, although the exact pathological mechanisms are not 
completely understood, the current understanding is that many similarities may exist on 
the pathophysiological level among clinically different disorders.
A growing number of neurodegenerative disorders has been linked to misfolding and 
intra- or extracellular accumulation of proteins with a strong tendency for self-association
[32], the so-called neurodegenerative conformational diseases or protein conformational 
disorders. These disorders include diseases such as Alzheimer's disease (AD), Parkinson's 
disease (PD), Huntington's disease (HD), Multiple system atrophy (MSA) and prion diseases
[62]. Despite the differences in disease progression and clinical symptoms, these disorders 
share common features. First of all, they are characterized by cerebral accumulation of 
fibrillar protein, which are formed as a result of misfolding and aggregation of a natively 
unfolded protein [22;23;90]. These insoluble fibrillar protein aggregates are generally 
referred to as amyloids. Although the various pathological proteins typical for each of the 
different diseases lack any significant primary sequence homology, their aggregates share 
specific morphological, structural and staining characteristics [98;157]. The common 
structural motif of virtually all amyloid fibrils is a cross-p-sheet in which the peptide 
strands are arranged perpendicular to the long axis of the fibril [167], Fig. 1. Secondly, 
these disorders are characterized by loss of neurons or dysfunction of interneuronal 
signaling and the characteristic late onset of the conformational diseases is explained by 
the gradual accumulation of these protein aggregates [32].
Fig. 1: Schematic representation of an amyloid fibril with p-sheets. The common structural m otif of 
virtually all amyloid fibrils is the presence of cross-p-sheets in which peptide strands are arranged 
perpendicular to the long axis o f the fibril.
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1.1.1 Alzheimer's disease
Alzheimer's disease (AD) is the most common progressive and age related 
neurodegenerative disorder and was first described in 1906 by Alois Alzheimer [4]. It 
affects 10% of individuals over the age of 65, and accounts for approximately 50% of all 
patients with dementia. In 2030, the number of people affected by AD in the Netherlands 
is estimated at 400.000 (for up-to-date information, see Hersenstichting Nederland [112]). 
Clinical symptoms begin with short term memory loss, and continue with more extensive 
cognitive and emotional dysfunction. In later stages of AD, patients may develop 
symptoms like restlessness, disorientation and hallucinations [27]. The incidence of AD 
increases every year, and thus results in an increasing pressure on the health care systems 
of all western countries.
Historically, AD diagnosis was made after exclusion of all other possible causes 
of dementia or other neurological disorders with better circumscribed diagnostic 
criteria [185]. Today, unequivocal diagnosis of AD still requires post mortem histological 
analysis of the brain to document the presence of pathological features that define the 
disease, but clinical criteria have been improved. By incorporating imaging findings or 
cerebrospinal fluid (CSF) analysis, the diagnosis of AD can be made earlier and with more 
specificity [5;76;185]. Key neuropathological features of the AD brain are cortical atrophy, 
severe enlargement of the ventricles, intraneuronal neurofibrillary tangles consisting of 
hyperphosphorylated tau protein and extracellular deposition of amyloid p protein (Ap) 
in the hippocampus and cerebral cortex as well as in the cerebrovascular wall [22;239]. 
Although the etiology of this disease is still not completely understood, many studies 
point to Ap as the major driving force in the pathogenesis of AD [238], see paragraph 
1.2.1.
1.1.2 Parkinson's disease
The most common neurodegenerative movement disorder is Parkinson's disease (PD). In 
the Netherlands, PD is estimated to affect about 1% of individuals older than 55 years of 
age. Prevalence increases with age to about 4.3% for people of 85 years and above [63;113] 
(for up-to-date information, see Hersenstichting Nederland [113]). PD was first described in 
1817 by James Parkinson [203]. However, it was recognized as PD four decades later, when 
Jean-Martin Charcot gave credit to Parkinson by referring to the disease as "maladie de 
Parkinson" [41;42]. PD is clinically characterized by motor symptoms such as hypokinesia, 
limb tremor and muscle rigidity. However, there are also non-motor symptoms, such as 
autonomic dysfunction, cognitive disturbances and sleep disorders [125].
The motor symptoms of PD can be attributed to a loss of dopaminergic neurons 
in the substantia nigra pars compacta (SNpc) [23], which leads to a malfunctioning of 
motor nuclei in the striatum [125]. Besides loss of dopaminergic neurons, the presence of 
Lewy Bodies (LB) in neuronal cells of the SNpc is also a neuropathological hallmark of PD. 
However, in many cases, nerve cell loss and LB are also found in other parts of the brain, 
like the thalamus and neocortex [23;90]. LB are primarily composed of the a-synuclein 
protein [257]. This protein has also been shown to play a major role in the pathology of 
dementia with LB (DLB), where LB are observed in cortical and limbic areas, and MSA, 
where a-synuclein is found in cytoplasmic inclusions in glial cells [256]. Therefore, the 
name synucleinopathies has been introduced to classify neurodegenerative diseases 
characterized by conformational changes in a-synuclein [128;256].
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1.2 Protein misfolding
Improper protein folding (misfolding) can lead to the formation of disordered (amorphous) 
or ordered (amyloid fibrils) aggregates [168]. The soluble monomeric forms of aggregating 
proteins are capable of self-aggregation, forming dimers, trimers, oligomers, protofibrils 
and eventually mature fibrils, of which the last three are rich in p-sheet structures [241], 
Fig. 2. Although protofibrils and mature fibrils are found in the pathological lesions in 
neurodegenerative disorders with misfolding proteins and are protease resistant, they 
are suggested to be less toxic than oligomers which are directly linked to neurotoxicity 
[64;121;168;200]. Aggregation starts with a slow lag phase, followed by a growth phase 
and eventually the process reaches equilibrium [168].
oligomer Protofibril Mature 
Monomers fibril
Fig 2: A simplified model of aggregation. Monomers can form oligomers, which can form larger structures 
called protofibrils. Monomers and oligomers are predominantly unstructured, but do contain 
p-sheets/p-turns. Protofibril formation involves substantial conformational rearrangements, during 
which structures transform into predominantly p-sheet conformation. The final step in the overall 
pathway is protofibril maturation into fibrils, a process that appears irreversible. Reproduced with 
permission from Paleologou et al., 2005, Biochemical Society Transactions, 33(5), 1106-10 © the 
Biochemical Society [202].
Two alternative assembly pathways to explain protein aggregation have been 
proposed: the nucleation-elongation and the template-assisted mode [192;253], Fig. 3. 
These two modes are not mutually exclusive. In the nucleation-elongation model, initial 
self-assembly is slow and unfavorable until a critical size is reached. Once the "nucleus" or 
"seed" is formed, further elongation by addition of monomers is rapid. In the template- 
assisted model, the first step in the misfolding of the monomer is mediated by binding 
to a molecular chaperone (protein X), thereby creating an intermediate state of the 
protein. This intermediate form of the protein is more likely to misfold compared to the 
native conformation, since it is already rich in p-sheets. When the first non-p protein has 
changed into a p-sheet conformation that is prone to aggregate, it can act as a template to 
convert other intermediate forms of the protein into p-sheet conformation more rapidly. 
According to these two models, one can consider protein aggregation either as a process 
of spontaneous self-assembly or induced by a pre-existing aggregate.
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Fig 3: Schematic representation of the nucleation-elongation and template-assisted models. In the 
nucleation-elongation model (A), the misfolding protein is a monomer or small oligomer that acts as 
a seed for recruiting, converting and stabilizing misfolding of the native protein. In the template- 
assisted conversion model (B), the main step is formation o f an intermediate state of one molecule 
(assisted by a molecular chaperone) which is more likely to misfold compared to the native form, 
since it is already p-sheet rich. When it has converted into a p-sheet conformation, it acts as a template 
for the other native molecules to change conformation and start aggregation.
Structure studies have strongly indicated that a hydrophobic domain is necessary for 
fibrillization of the proteins [97;243]. For example, the Ap protein has two hydrophobic 
regions, which are very likely involved in p-sheet formation of this protein [243]. In 
addition, the a-synuclein protein contains one hydrophobic region and also this part of 
the protein is suggested to be involved in p-sheet formation [18;97;176], Fig. 4. Moreover, 
in many instances, point mutations in the encoding genes increase the proteins' instability 
and tendency to fibrillize. In other words, point mutations can change the amino acid 
sequence resulting, for instance, in a change of the charge distribution along the protein, 
resulting in an increased propensity to aggregate and thereby raising the odds that the 
disease will have an early onset, generally in mid- to late life [58;92;147;158;239;286] (see 
paragraphs 1.2.1 and 1.2.2). Furthermore, aggregation and toxicity of amyloidogenic 
proteins can be modulated by several agents [220;275;314] (see paragraph 1.3).
C h ap ter 1
Fig. 4: Hydrophobic regions in the Ap and a-syn proteins. The Ap protein (A) contains 2 hydrophobic 
regions, which are involved in p-sheet formation and thus aggregation of the protein. The a-syn 
protein (B) is divided into three different regions, namely a N-terminal region (amino acids 1-59), a 
central hydrophobic NAC region (amino acids 60-95), and a C-terminal region (amino acids 96-140). 
Only the hydrophobic NAC domain is believed to be essential for aggregation of a-syn.
1.2.1 Amyloid-P
In AD, both senile plaques (SPs) and cerebral amyloid angiopathy (CAA) are formed by 
extracellular deposition of aggregated Ap. This protein is a 4 kDa proteolytic cleavage 
product of the amyloid precursor protein (APP), which has been suggested to play 
essential roles in the development of the nervous system relating to synapse structure and 
function [140;337], Fig. 5A. APP can be cleaved via two major pathways; the amyloidogenic 
pathway and the non-amyloidogenic pathway. In the non-amyloidogenic pathway, APP 
is first cleaved by a-secretase, which results in a C-terminal fragment (CTF) called C83 
that remains in the membrane, and a large sAPP-a fragment that is released into the 
extracellular space. The remaining C83 fragment is then cleaved by a Y-secretase, resulting 
in the production of a small peptide (p3). In the amyloidogenic pathway APP is first cleaved 
by p-secretase, generating the CTFp, also known as C99, fragment. The CTFp fragment is 
subsequently cleaved by Y-secretase, releasing Ap of 40 or 42 amino acids, Ap40 or Ap42 
respectively. Although Ap42 has only an additional 2 amino acids compared to Ap40, 
it is considerably different in its physicochemical properties, being more hydrophobic 
and having a much stronger tendency to aggregate [126]. Approximately 10% of the Ap 
peptides produced is Ap42, however, this isoform is the principal component of diffuse 
plaques, with little or no Ap40 immunoreactivity. In contrast, classic SPs, that contain an 
amyloid core, and CAA generally consist o f both Ap40 and Ap42 [225].
Although most patients develop AD at later age (> 65 years), it is mainly the research 
performed on the rare autosomal-dominant early-onset (< 65 years) form of AD that 
provided valuable insights into the disease pathogenesis. The first missense mutation 
in APP was found in patients with hereditary cerebral hemorrhages with amyloidosis 
of the Dutch type (HCHWA-D) [286]. The HCHWA-D mutation converts the normally 
nonpathologic Ap40 into a highly pathologic form of the peptide, resulting in increased 
propensity to aggregate and cellular degeneration in cell culture [58]. Several other
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mutations in APP have been found worldwide and the geography of the initial discovery 
is often used to name the mutant molecule (e.g., Swedish, Dutch, Iowa, Arctic, etc.), Fig. 5B. 
A few mutations occur within the Ap domain that result in increased intrinsic tendencyof 
Ap aggregation, except for the Arctic mutation, which decreases the levels of total Ap 
generation, but increases its propensity to oligomerize [196;201]. Other mutations affect 
APP processing in the amyloidogenic pathway since they are positioned near the a- or 
Y-secretase cleavage sites, resulting in increased Ap production or increased Ap42/Ap40 
ratio (reviewed in [95;239;242]; for up-to-date information, see AD Mutation Database [1]).
Fig. 5: APP processing and APP mutations associated with early-onset Alzheimer's disease. APP processing 
involves proteolytic cleavage by several secretases. The non-amyloidogenic pathway is initiated by 
a-secretase cleavage, which occurs in the middle o f the amyloid (AP) sequence (dark grey), and 
results in the release o f several soluble APP fragments. The amyloidogenic pathway releases AP 
peptides through cleavage by P- and Y-secretases (A). Part of the APP amino-acid sequence (B); 
mutations associated with early-onset Alzheimer's disease have been highlighted. Most mutations 
are clustered in close vicinity o f secretase-cleavage sites, thereby influencing APP processing, and a 
few mutations occur within the AP domain that result in increased intrinsic tendency to aggregate. 
The mutations are named after the nationality or region of the first family in which that specific 
mutation was demonstrated. The AP sequence is indicated in dark grey. APP, amyloid precursor 
protein; AP, amyloid-P; APP-NTF, N-terminal fragment o f the amyloid precursor protein; APP-CTF, 
C-terminal fragment of the amyloid precursor protein; PSEN, presenilin. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Drug Discovery, [281], copyright 2006.
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The existence of familial AD due to APP mutations provided compelling evidence that 
Ap is involved in early onset AD and may start with Ap aggregation. In addition, the risk 
for AD is increased in individuals with Down syndrome (DS). DS patients have 3 copies 
of chromosome 21, which is the chromosome where the gene for APP resides, i.e. APP 
is overexpressed in DS patients [130]. Furthermore, several transgenic mouse models 
have been developed, overexpressing Ap or APP, which develop Ap plaque pathology 
and cognitive impairment, comparable to the pathology found in humans [55]. Taken 
together, this suggests an important role of APP and thus Ap in the development of AD.
1.2.2 a-synuclein
Lewy bodies and Lewy neurites are composed of aggregated a-synuclein (a-syn). 
Although the biological function of this protein remains unclear, a protective function 
related to the synapse or synaptic vesicles is suggested [47]. For instance, in a recent study 
it was found that synucleins may function to sustain normal SNARE-complex assembly in 
a presynaptic terminal during aging [28]. Unlike Ap, a-syn is not cleaved from a precursor 
protein. It is a 14 kDa protein that has sequence homology to two other proteins termed 
p-synuclein and Y-synuclein [47]. Of these proteins, a-syn has the greatest sequence 
homology to p-synuclein. Furthermore, the expression and intracellular localization of 
a- and p-synuclein are very similar. Both are predominantly expressed in brain, while 
Y-synuclein is predominantly expressed in the spinal cord [47]. However, despite the 
similarities between a-syn and p-synuclein, only a-syn is found in fibrillar pathological 
lesions [86;179;257].
Fig. 6: The a-syn protein. The N-terminal region of a-syn contains the three point mutations linked to 
autosomal dominant early-onset PD. Reprinted from Molecular Brain Research, 134(1), Lundvig et al., 
Pathogenic effects of a-synuclein aggregation, 3-17, copyright (2005), with permission from Elsevier 
[168].
Today, three point mutations have been found to cause a familial variant of PD: 
Ala53Thr [211], Ala20Pro [147] and Glu46Lys [334], Fig. 6. These mutations are associated 
with early onset familial PD, which is similar to the mutations in the Ap protein, leading 
to early onset AD. The mutant forms of a-syn display differences in fibrillization. A53T and 
E46K fibrillize much faster than wild-type (WT) a-syn, but A30P formed fibrils at a much 
slower rate [51;92]. In addition, monomeric species of A30P were consumed at the same 
rate or slightly more rapid than the WT protein, indicating that the A30P variant forms 
more oligomeric intermediates [51].
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Similar to AD/DS, overexpression of WT a-syn by gene duplication or triplication is 
sufficient to cause inheritable PD [122]. In addition, overexpression of a-syn in transgenic 
animals causes a-syn pathology accompanied by neuronal dysfunction, loss of synaptic 
terminals, and/ or neuronal cell loss [86;179], suggesting an important role for a-syn 
accumulation in neurodegeneration.
1.3 Factors associated with protein misfolding
Misfolding proteins do not only associate with themselves, but also interact with various 
other proteins. This suggests that aggregation of misfolding proteins can be affected 
by several factors, and thus bioactivity and toxicity of these aggregating proteins might 
also be modulated. Although many macromolecules can modulate aggregation and/or 
toxicity of misfolding proteins, a few will be discussed here, i.e. proteoglycans, small heat 
shock proteins, cholesterol, apolipoprotein E and inflammatory factors /  inflammation. 
Their general biological function and their role in the fibrillization process of misfolding 
proteins will be discussed.
1.3.1 Proteoglycans
Proteoglycans are heterogeneous macromolecules consisting of a protein backbone 
to which one or more linear polysaccharides or glycosaminoglycan (GAG) chains are 
covalently linked [107]. The GAG chains consist o f repeating disaccharide units which are 
often sulfated [123] and the degree of sulfation may vary among different proteoglycans 
[230]. The repeating units are composed of an uronic acid (D-glucuronic acid or L-iduronic 
acid) and an amino sugar (D-galactosamine or D-glucosamine) [94]. The GAGs differ 
according to the type of hexosamine, hexose or hexuronic acid unit that they contain, 
as well as the geometry of the glycosidic linkage between these units. Based on their 
repeating disaccharide units, four major GAGs have been identified: chondroitin sulfate 
(CS), dermatan sulfate (DS), keratan sulfate (KS) and heparan sulfate (HS) [80]. The 
structural diversity of proteoglycans and GAGs makes them suitable for participating in 
a variety of biological functions. For instance, proteoglycans are present on all animal cell 
surfaces, in the extracellular matrix and some are known to bind and regulate a number 
of distinct proteins, including chemokines, cytokines, growth factors, enzymes and 
adhesion molecules [94]. In addition, they modulate growth factor activities and regional 
inflammatory processes, and influence tissue repair and remodeling [9;80;123;205]. 
Furthermore, proteoglycans and GAGs may play pivotal roles in cell-cell interactions, 
not only in the development, maintenance and aging of normal tissue, but also in the 
pathogenesis of neurodegenerative diseases [9;289].
Proteogycans and GAGs are associated with a variety of amyloid deposits, including 
SPs and CAA in AD and LBs in PD [70;160;248;287;288;290;298]. Moreover, it has been 
demonstrated that GAGs could be potent enhancers of Ap fibril formation and stabilize 
Ap fibrils once formed [36;186], which seems to be dependent of the degree of sulfation 
of the GAG [35]. In addition, sulfated GAGs inhibit Ap-mediated neurotoxicity [210;228]. 
In line with their effect on Ap aggregation, GAGs also have the ability to modulate the 
formation of a-synuclein fibrils in vitro [48;160]. In addition, GAGs may serve as chaperone 
proteins and thereby protect misfolded protein accumulations against proteolytic
17
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cleavage [205;229;289]. This implies that proteoglycans and GAGs may play an important 
role in the formation of aggregates in AD and PD by regulating the fibrillization process of 
the misfolding proteins.
1.3.2 (Small) heat shock proteins
Heat shock proteins are present in cells under normal conditions, but are expressed 
at high levels when exposed to a sudden change in temperature or other stress. They 
play an important role in protein-protein interactions such as folding and assisting in 
the establishment of proper protein conformation and prevention of unwanted protein 
aggregation [77;265]. Heat shock proteins are classified according to their molecular 
weight and function: high molecular weight heat shock proteins (HSPs) that have ATPase 
activity, such as Hsp70, and small Hsps (sHsps), which do not bind ATP [118]. High 
molecular weight Hsps are directly involved in ATP-dependent protein folding. Small Hsps 
may interact with partially denatured proteins, prevent their aggregation and thereby 
assist in actual protein folding by chaperones with ATPase activity. Based on sequence 
similarities, ten human sHsps have been identified so far [131], including aB-crystallin, 
Hsp27, Hsp20, HspB8, HspB3 and HspB2. Interestingly, HspB2 and HspB3 together form 
a unique and independent complex [264], in which they assemble together in a ratio 
of 3:1. A conserved 80-100 amino acid long stretch in the C-terminal region, called the 
a-crystallin domain, hallmarks the sHsp family. The N-terminal region is less conserved 
and more variable in length [265]. All sHsps are expressed, to a variable extent, in heart, 
striated muscle, brain and various other tissues [124;132;164;165;264;315;319].
Colocalization of HSPs and sHsps has been observed with pathological hallmarks 
of AD and PD [128;165;188;319]. In addition, Hsp70 was identified as an inhibitor of Ap 
aggregation [172]. Likewise, sHsps also inhibit aggregation of Ap [314;315], thereby 
protecting cells from Ap-mediated cell death. In line with its inhibiting effect on Ap 
aggregation, Hsp70 has also been found to reduce aggregation and neuronal death 
caused by a-syn aggregation [141]. In another study it was observed that Hsp70 binds 
pre-fibrillar species of a-syn and inhibits further aggregation [64]. Furthermore, it has 
been shown that Hsp27 and aB-crystallin have reducing effects on the aggregation and 
toxicity of a-syn [199;215;308]. This suggests that HSPs, and sHsps in particular, might be 
involved in the (early) development of neurodegenerative diseases by controlling protein 
(mis)folding.
1.3.3 Cholesterol
Cholesterol plays a central role in cell structure and function throughout the body, including 
the CNS, a site of high lipid turnover. It is an essential component of the cell membranes 
required for membrane lipid organization. Increased concentrations of cholesterol result 
in more rigid cell membranes, thus variations in cholesterol concentrations can regulate 
membrane fluidity, and thereby structural integrity. Of all the organs in the mammalian 
body, the brain contains the highest levels of cholesterol [71]. Therefore, cholesterol 
homeostasis is carefully maintained in the brain through a series of interdependent 
processes, including synthesis, storage, degradation and transport.
Cholesterol requirement of most mammalian cells is met by two separate, yet related 
processes. One process is the endogenous synthesis of cholesterol. The other process 
involves the utilization of lipoprotein-derived cholesterol to internalize cholesterol 
into the cell. Cells in the CNS are capable of de novo synthesis of lipid molecules, and
18
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can also bind and take up lipoproteins from their local environment. The endogenous 
synthesis o f cholesterol involves more than 20 reactions and is regulated primarily by the 
activity of 3-hydroxy-2-methylglutaryl-coenzyme A reductase (HMGR), which catalyzes 
the formation of mevalonate, the key precursor molecule in the synthesis of cholesterol 
[208]. Once produced, cholesterol can be used in the cell(membrane) or be transported 
out of the cell by mechanisms involving adenosine triphosphate (ATP) binding cassette 
A1 (ABCA1) transporters [115]. The uptake of exogenous lipoprotein-derived cholesterol 
requires internalization of the lipoprotein (usually an apolipoprotein E-rich complex) 
bound to its surface receptor, for instance low density lipoprotein receptor (LDLR) related 
protein 1 (LRP1) [6;8].
Recent studies suggest that high-level cholesterol is a risk factor in CNS pathophysiology 
associated with the development of neurodegenerative diseases such as AD and PD [162]. 
The most compelling evidence is that cholesterol-lowering drugs seem to reduce the risk 
of AD and PD [14;85;145;214;320;321]. Although the exact mechanism is not clear yet, it 
is suggested that cholesterol can interact with Ap and a-syn in the pathogenesis of these 
diseases [53;145]. For instance, an inverse correlation between membrane cholesterol 
level and binding of Ap to the cell surface, and subsequent cell death has been found 
(reviewed in [304]). These results suggest that interaction between Ap and cell surface 
is mediated by cellular cholesterol levels, the distribution of cholesterol within the cell 
and membrane fluidity. Interestingly, cholesterol also exerts various effects on APP 
secretase function. Increases in intracellular cholesterol concentrations lead to inhibition 
of a-secretase activity, but stimulates p- and Y-secretase activities [29;178;214], resulting 
in increased Ap production. Furthermore, it has been found that a-synuclein interacts 
with cholesterol rafts in its transport to nerve terminals, and excess of this protein-lipid 
complex is a hallmark of PD [145]. Together, these studies underscore the relevance of 
cholesterol metabolism in AD and PD.
1.3.4 Apolipoprotein E
Apolipoproteins present in lipoprotein particles function to mediate binding of the 
lipoproteins to cell-surface receptors, act as cofactors for enzymes of lipid metabolism, 
and maintain the structural integrity of lipoprotein particles as they are transported 
[173]. Apolipoprotein E (apoE) is a 34 kDa protein, produced by several cell-types 
[20;209;317], and is the main lipoprotein present in the brain. It is involved in transport 
and metabolism of plasma lipids [185], but is also implicated in neuronal regeneration 
[21]. The apoE gene exists as three alleles, apoE e2, e3 and e4 [116], resulting in 3 isoforms 
which differ in their amino acid composition at positions 112 and 158. The main class of 
apoE receptors expressed in the CNS is a group of structurally related proteins referred to 
as the low density lipoprotein receptor (LDLR) family [6;318]. Members of the family that 
can bind and internalize apoE-containing lipoproteins are: LDLR-related protein 1 (LRP1), 
megalin, very low-density lipoprotein receptor (VLDLR) and the sortilin-related receptor 
(SorLA) [6].
The e4 allele is a major genetic risk factor for AD: carrying one or two copies of this 
allele is associated with higher prevalence of AD [234;260]. ApoE e2 on the other hand has 
been reported to be relatively protective for AD [52]. Studies on cultured cerebrovascular 
cells with different apoE genotypes support these epidemiological data. Cells carrying 
two copies of the apoE e4 allele were more vulnerable for Ap-induced cytotoxicity than 
cells with other apoE genotypes [302;317]. The mechanism by which apoE and its different
19
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isoforms can modulate AD pathology has not been elucidated and is subject to much 
controversy. In AD, apoE colocalizes with SPs [8;193] and in vitro studies have demonstrated 
that apoE binds to Ap in an isoform specific manner [151;260]. Binding of Ap to apoE, 
especially the apoE e4 isoform, has also been linked to increased Ap aggregation [33]. In 
contrast, it has been found that apoE can also play a role in facilitating clearance of Ap 
from the brain [129;143], which is dependent of the apoE isoform and its lipidation status 
[109;129]. Furthermore, LRP1 and LDLR are thought to be involved in the internalization 
and clearance of Ap [21;26;245;280;318;335], indicating that binding of Ap to apoE might 
be essential for internalization and clearance via these receptors.
In PD, a possible association with the apoE e4 genotype remains elusive [134;148]. 
However, recently, it was found that after a-syn treatment, apoE was redistributed from 
the membrane to the cytosol in astrocytes and total levels of apoE were decreased [144], 
indicating that apoE could have an association with a-syn pathology.
1.3.5 Neuro-inflammation / inflammatory factors
Although the conversion of soluble protein into insoluble protein is the primary common 
feature of neurodegenerative conformational diseases, another common feature is chronic 
inflammation. The presence of inflammation is generally indicated by accumulation of 
activated microglia and astrocytes in damaged areas in the brain and around aggregated 
protein deposits [182;183]. Microglia are the macrophages of the brain parenchyma and 
can secrete inflammatory factors. Astrocytes also contribute to the process by releasing 
inflammatory factors [3]. Inflammation, both directly, via interaction of activated glial cells, 
and indirectly, via secreted neurotoxic mediators, may compromise neuronal function.
If microglial activation occurs either at a late stage of neurodegenerative conformational 
diseases as a consequence of substantial neuronal loss and excessive accumulation of 
protein, or already starts at an earlier stage of disease progression in an attempt to prevent 
neuronal loss and protein accumulation, is still a matter of debate. However, the existence 
of ongoing inflammatory processes that may contribute to progression of AD and PD 
is supported by the presence of excessive microglial activation [181;182] and increased 
cerebral levels of pro-inflammatory cytokines, possibly as a consequence of phagocytosis 
of aggregating proteins [3;336]. For example, in AD, IL-1 and IL-6 are associated with 
SPs, and both IL-6 and TNF-a levels are increased in AD brains [15;268;297;300]. Other 
signs of a neuro-inflammatory reaction in AD are activation of the complement system 
and co-deposition with Ap of several complement factors (such as C1q, C3, C4 and the 
membrane attack complex), acute phase proteins (such as a1-antichymotrypsin) and 
adhesion molecules (intercellular adhesion molecule-1) [3;181]. In PD, pro-inflammatory 
cytokines, e.g. IL-1p, TNF-a, IL-2 and IL-6, have been found at much higher levels in 
post mortem brains compared to control brains, as well as in serum and cerebrospinal 
fluid in vivo [19;72;191;263]. In addition, animal studies also support an involvement of 
pro-inflammatory cytokines in PD [87;96]. Furthermore, from epidemiologic studies 
it has become apparent that the chronic use of anti-inflammatory agents (especially 
non-steroid anti-inflammatory drugs (NSAIDs)) reduces the risk of developing AD and 
PD [93;184]. Both in humans and in transgenic mice, NSAIDs provide neuroprotection, 
indicating that neuro-inflammation could play an early role in the development of AD and 
PD [10;75;82;135;184;330].
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In summary, accumulation of Ap or a-syn in brain seems to be the key event in the 
pathogenesis of, respectively, AD and PD. Despite the differences in disease progression 
and clinical symptoms, these disorders share some common features. First, accumulation 
of these proteins seems to be triggered by self-aggregation, forming neurotoxic oligomers 
and protofibrils, and eventually insoluble fibrils, also referred to as amyloids. Second, 
several factors can modulate the aggregation and toxicity of misfolding proteins, such as 
cholesterol, apoE, sHsps and proteoglycans. Third, neuro-inflammation could play a role 
in early disease development. This suggests that these factors could affect aggregation 
of misfolding proteins and /  or modulate bioactivity and cytotoxicity of these misfolding 
proteins. Therefore, factors modulating aggregation and cytotoxicity of amyloidogenic 
proteins might play an important role in the development of AD and PD, and the 
similarities among these diseases could provide opportunities to enable a rational drug 
design to treat these diseases.
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Outline of this thesis 
Chapter 2
PD is a disease in which misfolded proteins play an important role in the pathogenesis. 
Besides a-syn, LB also contain several associated proteins including sHsps. Since a-syn 
accumulates intracellularly, molecular chaperones like sHsps may play an important role 
in regulating the (mis)folding and aggregation of a-syn. We, therefore, investigated in 
this chapter if the sHsps aB-crystallin, Hsp27, Hsp20, HspB8 and HspB2B3 could bind to 
a-synuclein and affect a-synuclein aggregation.
Chapter 3
In AD, the pathological lesions are associated with a local inflammatory reaction, including 
activation of microglial cells and astrocytes that produce cytokines, reactive oxygen 
species, etc. This neuro-inflammatory reaction is considered to be responsible for at least 
part of the cognitive decline. Intervention with the neuro-inflammatory reaction in AD 
brains could be a potential therapeutic target. Therefore, it is essential to identify the key 
players of this neuro-inflammatory response. Preliminary studies showed that several 
sHsps are associated with extracellular Ap depositions in the AD brain. In addition, it was 
observed that these sHsps, but not Ap, induced IL-6 production in various cerebral cell 
cultures, suggesting a central role for sHsps in the early phases of the neuro-inflammatory 
reaction and, thus, in contributing to cognitive decline. In this chapter, we studied co­
localization of sHsps with inflammatory factors near vascular Ap deposits. In addition, the 
extent of the inflammatory reaction induced by sHsps in cell culture was studied.
Chapter 4
Previously, a relation between Ap-mediated toxicity and apolipoprotein E (apoE) 
production by cultured pericytes on apoE genotype was found. Given their close 
association with the cerebrovascular wall, both astrocytes and pericytes may be involved 
in CAA development, a process that includes Ap deposition and clearance and that may 
be affected by interaction with locally produced apolipoprotein E (apoE). Although 
astrocytes are regarded as the major source of apolipoprotein E (apoE) in the brain, 
pericytes produce apoE as well. In this chapter we compared apoE production capacity, 
effects of apoE on Ap internalization, Ap cell surface accumulation and the vulnerability 
for Ap-induced toxicity of either cell type in order to quantify the relative contributions of 
astrocytes and pericytes in the various processes that contribute to CAA formation.
Chapter 5
It has been reported that heparan sulfate proteoglycans could enchance aggregation of 
Ab and that this enhancement is dependent on the degree of sulfation of the heparan 
sulfate proteoglycan. In addition, it has been reported that these sulfation epitopes do 
not occur randomly but have a defined tissue distribution. In this chapter, we investigated 
whether a specific epitope of heparan sulfate proteoglycan is associated with Ap plaques. 
Understanding the role of the degree of sulfation of heparan sulfate proteoglycans in 
the pathogenesis of AD may provide new perspectives to develop therapies against this 
disease.
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Chapter 6
Since aggregated forms of Ap are particularly neurotoxic, interference with the process 
of Ap aggregation is a long-envisioned target for therapy. In this chapter, hybrid ligands 
were developed to target Ap fibrillization by a combination of peptide-peptide and 
sulfate-peptide interactions. This idea is based on the knowledge that both sulfated 
(macro)molecules and small synthetic peptides interfere with Ap aggregation. Combining 
these two kinds of compounds in one hybrid ligand may offer opportunities for better 
specificity and activity in blocking the aggregation of Ap compared to the different 
compounds alone. A series of peptides, modified at the N-terminus with sulfated linkers, 
was successfully prepared by solid phase synthesis and tested in several biological assays. 
In addition, molecular modeling was applied to explain the nature of binding of the 
hybrid ligands to Ap.
Chapter 7
In the final chapter of this thesis we summarize and discuss the results of this thesis and 
propose future research plans.
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Abstract
The fibrillization of a-synuclein is a key event in the pathogenesis of a-synucleinopathies. 
Mutant a-synuclein (A53T, A30P or E46K), each linked to familial Parkinson's disease, has 
altered aggregation properties, fibril morphologies and fibrillization kinetics. Besides 
a-synuclein, Lewy bodies also contain several associated proteins including small heat 
shock proteins(sHsps).Since a-synuclein accumulates intracellularly,molecularchaperones 
like sHsps may regulate a-synuclein folding and aggregation. Therefore, we investigated if 
the sHsps aB-crystallin, Hsp27, Hsp20, HspB8 and HspB2B3 bind to a-synuclein and affect 
a-synuclein aggregation. We demonstrate that all sHsps bind to the various a-synucleins, 
although the binding kinetics suggest a weak and transient interaction only. Despite 
this transient interaction, the various sHsps inhibited mature a-synuclein fibril formation 
as shown by a Thioflavin T assay and atomic force microscopy. Interestingly, HspB8 was 
the most potent sHsp in inhibiting mature fibril formation of both wild-type and mutant 
a-synuclein. In conclusion, sHsps may regulate a-synuclein aggregation and, therefore, 
optimization of the interaction between sHsps and a-synuclein may be an interesting 
target for therapeutic intervention in the pathogenesis of a-synucleinopathies.
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2.1 Introduction
The a-synucleinopathies are a group of neurodegenerative disorders which are 
pathologically characterized by accumulation of the a-synuclein protein [128]. These 
disorders include Parkinson's disease (PD), Multiple System Atrophy (MSA) and dementia 
with Lewy bodies (DLB) [128], and are clinically characterized by a chronic progressive 
decline in motor function. Cognitive and/or autonomic dysfunction may also occur, 
depending on the disease. Lewy bodies (LB) [91], the neuropathological hallmark of PD, 
are mainly composed of a-synuclein [257]. Whereas the LB in PD are mainly observed 
in the substantia nigra, thalamus and sometimes the neocortex, in DLB the a-synuclein 
inclusions are observed in cortical and limbic areas and in MSA in the cytoplasm of glial 
cells [256]. The occurrence of LB is associated with nerve cell loss in human brain tissue 
[90]. In addition, overexpression of a-synuclein in transgenic animals causes a-synuclein 
pathology accompanied by neuronal dysfunction, loss of synaptic terminals, and/or of 
neuronal cells [86;179], suggesting an important role for a-synuclein accumulation in 
neurodegeneration.
a-Synuclein (a-syn) is a small (predicted molecular mass of 14.5 kDa), highly conserved 
protein that is abundantly expressed in various regions of the brain [257]. It is predominantly 
expressed in nerve terminals, in close proximity to synaptic vesicles [47], suggesting a 
possible role in neuronal plasticity. However, the exact physiological function of a-syn is 
poorly understood. Although it is intrinsically disordered in solution [309], conformational 
changes can cause the protein to adopt a p-sheet structure. Its aggregation follows a 
series of intermediate conformations, such as oligomeric assemblies, until it reaches a 
stable fibrillar state [50]. Although the oligomeric assemblies of a-syn are considered to 
be the primary toxic species [152;199;200;271], there are some reports which have also 
implicated the fibrillar assembly products in the cellular response in the disease [327;328]. 
These observations indicate that the aggregation state of a-syn is important in the 
development of a-synucleinopathies.
Up to now three point mutations in SNCA, the gene encoding for a-syn, have been 
described that are linked to dominantly inherited PD: Ala53Thr (A53T), Ala30Pro (A30P) 
and Glu46Lys (E46K) [147;211;334]. These mutant forms of a-synuclein show different 
aggregation abilities, fibril morphologies and fibrillization kinetics. For instance, the 
mutants A53T and E46K fibrillize much faster than wild-type a-syn. The A30P mutant forms 
mature fibrils at a slower rate, but the monomeric species are consumed at the same rate 
or slightly more rapidly than wild-type a-syn, which could indicate that the A30P variant 
forms more oligomeric intermediates [51;92;158]. These observations are additional 
indications that aggregation of a-syn is a critical step in the molecular mechanism of 
a-synucleinopathies.
Besides a-syn, LB contain several associated proteins including small heat shock 
proteins (sHsps) [77;188;199;265]. sHsps are a family of molecular chaperones that are 
known to bind partially unfolded proteins to prevent protein misfolding, return misfolded 
proteins to their normal state, or accelerate degradation of misfolded proteins [265]. 
Therefore, their association with LB suggests that they may be produced by the cell in 
response to a-synuclein aggregation. The human sHsps family comprises 10 sHsps [131], 
including aB-crystallin, Hsp27, Hsp20, HspB2, HspB3 and HspB8, and are expressed in 
heart, striated muscle, brain and various other tissues [124;131;132;164;165;315;319]. aB- 
crystallin and sHsp27 have been shown to protect against a-synuclein-induced toxicity
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and aggregation [188;199;215;308]. Furthermore, Hsp20, HspB8 and HspB2B3 can also 
affect aggregation of other amyloid-forming proteins such as the amyloid-p protein 
[314;315].
To our knowledge, reports about the interaction between sHsps and a-syn have been 
limited to the sHsps aB-crystallin and Hsp27 and to wild-type or A53T a-syn [199;215;308]. 
Aggregation of a-syn is an intracellular process, where close interaction with molecular 
chaperones such as sHsps can occur. Since mutations in the a-syn gene affect the 
aggregation properties of the protein, it is plausible that a modulating role of sHsps in 
a-syn aggregation will be affected by these mutations as well. Therefore, we systematically 
investigated the interaction of various sHsps with both wild-type and mutant a-syn, and 
their effect on a-syn aggregation.
2.2 Methods
2.2.1 Expression and purification of recombinant proteins
Expression of human wild-type and the A30P, E46K and A53T disease mutants of a-syn 
protein was performed as described previously [119;294]. Purified proteins were dissolved 
in 10 mM Tris-HCL, 50 mM NaCl, pH 7.4 buffer, at a concentration of 250 ^M.
Recombinant aB-crystallin was expressed and purified as described previously
[314]. Coding sequences for the following sHsps were ligated into the pET-46 Ek vector 
which also introduces a N-terminal His-tag sequence (Novagen, Merck Chemicals Ltd, 
Beeston Nottingham, United Kingdom): human Hsp27, human Hsp20, human HspB8 
and human HspB2/B3. Since it was demonstrated that HspB2 and HspB3 form functional 
heterogeneous complexes of 150 kDa [264], both proteins were expressed together in 
one vector. Hsp20 and HspB8 were expressed in Rosetta(DE3)pLysS competent cells 
(Novagen). Hsp27 and HspB2B3 were expressed in BL21(DE3)pLysS competent cells 
(Novagen). A culture inoculated from a single colony was induced by addition of 0.375 
mM isopropyl-thio-p-D-galactopyranoside (IPTG) for 4 hours at 37 °C, with the exception 
of Hsp20, which was induced for 16 hours at 25 °C. After incubation with IPTG, cells were 
harvested and lysed by sonication in native lysis buffer (NLB; 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0) supplemented with EDTA-free protease inhibitor (Roche Applied Science, 
Almere, the Netherlands). Insoluble proteins were removed by centrifugation. All sHsps 
were purified over a Ni-NTA agarose column (Qiagen, Venlo, the Netherlands) using NLB 
supplemented with increasing concentrations of imidazole (Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands) ranging from 20 up to 250 mM. After desalting, sHsps were 
concentrated in 10 mM Tris, 50 mM NaCl, pH 7.4 buffer by using an iCON concentrator spin 
column (Thermo Fisher Scientific Inc., Rockford, IL). Protein concentration was determined 
using a BCA Protein Assay kit according to the manufacturer's description (Thermo Fisher 
Scientific). Purified sHsps were aliquoted and stored at -  80 °C. Purity of the preparations 
was > 95%.
2.2.2 Surface plasmon resonance (SPR)
SPR experiments were performed using a Biacore 2000 (Uppsala, Sweden) biosensor 
instrument. Sensor chips and protein coupling chemicals were purchased from Biacore 
AB. Coupling of the human wild-type and the A30P, E46K and A53T disease mutants of
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a-syn protein to the surface of the sensor flow cell was performed by dissolving a-syn 
(250 ^M) in 10 mM sodium acetate (pH 3.5). Bovine serum albumin (BSA) served as a 
negative control and was coupled to the surface o f the sensor flow cell by dissolving BSA 
(20 ^g/ml) in 10 mM sodium acetate (pH 4.00). The procedure for coupling proteins to 
the sensor chips was performed as recommended by the manufacturer using N-ethyl-N'- 
(dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide and blocking the excess of 
activated groups by 1 M ethanolamine, pH 8.5. Kinetic steady state measurements were 
performed at 25 °C with a flow rate of 10 ^l/min in HBS-EP buffer (10 mM HEPES, pH 7.4, 
150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20). Surface coverage was in the same order 
of magnitude for all proteins, as was assessed by the Biacore 2000 software (BIAcore).
Interaction of sHsps with human wild-type and the A30P, E46K and A53T disease 
mutants of a-syn protein was performed using 6 different concentrations of sHsp (5­
50 ^M). Regeneration of the sensor surface was performed with 20 ^l o f 10 mM NaOH. 
Interaction of sHsps with wild-type and the A30P, E46K and A53T disease mutants of a-syn 
protein was compared with BSA as a negative control. The kinetic evaluation software 
(BIAcore), with correction for the negative control, was used to generate overlay plots of 
6 concentrations of analyte to determine the dissociation rate constant kd (expressed in 
s-1) and relative equilibrium dissociation constant KD (expressed in M). Furthermore, all 
experiments were performed in duplicate per chip, and at least two different sensor chips 
were used to exclude chip-to-chip variations.
2.2.3 Induction of a-syn aggregation
Aggregation was studied by incubating monomeric a-syn (wild-type or the three mutants 
A30P, E46K and A53T) at a concentration of 100 ^M at 37 °C in 10 mM TRIS, 50 mM NaCl, 
pH 7.4 with constant agitation at 1000 rpm for up to 8 days (Thermomixer, Eppendorf, 
Hamburg, Germany), either with or without sHsps (molar ratio 1:1). All experiments 
were at least performed in duplicate. Aliquots were withdrawn at regular intervals 
to accommodate for both thioflavin T (ThioT) fluorescence analysis and atomic force 
microscopy (see below). While ThioT measurements were performed immediately, 
samples for AFM imaging were stored at 4 °C in 10 ^l aliquots until analysis. No differences 
in aggregate morphology were observed between fresh samples and samples stored at
4 °C (unpublished data).
2.2.4 Kinetics of a-syn aggregation monitored by thioflavin T (ThioT) fluorescence
The increase in ThioT fluorescence signal, observed upon binding to a protein folded in 
p-sheet conformation, was used as an indicator of protein aggregation state [157]. At 
regular time intervals 10 ^L aliquots of aggregated protein were added to 990 ^L of 5 
ThioT (Sigma-Aldrich) in 50 mM glycine, pH 8.2. Fluorescence was measured in duplicate 
in a LS-5 Perkin-Elmer luminescence spectrometer with excitation at 457 nm, emission 
detection at 485 nm and 10 nm excitation and emission bandwidths. ThioT reference 
spectra were subtracted from every measurement. Boltzmann sigmoidal models were 
used to globally fit the data in Graph pad 4.00 for Windows (Graph Pad Software, San 
Diego, California, USA).
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Table 1: Summary of the dissociation rate constants of the various sHsps from the
different types of a-syn
aB-rystallin Hsp27 Hsp20 HspB8 HspB2B3
Dissociation 
rate constant
WT 1.67 ± 0.35 * 10-3 2.74 ± 0.30
* 10-3
1.11 ± 0.65
* 10-3
5.73 ± 2.56
* 10-3
7.72 ± 1.01
* 10-3
(kd (1/s), mean 
± SEM)
E46K 7.37 ± 0.62 * 10-3 1.99 ± 0.85
* 10-3
2.96 ± 0.44
* 10-3
1.85 ± 0.12
* 10-3
6.39 ± 2.51
* 10-3
A30P 5.82 ± 0.76 * 10-3 1.90 ± 0.18
* 10-3
5.93 ± 2.10
* 10-3
2.45 ± 0.59
* 10-3
8.49 ± 1.20
* 10-3
A53T 1.01 ± 0.72 * 10-3 4.64 ± 0.41
* 10-3
4.41 ± 0.20
* 10-3
2.06 ± 0.21
* 10-3
5.93 ± 0.45
* 10-3
2.2.5 Morphology of aggregates imaged by atomic force microscopy (AFM)
After completing the ThioT fluorescence analysis, two samples of each experiment were 
chosen to accommodate the AFM analysis. One sample was chosen in the growth phase 
of the aggregation process and the other sample was chosen when steady state in the 
fluorescence signal was reached. Samples for AFM were prepared by depositing 4 ^l of a 
ten times diluted protein solution onto freshly cleaved mica. After 2 minutes of adsorption 
the sample was washed carefully two times with 50 ^l MilliQ water and dried under a 
gentle stream of nitrogen.
AFM images were made on a custom built instrument [285] using Si3N4 tips (Veeco 
Instruments, Woodbury NY, USA, type MSCT-AUHW) with a spring constant of 0.5 N/m and 
a nominal tip radius of 10 nm. Imaging was performed in tapping mode in air at low force 
settings to minimize the interaction with the sample [119], thus preventing any effects of 
scanning on the aggregate morphology. Since the AFM scan area is only 2.5 x 2.5 ^m 2, the 
a-syn fibrils (without sHsp present) are often too long to image entirely, thus preventing 
measurement of mean fibril lengths. Furthermore, a-syn fibril diameter was difficult (if 
not impossible) to assess after co-incubation with sHsps, since unbound sHsps present in 
each sample appear in the background of every image and sometimes also on top of the 
fibrils, making assessment of fibril diameters inaccurate. Therefore, in this study the AFM 
imaging is used as a qualitative technique to confirm the ThioT results.
All AFM images have 512x512 pixels dimensions and were acquired at a typical scan 
speed of 50 ^m/s. In images used for presentation purposes, height discontinuities 
between subsequent scan lines were removed by 0th order line-wise leveling, and piezo 
drift was compensated by a 3rd order least-mean-squares average profile using SPIP 
software (Image Metrology A/S, Lyngby, Denmark).
2.2.6 Statistical analysis
ThioT data are expressed as mean ± SEM and were statistically analyzed using an 
independent sample t-test in SPSS 14.0 for Windows software (SPSS inc., Chicago, IL). 
Statistical significance was set at p<0.05.
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Fig. 1: Surface plasmon resonance sensorgrams of HspB8 (A), HspB2B3 (B), Hsp20 (C), aB-crystallin (D) and 
Hsp27 (E) for wild-type a-synuclein. Interactions o f sHsps with a-synuclein was analyzed using 6 
different concentrations o f sHsps (5-50 |jM). Injection point o f sHsps onto the sensor chip is depicted 
as a black triangle (association), and injection point washing buffer is depicted as a grey triangle 
(dissociation).
2.3 Results
2.3.1 Interaction of sHsps with a-syn using Surface Plasmon Resonance (SPR)
The dissociation rate constant (kd) of the interaction of the various sHsps with the 
different types of a-syn was in the range of 10-3 s-1 (table 1), indicating a short, transient 
interaction of the sHsps with the different a-syn variants. Since steady-state is reached 
(net association equals dissociation) during the SPR experiments, we also calculated the 
relative equilibrium dissociation constant (KD) using the Biacore evaluation software to 
estimate the affinity of sHsps to the various types of a-syn under steady state conditions. 
Table 2 depicts the KD calculated from the SPR data. In general, the KD for a-syn was 
lowest for aB-crystallin and highest for HspB8. The other sHsps showed variable affinities 
with values varying between these limits (i.e. KD varying from 10-6 to 10-8 M ). For SPR 
sensorgrams, see Figs. 1 and 2.
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Control experiments showed that binding of bovine serum albumin (BSA) to wild-type 
and disease mutants E46K, A30P and A53T a-syn was not detectable (data not shown). 
In addition, binding of sHsps to BSA was also not detectable (data not shown), indicating 
that the interaction between the sHsps and a-syn is specific.
Fig. 2: Comparison of the surface plasmon resonance sensorgrams of the different sHsps (binding to w ild­
type a-synuclein) at the highest concentration (50 pM). Although the sensorgrams of the different 
sHsps appear very different, the dissociation rate of the different sHsps from wild-type a-synuclein is 
comparable.
2.3.2 Effect of sHsps on p-sheet formation and morphology of a-syn aggregates
It is conceivable that binding of sHsps to a-syn might affect the capability of a-syn to 
form p-sheets. Therefore, quantitative changes in p-sheet formation of WT and mutant 
a-syn, either in the presence or absence of aB-crystallin, Hsp27, Hsp20, HspB8 or HspB2B3 
were studied by a ThioT assay. Without sHsps present, the sigmoidal kinetic curves 
observed for WT and mutant A30P a-syn aggregation are compatible with the nucleation- 
polymerization process which has been proposed for amyloid formation [322] (Figs. 3 
and 5). A lag phase without detectable ThioT fluorescence is followed by a growth phase 
in which fluorescence intensities of the dye increase until a final steady state is reached. 
It is suggested that mutants E46K and A53T a-syn fibrillize much faster than WT a-syn 
[51;92;158]. However, in this study only mutant E46K a-syn aggregated faster than WT 
a-syn, which is observed in the short and sometimes absent lag phase of the aggregation 
curves (Fig. 4). We found comparable aggregation rates of mutant A53T and WT a-syn 
(Fig. 3 and 6). It should be mentioned that the kinetics of the ThioT curves obtained for
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a specific a-syn variant were not always identical in each repeat of the assay. Therefore 
we always compared the effects of sHsps on aggregation of a-syn to the reference curve 
obtained in the same assay.
WT a-syn alone +aB-crystallin
B WT a-syn alone + sHsp27
C WT a-syn alone + sHsp20
WT a-syn alone +sHspB2B3
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Fig. 3: Analysis o f the effects o f sHsps on WT a-syn fibril formation using thioflavin T assay and atomic 
force microscopy (AFM). Quantitative changes in p-sheet formation o f 100 pM WT a-syn (red lines) 
incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 (B), Hsp20
(C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the sHsps 
alone and purple lines represent aggregation curves o f WT a-syn co-incubated with the different 
sHsps. Arrows indicate the time point in the aggregation process (steady state) where a sample was 
taken to study the morphology of the WT a-syn aggregates by AFM. Significant differences in the 
kinetic aggregation curves of WT a-syn co-incubated with or w ithout sHsps are shown. The level o f 
significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The reference curves and AFM 
images o f (b) and (e) were measured in the same assay. Size o f atomic force microscopy images is 2.5 
x 2.5 pm2.
When doing this, consistent effects of the sHsps could be clearly detected. In addition to 
the ThioT assays, we confirmed the effects of sHsps on a-syn aggregation by using atomic 
force microscopy (AFM) as an alternative and independent technique. Although two 
samples at different incubation times were analyzed by AFM, only the images at steady 
state are shown. As can be seen from the images, incubation for a maximum of 8 days of 100 
pM WT or mutant a-syn in the absence of sHsps resulted in the formation of a network of 
predominantly mature fibrils (Figs. 3-6). Upon incubation of sHsps alone for a comparable 
period of time, no fibrils could be observed. However, round compact structures were 
consistently found in each sample containing sHsps (Fig. 7). Representative aggregation 
curves and images of fibril morphology of WT, E46K, A30P and A53T a-syn incubated 
either with or without sHsps (molar ratio 1:1) are shown in figures 3 to 6 and the effects 
on p-sheet formation and ultrastructural morphology are described accordingly below.
2.3.3 Effects on WT a-syn
Co-incubation of WT a-syn with aB-crystallin, Hsp27, HspB8 and HspB2B3 affected the lag 
phase and/or growth phase of WT a-syn aggregation, resulting in a decreased fluorescent 
signal at steady state (Fig. 3 and Table 2). In contrast to the extensive fibrillar network 
observed with WT a-syn, co-incubation of WT a-syn with aB-crystallin resulted in fewer 
fibrils (Fig. 3A) and co-incubation of WT a-syn with Hsp27 or HspB2B3 resulted in relatively 
short fibrils (Figs. 3B and 3E). After co-incubation of WT a-syn with HspB8, only round 
compact structures but no fibrils were observed (Fig. 3D). Although co-incubation of 
WT a-syn with Hsp20 resulted in a maximum ThioT fluorescence intensity at steady state 
similar to that of WT a-syn alone, the lag phase of the aggregation process appeared to be 
prolonged. AFM imaging of the fibrils also showed that under these conditions a-syn fibril 
formation was slowed down (data not shown). However, eventually, fibrils morphologically 
similar to those resulting from incubating WT a-syn alone were formed (Fig. 3C).
Fig. 4: Analysis of the effects of sHsps on mutant E46K a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant E46K a-syn 
(red lines) incubated at 37 °C, either in the presence or absence o f 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves of E46K a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology of the mutant E46K a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves o f mutant E46K a-syn co-incubated with or w ithout 
sHsps are shown. The level o f significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The 
reference curves and AFM images o f (a) and (c), and (b) and (e) were measured in the same assay. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2.
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2.3.4 Effects on mutant E46K a-syn
Co-incubation of mutant E46K a-syn with aB-crystallin, Hsp27, Hsp20 and HspB8 resulted 
in a decreased fluorescent signal at steady state, by affecting the lag phase and/or growth 
phase of the aggregation process (Fig. 4 and Table 2). In AFM images no mature fibrils 
could be observed when mutant E46K a-syn was co-incubated with these sHsps. Instead
Table 2: Summary of the interactions of sHsps and a-synuclein
Analysis aB-crystallin Hsp27 Hsp20 HspB8 HspB2B3
Equilibrium Binding SPR 6.24 ±  1 .7*  10'8 3.55 ± 0 .5  * 10'7 3.88 ±  1.6 * 10'7 4.82 ± 1.6 * 10'6 3.03 ±  2.3 * 10'6
affinity for a-syn 6.82 ±  1.2 * IO'7 4.05 ± 2 . 8 *  10'6 4.01 ±5 .1  * IO'7 2.89 ± 1 .7*  10'6 9.66 ±  5.2 * IO'7
(relative Kp in M , mean 
+  SEM)
3.94 ± 2 . 8 *  IO'7 2.08 ± 4 . 4 *  IO'7 5.93 ±0 .1  * 10'6 2.50 ± 0 .6  * 10'6 1.44 ± 0 .1  * IO'7
A53T 1.52 ± 0 . 7 *  IO'7 4.64 ± 2 .5  * 10'6 6.35 ± 1 . 0 *  10'8 2.07 ±  1.0 * 10'6 6.08 ± 0 .6 * 10'6
Steady state ThioT WT 30%, * * * 65%, ** 100%, n.s. 10%, ** 35%, **
fluorescentsignal1 E46K 15%, ** 30%, ** * 45%, ** 70 ó * * * 100%, n.s.
A30P 80%, ** 75%, ** 100%, n.s. 5%, ** 65%, **
A53T 100%, n.s. 195%, ** 30%, ** * 10%, ** * 175%, **
Reduction of mature AFM WT - - 0 — -
a-syn fibril formation2 E46K - - - — 0
A30P - - 0 — -
A53T - ++ - - +++
SPR (surface plasmon resonance), ThioT (thioflavinT assay), AFM (atomic force microscopy), SEM (standard error o f the mean). Statistical analysis was performed using an 
independent sample t-test in SPSS 14.0 for Windows software (SPSS Inc., Chicago, IL).The level o f significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001, n.s. 
not significant.
1 Shown is the percentage o f steady state fluorescent signal compared to control (set at 100%). The level o f significance o f the difference with control steady state 
fluorescent signal is shown.
2 Effects on fibril formation is categorized as follows: —  (strong inhibiting effect), -- (moderate inhibiting effect), - (minor inhibiting effect, 0 (no effect), ++ (moderate 
stimulating effect), +++ (strong stimulating effect).
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only a few short fibrils could be observed (aB-crystallin, Hsp27, Hsp20; Fig. 4A-4C) or only 
small compact structures (HspB8; Fig. 4D), similar to those resulting from co-incubation of 
WT a-syn and HspB8. Although co-incubation of mutant E46K a-syn with HspB2B3 did not 
affect the fluorescent signal at steady state compared to incubation of mutant E46K a-syn 
alone, HspB2B3 appeared to extend the growth phase (Fig. 4E), without affecting a-syn 
fibril morphology (Fig. 4E).
2.3.5 Effects on mutant A30P a-syn
Like WT a-syn, co-incubation of mutant A30P a-syn with aB-crystallin, Hsp27, HspB8 
and HspB2B3 resulted in a (moderate) decrease in fluorescent signal at steady state, 
by affecting the lag phase, the growth phase, or both, of the aggregation process (Fig.
5 and Table 2). AFM analysis of mutant A30P a-syn co-incubated with aB-crystallin and 
Hsp27 showed fibrils morphologically similar to those resulting from the incubation of 
mutant A30P a-syn alone (Fig. 5A and 5B). In the presence of HspB2B3, clustered fibrils 
were observed (Fig. 5E). Furthermore, co-incubation with HspB8 again resulted in the 
absence of mature fibrils (Fig. 5D). Instead, only small compact structures were observed. 
Although co-incubation of mutant A30P a-syn with Hsp20 did not affect the fluorescent 
signal at steady state, the lag phase of the aggregation process appeared to be extended 
(Fig. 5C). AFM imaging of the fibrils also showed that co-incubation of mutant A30P a-syn 
with Hsp20 slowed down the fibril formation process (data not shown), w ithout affecting 
mutant A30P a-syn fibril morphology (Fig. 5C).
2.3.6 Effects on mutant A53T a-syn
In contrast to WT and the other a-syn mutants, the fluorescent signal at steady state of 
A53T a-syn was only reduced in the presence of Hsp20 and HspB8. Again, these sHsps 
affected the lag phase and/or the growth phase of the aggregation process of mutant 
A53T a-syn (Fig. 6 and Table 2). No mature fibrils were observed with AFM when mutant 
A53T a-syn was co-incubated with Hsp20 and HspB8. Instead, shorter fibrils (Hsp20; Fig. 
6C) or fewer fibrils were observed (HspB8; Fig. 6D). In contrast, co-incubation of mutant 
A53T a-syn with Hsp27 and HspB2B3 increased the fluorescent signal at steady state (Fig.
6 and Table 2). However, the morphology of the fibrils was comparable to that of the fibrils 
of mutant A53T a-syn alone (Fig. 6B and 6E). Furthermore, co-incubation of mutant A53T 
a-syn with aB-crystallin neither had an effect on fluorescent signal of the final steady 
state, nor on the aggregation process (Fig. 6A). AFM analysis showed a high number of 
fibrils after co-incubation with aB-crystallin compared to incubation with mutant A53T 
a-syn alone (Fig. 6A).
37
C h ap ter 2
38
Inhibition  o f  a -sy n u cle in  a g g reg a tio n  by small h e a t  sh o ck  p rote in s
Fig. 5: Analysis of the effects o f sHsps on mutant A30P a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant A30P a-syn 
(red lines) incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves o f A30P a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology of the m utant A30P a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves of mutant A30P a-syn co-incubated with or w ithout 
sHsps are shown. The level o f significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2.
2.4 Discussion
We investigated the interaction between sHsps and a-syn using surface plasmon 
resonance analysis and demonstrated that various sHsps affect the aggregation of a-syn 
in vitro. In general, sHsps had an inhibiting effect on the aggregation of a-syn, as was 
demonstrated by both thioflavin T assays and AFM imaging. We observed that sHsps can 
(weakly) bind to and affect fibrillization of WT and mutants a-syn, mostly by inhibiting 
or slowing down the aggregation process, but the extent of their interaction depends 
on the type of sHsp and a-syn peptide used. In general, although the potential of the 
various sHsps to inhibit mature fibril formation (as established by AFM) correlated to the 
decrease in fluorescence signal in the ThioT assay, the relative equilibrium dissociation 
constants (KD) were not evidently correlated to these findings (summarized in Table 1), as 
the following examples demonstrate. First, HspB8 demonstrated the highest KD towards 
the various a-syn proteins, compared to the other sHsps, but inhibited the aggregation 
of all variants of a-syn most strongly. Second, both Hsp27 and HspB2B3, but not HspB8, 
increased the maximum fluorescence signal in the ThioT assay when co-incubated with 
mutant A53T a-syn, although all had a comparable KD.
The calculated dissociation rate constant kd of the interactions between the sHsps and 
the various types of a-syn was in the range of 10-3 s-1, indicating a short interaction time 
and thus a weak, transient interaction of the sHsps with the different types of a-syn. This is 
compatible with previous NMR measurements of a weak interaction between aB-crystallin 
and a-syn, suggesting that the interaction between a-syn and aB-crystallin is transient 
[215;308]. Since the interactions are weak, the KD is easily studied using SPR, thereby 
providing an estimation of the affinities of the interactions. However, unfortunately, the 
Kd values do not explain the differences we observed in the Thio T assays, suggesting that 
Kd values alone are an insufficient predictor of the effects of sHsps on a-syn aggregation.
Consistent with other studies, we observed different fibrillization rates for the a-syn 
variants: E46K>A53T>WT>A30P [51;92]. Furthermore, we found that aB-crystallin 
inhibited the fibrillization of WT and mutant A30P a-syn, which is in line with earlier 
studies [51;92;158]. In contrast, we observed a lack of inhibition of fluorescent signal in the 
ThioT assay when co-incubating mutant A53T a-syn with aB-crystallin in a 1:1 molar ratio. 
In a previous study it was found that aggregation of mutant A53T a-syn was only inhibited 
using substoichiometric molar ratios of aB-crystallin/a-syn, while higher ratios were less 
effective [215]. This might explain the lack of inhibition of fluorescence signal in this study. 
However, after incubation of mutant A53T a-syn with aB-crystallin, we did observe a high
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Fig. 6: Analysis of the effects of sHsps on mutant A53T a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant A53T a-syn 
(red lines) incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves of A53T a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology o f the mutant A53T a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves o f mutant A53T a-syn co-incubated with or w ithout 
sHsps are shown. The level o f significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The 
reference curves and AFM images o f (a) and (c), and (b) and (e) were measured in the same assay. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2
number of fibrils that exhibited a lower height, and by extension, appear to have a smaller 
diameter. This may indicate that aB-crystallin prevents the formation of mature fibrils, 
resulting in only protofibrillar structures. Further study is, however, required for a definite 
conclusion on the dose-dependent effect of aB-crystallin on a-syn aggregation.
Aggregation of WT and mutant A30P a-syn was reduced after co-incubation with Hsp27 
in a 1:1 molar ratio, which confirms other studies [199;339]. Remarkably, we observed 
that Hsp27 increased mutant A53T a-syn aggregation. This is in contrast with a previous 
study in which it was observed that Hsp27 reduces mutant A53T a-syn aggregation in co­
transfected cells [199;339]. Differences in the relative concentrations of Hsp27 and mutant 
A53T a-syn may explain these discrepant results [215]. In addition, it is also possible that 
the lack of post-translational modifications of the purified proteins that we have used 
[146] affects the interaction between mutant A53T a-syn and Hsp27 and, thereby, may 
result in increased aggregation of mutant A53T a-syn.
Hsp20 delayed aggregation of all forms of a-syn, but only reduced fibril formation of the 
mutant proteins E46K and A53T a-syn. It has been suggested that Hsp20 has a particular 
affinity to non-fibrillar amyloid-p (Ap) [319]. This may be extended to the interaction with 
a-syn, since Hsp20 interacted with soluble non-fibrillar WT and mutant A30P a-syn and 
could delay its fibrillization, but did not inhibit its final aggregation into fibrils. In addition, 
as mutants A53T and E46K a-syn have increased oligomerization rates compared to WT 
a-syn [51;92], Hsp20 might arrest these a-syn variants in the oligomeric state. It is known 
that the efficiency of interaction between sHsps and partially folded species of a-syn 
depends on the conformational properties of the target protein [159;233]. This suggests 
that mutants A53T and E46K a-syn have the optimal conformational properties to interact 
with Hsp20 for an extended period of time, but WT and mutant A30P a-syn do not, which 
may explain why Hsp20 is not able to keep these a-syn variants in the oligomeric state.
Interestingly, although the relative equilibrium dissociation constant (KD) and the 
dissociation rate constant (kd) of HspB8 to all forms of a-syn were high, HspB8 was very 
potent in inhibiting aggregation of all types of a-syn. This suggests that HspB8 has a 
transient, but efficient, interaction with a-syn that prevents aggregation of a-syn. These 
observations are in line with the findings that HspB8 can inhibit aggregation and toxicity 
of Ap [315] and mutated superoxide dismutase 1 [56] and prevent formation of inclusion 
bodies by Htt43Q (mutated huntingtin fragment containing 43 glutamines) [31]. Taken 
together, this indicates that HspB8 might be important in influencing fibrillization of 
amyloidogenic and misfolding proteins in general.
HspB2B3 inhibited fibrillization of WT and mutant A30P a-syn, but not of mutants E46K 
and A53T a-syn. It is suggested that mutants E46K and A53T a-syn fibrillize faster than the 
WT and mutant A30P a-syn [51;92], indicating that HspB2B3 can only inhibit fibrillization
41
C h ap ter 2
of the slowly aggregating a-syn proteins. This is in line with an earlier study, where it was 
found that HspB2B3 did not affect fibril formation of Ap, a protein with a high fibrillization 
rate [314]. Thus, the interaction and modulation of aggregation by HspB2B3 seems to 
depend on the aggregation rate of the protein of interest.
It has become apparent in the last few years that amyloid fibrils may form through a 
nucleation-elongation mechanism [192;267]. In a recent study [142] an analytical solution 
of this model was described. Although this model was designed for homogeneous 
amyloid-forming proteins, we have used this model to obtain more mechanistic insight in 
the action of sHsps on the aggregation of WT a-syn. According to this model the sHsps may 
act by slowing down the elongation rate of a-syn, thereby affecting the lag and/or growth 
phase of the aggregation process. These conclusions, drawn from a theoretical model, 
nicely agreed with the interpretation of our ThioT/AFM data. Unfortunately, the model 
was not capable to fit all our data, possibly due to the fact that we studied heterogeneous 
conditions of sHsps affecting aggregation on a-syn. Therefore, we were not able to 
obtain insight in every interaction between sHsps and a-syn. In addition, another study 
showed that aB-crystallin interrupted a-syn aggregation at its earliest stages, most likely 
by binding to partially folded monomers and thereby preventing their aggregation into 
fibrillar structures [216]. Again, this could indicate that sHsps in general might inhibit the 
elongation rate of a-syn.
HspB8 HspB2B3mm
Fig. 7: Analysis o f sHsps using atomic force microscopy. Ultrastructural analysis of buffer (a), 100 pM aB- 
crystallin (b), 100 pM Hsp27 (c), 100 pM Hsp20 (d), 100 pM HspB8 (e) and 100 pM HspB2B3 (f) 
incubated at 37 °C for the indicated period o f time revealed only round compact structures, but no 
fibrils. Image size is 2.5 x 2.5 pm2
Several phases in the aggregation process in which the sHsps can interfere have 
been proposed [77] (Fig. 8). sHsps may bind to aggregating proteins and prevent protein 
misfolding [265], which is consistent with most of the a-synuclein-sHsps combinations 
in this study. Alternatively, sHsps may also return misfolded proteins to their normal 
conformation or facilitate the transformation of oligomers into amorphous aggregates, 
rather than towards stable fibrils [215;265]. We have not gathered evidence for this latter 
option, but we cannot rule it out since, after co-incubation of a-syn with sHsps, round 
compact structures were observed using AFM analysis. Although similar structures were 
observed when sHsps were examined by AFM and it is known that sHsps can self-associate 
into large, polydispersed assemblies [7], we cannot exclude that these structures may 
represent amorphous sHsp-a-syn complexes. Finally, another, contrasting, possibility 
is that sHsps may act by promoting the fibrillar pathway [18], which was also observed 
in a few cases in this study. Fibrils may be regarded as relatively inert end products of
buffer aB-crystallin Hsp27 Hsp20
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the aggregation process [98]. Thus, sHsps might aid in maintaining the delicate balance 
between a-syn aggregation and disaggregation and may reduce levels of (oligomeric) 
toxic a-synuclein aggregates by controlling its protein folding state.
In conclusion, in this study we have shown that various members of the sHsps family 
can influence aggregation of WT and mutant a-syn. The interaction of a-syn with the 
various sHsps is affected by disease-associated mutations in a-syn. Most sHsps inhibited 
a-syn aggregation but some promoted the aggregation, suggesting that the local 
concentrations of these chaperone molecules relative to each other and relative to a-syn 
may regulate intracellular a-syn fibrillization. It is suggested that toxicity associated with 
aggregating proteins is reduced if the aggregation process is inhibited [199]. Therefore, 
sHsps may inhibit the formation of toxic a-syn aggregation intermediates and optimization 
of the interaction between sHsps and a-syn may be an interesting target for therapeutic 
intervention in the pathogenesis of a-synucleinopathies.
Fig. 8: Overview of possible phases in the aggregation of a-synuclein in which sHsp can inhibit the toxicity 
of a-synuclein. sHsps may inhibit the formation o f a-syn oligomers from monomers, stimulate the 
disaggregation o f a-syn oligomers into monomers or the assembly into amorphous aggregates, or 
promote mature fibril formation and degradation. All these mechanisms may divert a-syn aggregation 
from the formation of toxic species.
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Abstract
More than 80% of Alzheimer's disease (AD) patients have some degree of cerebral amyloid 
angiopathy (CAA). In addition to arteries and veins, capillaries can also be affected. Capillary 
CAA (capCAA), rather than CAA in larger vessels, is associated with flamelike Ap deposits 
that may extend beyond the vessel wall and radiate into the neuropil, a phenomenon 
also known as "dyshoric angiopathy". Ap deposits in AD, parenchymal as well as (cap)CAA 
and dyshoric angiopathy, are associated with a local inflammatory reaction, including 
activation of microglial cells and astrocytes that, amongst others, produce cytokines and 
reactive oxygen species. This neuro-inflammatory reaction may account for at least part 
of the cognitive decline. In previous studies we observed that small heat shock proteins 
(sHsps) are associated with Ap deposits in AD. In this study the molecular chaperones 
Hsp20, HspB8 and HspB2B3 were found to co-localize with CAA and capCAA in AD brains. 
In addition, Hsp20, HspB8 and HspB2B3 co-localized with intercellular adhesion molecule 1 
(ICAM-1) in capCAA-associated dyshoric angiopathy. Furthermore, we demonstrated that 
Hsp20, HspB8 and HspB2B3 induced production of interleukin (IL)-8, soluble ICAM-1 and 
monocyte chemoattractant protein 1 (MCP-1) by human leptomeningeal smooth muscle 
cells and human brain astrocytes in vitro and that Hsp27 inhibited production of TGF-P1 
and CD40 ligand. Our results suggest a central role for sHsps in the neuro-inflammatory 
reaction in AD and CAA and thus in contributing to cognitive decline.
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3.1 Introduction
In Alzheimer's disease (AD) amyloid-p (AP) is deposited as plaques in the parenchyma, but 
also as cerebral amyloid angiopathy (CAA) [237]. Capillary Ap deposits (capCAA) correlates 
with severity of AD pathology and clinical deterioration, whereas larger vessel CAA does 
not [12;81]. Furthermore, in capCAA, flamelike Ap deposits may extend beyond the vessel 
wall and radiate into the neuropil, a phenomenon known as "dyshoric angiopathy" [11]. 
Neuropathological examination of (cap)CAA reveals activated microglia and astrocytes 
surrounding these lesions [3;11;183;223;227;329] and co-localization of inflammatory 
factors such as intercellular adhesion molecule 1 (ICAM-1) [300].
In AD brains, an inflammatory reaction may occur in conjunction with Ap deposits, 
characterized by the increased expression of, amongst others, transforming growth factor 
p1 (TGF-p1) [324], interleukin (IL) 1p, IL-8, monocyte chemoattractant protein 1 (MCP- 
1), ICAM-1 and CD40 ligand [3;30;111;252;]. This inflammatory reaction may occur in 
response to the presence of extracellular Ap or phagocytosis of Ap deposits by microglia 
[175]. Inflammation, both directly via interaction of activated glial cells and indirectly via 
secreted neurotoxic mediators may compromise neuronal function. Indeed, transgenic 
mice with extensive CAA showed cognitive decline as a result of increased microglial 
activation and neuro-inflammation, which could be reduced by treatment with the anti­
inflammatory drug minocycline, and thereby improved cognition [82]. Epidemiologic 
studies demonstrated that most patients with CAA-related inflammation show at least 
a partial clinical improvement to high dose corticosteroids or other immunosuppressive 
agents [45]. Thus both human and mouse studies provide evidence for a contribution of 
Ap to CAA-related neuro-inflammation and subsequent cognitive decline. However, the 
neuro-inflammatory reaction in AD patients may be more complex.
In AD, several macromolecules co-localize with plaques and CAA, including small 
heat shock proteins (sHsps) [315;319]. Previous research showed that expression of aB- 
crystallin and Hsp27 is increased in reactive astrocytes of AD brains [217;218;319]. Hsp20 
co-deposited with Ap in diffuse and classic plaques and HspB2 with classic plaques 
and CAA [319]. Moreover, HspB8 co-localized with classic plaques in AD and with CAA 
in hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D)
[315]. Furthermore, we observed that these sHsps, but not Ap, induced IL-6 production 
in various cerebral cell cultures [313], suggesting that sHsps may play a pivotal role in 
inducing neuro-inflammation. Therefore, we investigated the association of sHsps with 
(cap)CAA and CAA-associated inflammation in post mortem brain and investigated the 
effect of selected sHsps on the production of inflammatory factors by cultured human 
leptomeningeal smooth muscle cells and astrocytes in vitro.
3.2 Methods
3.2.1 Reagents
Lyophilized Ap1-42 (95% pure) and Ap1-40 (98% pure) were purchased from Quality 
Controlled Biochemicals, MA, USA. Ap with the "Dutch" mutation (22 Glu^Gln, D-Ap1- 
40, 96% pure) was purchased from 21st Century Biochemicals, MA, USA. D-Ap1-40 was 
used as a model peptide, because it causes CAA in hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (HCHWA-D) [58;296;316]. Ap1-42, Ap1-40 and D-AP1-40
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were dissolved in 1,1,1,3,3,3-hexafluoro-2 propanol (HFIP) (Sigma-Aldrich, Zwijndrecht, 
The Netherlands), air-dried and dissolved in DMSO at a concentration of 5 mM. Aliquots of 
the solutions were stored at -80°C.
Table 1: Overview of the origin of astrocyte and HBP cell cultures and tissue sections.
Number Diagnosis Age PMI
(h:m)
Gender NFT
stage
(Braak)
Plaque
score
(CERAD)
CAA
grade
Cell
type
Cell culture
1 AD 84 6:30 F V C N.D. Astrocyte
2 AD 92 7:00 F V 0 N.D. Astrocyte
3 Control 76 4:40 F i B N.D. Astrocyte
4 AD 77 3:00 M VI C ++ SMC
5 Parkinson 91 4:00 F V C +++ SMC
6 Control 83 4:00 F III B - SMC
IHC
7 AD + CAA 65 7:20 M V C +++ N.A.
8 AD + CAA 89 6:55 F V C +++ N.A.
9 AD + CAA 74 3:25 M VI C +++ N.A.
10 Control 81 3:45 M I 0 - N.A.
11 Control 71 6:05 F III C - N.A.
12 Control 92 6:25 F III A + N.A.
Overview o f the cases used in this study. AD = Alzheimer's disease; SMC, human brain smooth muscle cells; 
IHC, tissue used for immunohistochemistry; PMI, post-mortem interval in hours:minutes; F, Female; M, Male; 
N.D., not determined; N.A., not applicable. Grading of AD (Braak scores) was performed as described in 
Methods.
3.2.2 Autopsy material
Patient selection was based on neuropathological findings at autopsy. Tissue samples 
were selected for the presence of capCAA [223]. For immunohistochemistry, tissue 
samples from the occipital neocortex from 3 AD patients with capCAA (age 76 ± 12 years; 
post-mortem delay 5:53 ± 2:09 hours) were obtained after rapid autopsy and immediately 
frozen in liquid nitrogen. Informed consent was obtained according to European 
guidelines. Table 1 provides an overview of the diagnosis, Braak stage, CERAD score, CAA 
grade, age, post mortem interval (PMI) and gender. Neuropathological evaluation was 
performed on frozen tissue from occipital pole cortex. CAA score was defined as follows: 
severe (+++), moderate (++), mild (+) as previously described [223]. Staging of AD was 
evaluated according to the criteria established by Braak & Braak and CERAD [22;189].
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3.2.3 Immunohistochemistry
In Table 2 the primary antibodies used in this study are listed. Unless mentioned otherwise, 
we used biotin-labeled horse anti-mouse antibodies (Vector Laboratories, Burlingame, 
CA, USA) as the detection antibody for mouse monoclonal antibodies, or biotin-labeled 
goat-anti-rabbit antibodies (Vector) in case of rabbit polyclonal antibodies.
Serial cryo-sections (4 ^m) were air-dried and fixed in acetone for 5 minutes. 
Endogenous peroxidase activity was blocked using acetone containing 0.15% H2O2 for
5 minutes. Sections were pre-incubated for 30 minutes with 20% animal serum, the type 
of which was determined by the specific biotin-labelled antibody used. Subsequently, 
sections were incubated overnight at 4 °C with primary antibody (Table 2), with secondary 
antibodies for 60 minutes at room temperature, and with the avidin-biotin complex 
according to the manufacturer's description. Between incubation steps, sections were 
extensively washed using PBS. 3-Amino-9-ethyl carbazole (AEC) was used as a chromogen. 
After a short rinse in tap water the preparations were incubated with hematoxylin for 
1 minute and thoroughly washed with tap water for 10 minutes. Finally, sections were 
mounted with Imsol mount (Klinipath, Duiven, Netherlands). All antibodies were diluted 
in PBS containing 1% Bovine Serum Albumin (BSA), which also served as a negative 
control. At regular intervals, sections were stained with anti-Ap to allow for topographical 
alignment of CAA with the stains for sHps and inflammatory factors.
Table 2: Primary antibodies used in this study
Primary
antibody
Antigen Species 
raised in
Dilution Source (reference)
6C6
ca< Mouse 1:250 Dr. Schenk, Elan Pharmaceuticals, 
San Francisco, CA, USA
GFAP GFAP Mouse 1:10 Monosan, Sanbio, Uden, 
The Netherlands
LN3 HLA-DR Mouse 1:50 eBioscience, San Diego, CA, USA
MAB208 IL-8 Mouse 1:100 R&D systems, Abingdon, UK
LS-C8642 MCP-1 Mouse 1:100 Lifespan Biosciences, Huissen, 
The Netherlands
CL203 ICAM-1 Mouse 1:500 [301]
PN-E12 ICAM-1 Mouse 1:25 [301]
Pab-aBcr aB-crystallin Rabbit 1:500 [68]
1426 Hsp27 Rabbit 1:2000 Abcam Limited, Cambridge, UK
VDK-p20 Hsp20 Rabbit 1:4000 [282]
J92 HspB8 Rabbit 1:2000 [305]
F34 HspB2 Rabbit 1:2000 [305]
For double immunostaining of Ap and/or astrocytes/microglia, sections were stained 
using the EnVision method as previously described [223]. Briefly, sections were incubated 
overnight at 4 °C with primary antibodies (Table 2), followed by incubation with EnVision 
HRP. EnVision 3,3-diaminobenzidine (DAB) was used as chromogen. Antibodies were 
diluted in PBS/1% BSA, which also served as a negative control. After each incubation, 
slides were extensively washed with PBS. For the detection of fibrillar Ap in plaques and
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CAA, sections were stained with Congo Red (0.5% in Ethanol 80%, 3% NaCl) for 20 minutes 
at room temperature. Finally, sections were mounted with DePeX mounting medium 
(Gurr, Germany).
3.2.4 Expression and purification of recombinant proteins
Recombinant human aB-crystallin and HspB2B3 were expressed and purified as described 
previously [314]. Since it was demonstrated that HspB2 and HspB3 form functional 
heterogeneous complexes of 150 kDa [264], both proteins were expressed together 
in one vector. Coding sequences for the following sHsps were ligated into the pET-46 
Ek/LIC vector which also introduces a N-terminal His-tag sequence (Novagen, Merck 
Chemicals Ltd, Beeston Nottingham, United Kingdom): human Hsp27, human Hsp20 
and human HspB8. Hsp20 and HspB8 were expressed in Rosetta(DE3)pLysS competent 
cells (Novagen). Hsp27 was expressed in its BL21(DE3)pLysS competent cells (Novagen). 
A culture inoculated from a single colony was induced by addition of 0.25 mM isopropyl- 
thio-p-D-galactopyranoside (IPTG) for 4 hours at 37 °C, with the exception of Hsp20, 
which was induced for 16 hours at 25 °C. After incubation with IPTG, cells were harvested 
and lysed by sonication in native lysis buffer (NLB; 50 mM NaH2PO4, 300 mM NaCl, pH 
8.0) supplemented with EDTA-free protease inhibitor (Roche Applied Science, Almere, the 
Netherlands). Insoluble proteins were removed by centrifugation. All sHsps were purified 
over a Ni-NTA agarose column (Qiagen, Venlo, the Netherlands) using NLB supplemented 
with increasing concentrations of imidazole (Sigma-Aldrich Chemie BV, Zwijndrecht, the 
Netherlands) ranging from 20 up to 250 mM. After desalting, sHsps were concentrated 
in 10 mM Tris, 50 mM NaCl, pH 7.4 buffer by using an iCON concentrator spin column 
(Thermo Fisher Scientific Inc., Rockford, IL). Protein concentration was determined using 
a BCA Protein Assay kit according to the manufacturer's description (Thermo Fisher 
Scientific). Purified sHsps were aliquoted and stored at -  80 °C. Purity of the preparations 
was > 95%.
3.2.5 Cell culture
Smooth muscle cells (SMC) and astrocytes were both isolated from human brain tissue 
obtained after rapid autopsy, as described previously [61;295;299] (Table 1). Diagnosis and 
grading of patients was performed according to the criteria mentioned previously. SMCs 
were maintained in Eagle's modification of essential medium (EMEM; PAA Laboratories 
GmbH, Pasching, Austria), supplemented with 10% human serum (Lonza BioWhittaker 
Benelux BV, Breda, the Netherlands), 20% fetal bovine serum (PAA Laboratories GmbH), 
recombinant basic fibroblast growth factor (1 ng/ml) and gentamycin (2.5 ^g/ml). 
Astrocytes were maintained in a mixture (1:1 vol/vol) of Dulbecco's modification of 
essential medium (DMEM) and HAMs F10 supplemented with 10% fetal bovine serum, 2 
mM L-glutamine (Cambrex, Workingham, UK) and gentamycin (2.5 ^g/ml). All primary cell 
cultures were cultured at 37°C, 5% CO2 and 90% relative humidity. Although the cultured 
astrocytes and SMCs were derived from different clinical backgrounds (i.e. either AD or 
control patients), we did not observe differences with respect to their responses in the 
various types of experiments.
Cell passages 3-9 were used for the experiments. Control cells incubated with 
EMEM or DMEM/HAM-F10 and 0.1% bovine serum albumin (BSA; serum-free medium) 
demonstrated normal morphology. Experiments were performed at least twice.
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3.2.6 ELISA
Duplicate wells (12-wells plate; Corning Incorporated, NY, USA) with cultured cells were 
preincubated with serum free medium for a minimum of 4 h. Subsequently, cells were 
incubated with 12.5 |jM synthetic AP1-40, AP1-42, D-AP1-40 or 12.5 |jM purified sHsps (aB- 
crystallin, Hsp27, Hsp20, HspB8 and HspB2B3) at 37 °C and 5% CO2. This concentration was 
the lowest concentration to induce a significant effect across all sHsps tested. In addition, 
the same concentration of Ap induced biological effects in cultured SMCs and astrocytes 
[296] and was therefore chosen in the experiments. Lipopolysaccharide (LPS; 055:B5; 
Sigma-Aldrich) stimulation (1 ^g/ml) was used as a positive control for inducing cytokine 
production. After 48 hours of incubation, supernatants and cell lysates (solubilized in RIPA; 
50mM Tris HCl pH 7.4, 150mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1% 
SDS in milliQ) were collected, centrifuged at 13.200 rpm for 10 minutes at 4 °C and stored 
at -80 °C until further use. To exclude endotoxin contamination, potentially present in 
the purified sHsp samples, co-incubation with polymixin B (PMB; Sigma-Aldrich; 10 ^g/ 
ml) was used to inhibit LPS-mediated inflammation. In these experiments, PMB was pre­
incubated with both the LPS and the sHsps for 1 hour at 37 °C before addition to the cells.
Il-8, ICAM-1, MCP-1, CD40 ligand and TGF-p1 levels in cell culture supernatant were 
measured using commercial enzyme immunoassay kits according to the manufacturer's 
instructions (DuoSet ELISA, R&D systems, UK). To correct for differences in cell density, 
inflammatory factor production was normalized to protein content of the cell lysate 
which was determined by using a BCA Protein Assay kit according to the manufacturer's 
description (Thermo Fisher Scientific Inc., Rockford, IL). Concentrations of the various 
inflammatory factors were expressed as pg/mg protein.
3.2.7 Statistical analysis
Statistical analyses were performed using an independent sample t-test in SPSS 14.0 for 
Windows software (SPSS inc., Chicago, IL). Statistical significance was set at p<0.05.
3.3 Results
3.3.1 Inflammatory cells in AD brains with severe CAA pathology, capCAA and 
dyshoric angiopathy.
Double staining for GFAP and Congo red demonstrated the presence of astrocytes around 
Ap-laden vessels, with a more prominent GFAP staining around the larger vessels (Figures. 
1A and C). Clusters of HLA-DR positive microglia were also observed around larger vessels 
and capillaries laden with Ap and were particularly prominent around the capillaries 
(Figure. 1B and D).
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Fig 1: Immunohistochemical staining of glial fibrillary acidic protein (GFAP; A and C) and microglial cell 
marker (LN3; B and D) in CAA (A and B) and capillary cerebral amyloid angiopathy (capCAA; C and D).
All sections are double stained with Congo Red. GFAP-positive reactive astrocytes are present around 
both larger vessels and capillaries (A and C). Microglial activation is associated with both large vessels 
and capillaries, however more prominent around the latter (B and D).
3.3.2 Expression of sHsps in AD brains with severe CAA pathology, capCAA and 
dyshoric angiopathy
In control brains, aB-crystallin staining was observed in glial cells (Fig. 2B). Furthermore, 
leptomeningeal vessels as well as a few astrocytes in the white matter were also stained 
(data not shown). Hsp27 staining in control brains was limited to leptomeningeal vessels 
(data not shown), but not observed in parenchymal vessels (Fig. 2D). Hsp20 staining in 
control brains was occasionally observed in astrocytes in white and grey matter (data not 
shown). Weak immunoreactivity of Hsp20 was also observed in large parenchymal (Fig. 
2F, open arrow) and leptomeningeal vessels (data not shown). HspB8 staining in control 
brains was observed in astrocytes in both grey and white matter (Fig. 2H, arrow) and in 
cerebrovascular cells of large parenchymal vessels (Fig. 2H, open arrow). Furthermore, 
weak staining for HspB2 was observed in cerebrovascular cells in large parenchymal 
vessels (Fig. 2J, open arrow) and in an occasional astrocyte or microglial cell in the brain 
parenchyma (data not shown). IL-8 (Fig. 2L) and MCP-1 (Fig. 2P) staining was not observed 
in normal parenchymal or leptomeningeal vessels in control brains, whereas ICAM-1 
staining was observed in endothelial cells in control brains (Fig. 2N, arrow).
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Fig 2: Immunohistochemical staining of Ap (A, C, E, G, I, K, M, O), sHsps (B, D, F, H, J; open arrow) and 
inflammatory factors (L, N, P; open arrow) in or near normal vessels in the occipital cortex of control 
patients. Serial sections: A, B; C, D; E, F; G, H; I, J; K, L; M, N; O, P. Anti-aB-crystallin antibodies stained 
glial cells throughout the cortex (B, arrow). Anti-Hsp27 antibodies were only occasionally 
immunoreactive with leptomeningeal vessels (data not shown), but not with parenchymal vessels
(D). Hsp20 was occasionally demonstrated in astrocytes in normal brains (data not shown). Weak 
immunoreactivity of Hsp20 was also observed in large parenchymal (F, open arrow) and 
leptomeningeal vessels. HspB8 staining was observed in astrocytes in both grey and white matter (H, 
arrow) and in cerebrovascular cells of large parenchymal vessels (H, open arrow). Weak staining for 
HspB2 was observed in cerebrovascular cells in large parenchymal vessels (J, open arrow) and in an 
occasional astrocyte or microglial cell in the brain parenchyma (data not shown). Furthermore, anti- 
IL-8 (L) and anti-MCP-1 (P) staining was absent from normal parenchymal or leptomeningeal vessels. 
The anti-ICAM antibodies stained endothelial cells (N, arrow). Original magnification 200x
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In AD brains with severe (cap)CAA pathology, the anti-Ap antibody (6C6) stained Ap- 
affected vessels and capillaries in (Figures. 3A and 3B). In addition, dyshoric angiopathy 
(Figure. 3A) was often observed. The antibodies directed against aB-crystallin, Hsp27, 
Hsp20, HspB8 and HspB2 showed different staining patterns for these sHsps in CAA, 
capCAA and dyshoric angiopathy. Representative staining results are shown in Fig. 3 and 
a summary of the immunohistochemical results is shown in Table 3. Anti-aB-crystallin 
antibody stained reactive astrocytes and activated microglia associated with CAA (Fig. 3C) 
and capCAA (Fig. 3D). Hsp27 staining was not observed in grey matter (Fig. 3E and 3F), but 
was occasionally observed in reactive astrocytes and microglia in the white matter (data 
not shown). In addition, reactive astrocytes surrounding CAA were immunopositive for 
Hsp20 (Figure. 3G) and occasionally Hsp-20-positive reactive astrocytes were observed 
surrounding capCAA (data not shown). Anti-HspB8 stained reactive astrocytes and 
microglia in both white and grey matter and occasionally immunoreactivity of HspB2 was 
observed with reactive astrocytes and microglia. Whereas HspB2 (Fig. 3L) co-localized with 
Ap in capCAA and CAA, no immunostaining for aB-crystallin (Fig. 3C and 3D), Hsp27 (Fig. 
3E and 3F), Hsp20 (Fig. 3G and 3H) and HspB8 (Fig. 3I and 3J) was observed. Furthermore, 
co-localization of Hsp20 (Fig. 3G), HspB8 (Fig. 3I) and HspB2 (Fig. 3K), but not of aB- 
crystallin (Fig. 3C) and Hsp27 (Fig. 3E), with Ap surrounding CAA and capCAA (dyshoric 
angiopathy) was observed.
Table 3: Summary of the immunohistochemical results
capCAA CAA Dyshoric angiopathy
aB-crystallin 0% 0% 0%
Hsp27 0% 0% 0%
Hsp20 10% 0% 90%
HspB8 10% 0% 100%
HspB2 80% 100% 95%
Quantification o f the percentages o f Ap deposits that are stained by the sHsp antibodies in all patients 
(average o f n=3 patients). CAA, cerebral amyloid angiopathy; capCAA, capillary CAA
3.3.3 Expression of inflammatory factors in AD brains with severe CAA pathology, 
capCAA and dyshoric angiopathy
ICAM-1 was associated with dyshoric Ap deposits surrounding CAA and capCAA, but not 
with the Ap deposits within the vessel wall (Figures 3O and 3P), suggesting co-localization 
of Hsp20, HspB8 and HspB2 with ICAM-1 in dyshoric angiopathy near (cap)CAA. Although 
ICAM-1 has also been detected in a soluble form [226;105], it is mainly described as a 
membrane-bound cell adhesion molecule. Therefore, the ICAM-1 staining we observed 
is very likely due to membrane-bound ICAM-1. In earlier studies an increase in IL-8 and 
MCP-1 in AD brains was observed after soluble protein extraction of human brain lysates 
or in paraffin-embedded formalin-fixed tissue [3;30;252]. In the present study, no IL-8 and 
MCP-1 was detectable in tissue from AD patients with severe CAA pathology (Figures 3M, 
3N, 3Q and 3R). In cryosections, these soluble factors might escape detection due to mild 
fixation of the tissue.
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CAA capCAA
Fig 3: Immunohistochemical staining of sHsps and inflammatory factors in or near CAA vessels (A, C, E, G, I, 
K, M, O, Q; serial sections) and capCAA (B, D, F, H, J, L, N, P, R; serial sections; arrows indicate the same 
capillary in each panel to serve as a reference to allow optimal comparison with other panels) in the 
occipital cortex of AD brains. The anti-Ap antibody 6C6 stained CAA, capCAA and dyshoric angiopathy 
in AD brains (A, B; to allow optimal comparison with other stains, these panels are shown twice). Both 
anti-aB-crystallin (C, D) and anti-Hsp27 (E, F) antibody staining was absent in Ap deposits. No anti- 
Hsp20 and anti-HspB8 staining was observed in CAA and capCAA, however, colocalization of Hsp20 
and HspB8 (G, H, and I, J) with dyshoric angiopathy (Ap surrounding CAA) was observed. Presence of 
HspB2 in CAA (K) and capCAA (L) of AD brains with severe CAA was observed, but also colocalization 
o f HspB2 with dyshoric angiopathy (K) was observed. The anti-aB-crystallin (C), anti-Hsp20 (G) and 
anti-HspB8 antibodies (I) stained reactive astrocytes and microglia associated with CAA. Occasionally, 
immunoreactivity o f HspB2 with reactive astrocytes and microglia was observed. Furthermore, anti- 
IL-8 (M, N, arrow) and anti-MCP-1 (Q, R, arrow) staining was absent from CAA and capCAA vessels. In 
addition, ICAM-1 was associated with dyshoric angiopathy, but not with the Ap deposits in the vessel 
wall (O, P, arrow; insert ICAM-1 staining (left) and Ap staining (right) o f another capCAA vessel). 
Original magnification 200x
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3.3.4 sHsps induce the production of inflammatory factors by human 
leptomeningeal smooth muscle cells and human brain astrocytes
Our immunohistochemical studies suggest that both Ap and sHsps accumulate in 
or near (cap)CAA, where an inflammatory reaction is observed as well. Since human 
leptomeningeal smooth muscle cells (SMCs) are already early affected by Ap in CAA 
[306], we studied if Ap or sHsps were able to induce production of cytokines and other 
inflammatory factors by cultured SMCs. In addition, since reactive astrocytes co-localize 
near (cap)CAA (Figure 1), we also studied the potential of Ap and sHsps to induce an 
inflammatory reaction in human brain astrocytes.
Neither Api-40, Api-42, nor D-Api-40 (12.5 ^M) induced production of IL-8, ICAM- 
1, MCP-1, TGF-pi or CD40 ligand by SMCs or astrocytes, above control levels (Figures 4 
and 5). Incubation of 1 ^g/ml LPS induced IL-8 production (Figure 4A; p< 0.05) by SMCs, 
but not production of soluble ICAM-1 (sICAM-1; Figure 4B), MCP-1 (Figure 4C) and TGF-p1 
(Figure 4D). Furthermore, incubation of 1 ^g/ml LPS induced IL-8 (Figure 5A; p< 0.01), 
sICAM-1 (Figure 5B; p<0.01) and MCP-1 (Figure 5C; p<0.05) production by astrocytes, but 
not production of TGF-p1 (Figure 5D) and CD40 ligand (Figure 5E). After pre-incubation 
and co-incubation of LPS with PMB, production of inflammatory factors by SMCs and 
astrocytes returned to control levels (Figure 5; p<0.05), indicating that PMB efficiently 
inhibited the LPS-induced inflammatory reaction.
Incubation of SMCs with 12.5 ^M Hsp20, HspB8 or HspB2B3 resulted in a strong 
induction of IL-8 (Figure 4A; p<0.01), sICAM-1 (Figure 4B; Hsp20, HspB2B3, p<0.001; HspB8, 
p<0.01) and MCP-1 (Figure 4C; Hsp20, HspB2B3, p<0.001; HspB8, p<0.01) secretion, but not 
of TGF-p1 (Fig. 4D). In contrast to the increased levels of IL-8 production after incubation 
with 12.5 ^M Hsp27 (Figure 4A; p<0.001), decreased (p<0.01) TGF-p1 production was 
observed after Hsp27 treatment compared to control (Figure 4D). In addition, incubation 
with Hsp27 did not induce levels of sICAM-1 (Figure 4B) and MCP-1 (Figure 4C) above 
control levels in SMCs. Furthermore, SMCs did not seem to secrete CD40 ligand, since 
after incubation of these cells with either Ap1-40, Ap1-42, and D-Ap1-40 or sHsps, the 
concentrations of CD40 ligand remained below the detection level (data not shown).
Incubation of astrocytes with 12.5 ^M Hsp20, HspB8 or HspB2B3 also resulted in a 
strong induction of IL-8 (Figure 5A; p<0.001), sICAM-1 (Figure 5B; p<0.001) and MCP-1 
(Figure 5C; p<0.001) secretion, but not of TGF-p1 (Figure 5D). In addition, only 12.5 
HspB8 and HspB2B3 induced CD40 ligand production by astrocytes (Figure 5E; p<0.05 
and p<0.01 respectively). Comparable to the effects of Hsp27 in SMCs, IL-8 production by 
astrocytes was also increased after incubation with 12.5 ^M Hsp27 (Figure 5A; p<0.01), 
however, Hsp27 induced a decrease in the production of TGF-p1 (Figure 5D; p<0.001) 
and CD40 ligand (Figure 5E; p<0.01) compared to control. Furthermore, incubation with 
Hsp27 did not result in levels of sICAM-1 (Figure 5B) and MCP-1 (Figure 5C) above control 
levels in astrocytes.
To exclude LPS contamination, potentially present in the purified sHsp samples, 
we co-incubated cell samples with PMB and sHsps to inhibit potential LPS-mediated 
inflammation. After pre-incubation and co-incubation of LPS with PMB, production of 
inflammatory factors by SMCs and astrocytes returned to control levels (Figures 6A and 
6B; p<0.05), indicating that PMB efficiently inhibited the LPS-induced inflammatory 
reaction. Whereas 12.5 ^M aB-crystallin seemed to induce IL-8 secretion by SMCs and 
astrocytes, this effect was completely abolished by pre-incubation and co-incubation
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Fig 4: Production of inflammatory factors by human brain leptomeningeal smooth muscle cells (SMCs). 
Cultured SMCs were incubated with 12.5 pM D-AP40, Ap42, Ap40, Hsp27, Hsp20, HspB8, HspB2B3 or 
1 pg/ml LPS for 2 days at 37 °C. Supernatant was collected and IL-8 (A), sICAM-1 (B), MCP-1 (C) and 
TGF-pi (D) concentrations were measured using ELISA. Statistical analysis was performed using an 
independent sample t-test. The level o f significance o f the difference compared to control is indicated 
as follows: * p<0.05; ** p<0.01; *** p<0.001; p>0.05 is not indicated. Mean ± SEM are shown.
with PMB (Figures 6A and 6B; P<0.05), indicating that traces of LPS in the aB-crystallin 
preparations are responsible for the observed effects. In contrast, PMB had no, or only a 
minimal effect, on the production levels of IL-8 by SMCs and astrocytes induced by the 
other sHsps samples (Figures 6A and 6B), suggesting a strong inducing effect of these 
sHsps on cytokine production.
3.4 Discussion
The main findings of this study are: 1) Hsp20, HspB8 and HspB2 are associated with (cap) 
CAA and dyshoric angiopathy in AD brains with severe CAA pathology; 2) these sHsps 
colocalize with ICAM-1 in dyshoric angiopathy near (cap)CAA; 3) sHsps (especially Hsp20, 
HspB8 and HspB2B3), but not Ap, increased secretion of IL-8, sICAM-1 and MCP-1 by 
cultured human leptomeningeal SMCs and human brain astrocytes; 4) Hsp27 reduced 
secretion of TGF-pi by SMCs and astrocytes and CD40 ligand secretion by astrocytes.
The observed astrocytic and microglial activation, indicative of an inflammatory 
reaction, around (cap)CAA in this report is in line with earlier studies [11;223]. In addition, 
co-localization of Hsp20, HspB8 and HspB2, but not aB-crystallin and Hsp27, with (cap)
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CAA and dyshoric angiopathy near (cap)CAA is also in line with our previous studies in 
which co-localization of these sHsps was found with CAA and/or parenchymal deposits of 
Ap [[313;315;319]. It has been suggested that Hsp20, HspB8 and HspB2 are predominantly 
associated with fibrillar Ap in vivo [313;315;319] and our results suggest a similar 
association of these sHsps with fibrillar Ap in (cap)CAA and with dyshoric angiopathy near 
(cap)CAA. Thus, Hsp20, HspB8 and HspB2 are clearly associated with various types of Ap 
deposits in AD brains and may participate in the local inflammatory reaction.
Fig 5: Production of inflammatory factors by human brain astrocytes. Cultured astrocytes were incubated 
with 12.5 pM D-AP40, Ap42, Ap40, Hsp27, Hsp20, HspB8, HspB2B3 or 1 pg/ml LPS for 2 days at 37 °C. 
Supernatant was collected and IL-8 (A), sICAM-1 (B), MCP-1 (C), TGF-p1 (D) and CD40 ligand (E) 
concentrations were measured using ELISA. Statistical analysis was performed using an independent 
sample t-test. The level o f significance o f the difference compared to control is indicated as follows: * 
p<0.05; ** p<0.01; *** p<0.001; p>0.05 is not indicated. Mean ± SEM are shown..
CAA-related inflammation is of clinical importance since patients with this type 
of pathology present with cognitive decline, seizures and headaches, that improve 
upon anti-inflammatory treatment [45;79;136]. In addition, it has been suggested that 
especially capCAA with spreading of the Ap deposits into the neuropil could contribute 
to a rapid clinical deterioration [81], suggesting an important role of capCAA and dyshoric 
angiopathy, rather than plaques and CAA, in cognitive decline. In AD, Ap has been shown 
to trigger neuro-inflammation by e.g. activation of the complement system [111], and 
activation of microglia and astrocytes [111;266]. In addition, the pro-inflammatory factors 
IL-8, MCP-1 and CD40 ligand are increased in AD [3;30;252] and ICAM-1 and TGF-p1 co- 
localize with Ap deposits [301;324], suggesting that Ap may induce the expression of 
these inflammatory factors. In contrast, however, the results of the present study suggest 
that sHsps may be much more potent inducers of an inflammatory reaction in AD brains 
than Ap. Interestingly, the pro-inflammatory effect of these sHsps does not seem to be
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Fig 6: Production of IL-8 by human brain leptomeningeal smooth muscle cells (SMCs; A) and human brain 
astrocytes (B) after co-incubation with polymyxin B (PMB). Cultured cells were co-incubated with 1 
pg/ml LPS or 12.5 pM of the indicated sHsp with or w ithout 10 pg/ml PMB for 2 days at 37 °C. In these 
experiments, PMB was pre-incubated with both the LPS and the sHsps for 1 hour at 37 °C before 
addition to the cells. Supernatant was collected and IL-8 concentrations were measured using ELISA. 
PMB efficiently abolished the effects o f LPS and aB-crystallin on IL-8 production, but not o f the other 
sHsps. Statistical analysis was performed using an independent sample t-test. The level o f significance 
of the difference compared to control is indicated as follows: * p<0.05; p>0.05 is not indicated. Mean 
± SEM are shown.
limited to a single parameter such as IL-6 [313], but includes multiple inflammatory factors 
that are observed in vivo. We obtained in vivo evidence for the co-localization of sHsps 
near sites of Ap-associated inflammation in the cerebral vasculature and demonstrated 
in vitro that Hsp20, HspB8 and HspB2B3 induced production and secretion of IL-8, MCP-1 
and sICAM-1 in SMCs and astrocytes, with little or no effect of Hsp27 and no effect of aB- 
crystallin on these factors. These results are in line with, and extend, our previous findings 
that sHsps may be among the key mediators of the inflammatory reactions associated 
with (cap)CAA, since they also induced IL-6 production in cultured SMCs, astrocytes and 
microglia [313]. Interestingly, our results suggest that those sHsps that occur extracellularly 
in plaques or dyshoric angiopathy and (cap)CAA (i.e. Hsp20, HspB8 and HspB2B3) have a 
potent pro-inflammatory effect, indicating that especially these sHsps are important in 
the inflammatory reaction in CAA. Interestingly, HspB8 and HspB2B3 induced CD40 ligand 
expression in astrocytes, but not in SMCs, suggesting that the reported upregulation of 
CD40 ligand in AD [30;284] might be due to astrocytic production. In contrast to these 
findings, however, Hsp20, HspB8 and HspB2B3 did not induce production of TGF-P1 in 
both SMCs and astrocytes, although these factors are also reported to be upregulated 
in AD [30;284]. This suggests that this cytokine might be upregulated by alternative 
mechanisms or cell types.
Hsp27 is a member of the sHsp family with remarkable capacities compared to 
the other sHsps tested in this study. Hsp27 was able to induce IL-8 and inhibit TGF-P1 
production in both human SMCs and astrocytes in vitro. Furthermore, Hsp27 inhibited 
CD40 ligand production in astrocytes. Interestingly, IL-8 is a pro-inflammatory cytokine 
and TGF-P1 can act as an anti-inflammatory factor by inhibition of local inflammation 
resulting in reduced tissue injury that may occur as a response to inflammation [307]. 
Furthermore, the interaction of CD40 ligand with its receptor has been implicated in 
the modulation of anti-inflammatory responses [161]. Thus, Hsp27 may exert a pro- 
inflammatory effect, both through inducing a pro-inflammatory reaction (e.g. IL-8) and
59
reducing the production of the anti-inflammatory factors (e.g. CD40 ligand and TGF-P1) 
[161]. In addition, Hsp27 may also function as an indirect anti-apoptotic molecule [49] by 
inhibiting the pro-apoptotic proteins caspase-3 [259] and Bax [110]. Since both TGF-P1 
and CD40 ligand may be involved in apoptosis during inflammation [30;236], reduced 
TGFP1 and CD40 ligand levels induced by Hsp27 may add to the anti-apoptotic effect 
of Hsp27. Furthermore, in transgenic mice models for AD it has been demonstrated that 
TGF-P1 overexpression may lead to AP deposits in cerebral blood vessels and meningeal 
vessels [324]. Moreover, elevated levels of CD40 ligand may lead to endothelial dysfunction 
and atherothrombosis, whereas inhibition of CD40/CD40 ligand interaction may prevent 
atherogenesis in animal models [39;73;279;332]. Thus, since Hsp27 affects the expression 
of TGF-P1 and CD40 ligand, Hsp27 may create a pro-inflammatory environment, likely 
both by reducing the production of anti-inflammatory factors and inducing production 
of pro-inflammatory cytokines, inhibit apoptotic processes and may alter the vascular 
micro-environment. However, more study is required to elucidate the exact role of Hsp27 
in neuro-vascular inflammation in AD.
It has been suggested that AP itself can induce neuro-inflammation [111]. In our study, 
however, AP1-40, AP1-42, and D-AP1-40 had no effect on the production of inflammatory 
factors by SMCs and astrocytes. Previously, we also demonstrated that AP did not induce 
IL-6 production by cerebrovascular cells and astrocytes [313]. However, in the same study 
it was shown that AP slightly induced IL-6 production by microglia [313]. In addition, 
in another study dose-dependent increases of IL-8 and MCP-1 production by human 
brain microglia were observed after exposure to AP [166]. Taken together, these studies 
suggest that in the brain, microglial cells may be particularly susceptible to AP, resulting 
in an inflammatory reaction, but that other cerebral cell types, such as vascular cells and 
astrocytes, do not respond to AP in a pro-inflammatory way, but may be stimulated to do 
so by sHsps.
In conclusion, Hsp20, HspB8 and HspB2 are associated with (cap)CAA and dyshoric 
angiopathy in AD brains with severe CAA pathology. In addition, co-localization of these 
sHsps with ICAM-1 around AP-laden vessels was observed. Furthermore, we demonstrated 
that Hsp20, HspB8 and HspB2B3 induced the production of inflammatory factors in vitro, 
suggesting that these sHsps might be among the key mediators of the inflammatory 
reactions associated with (cap)CAA and dyshoric angiopathy. An interesting role for 
Hsp27 was found, since this sHsp seems to induce a pro-inflammatory effect by reducing 
the normal anti-inflammatory effect in human SMC and astrocytes in vitro. Furthermore, 
although it has been suggested that AP itself can induce inflammation [111], we did not 
observe such an effect in cultured SMCs and astrocytes. The results of this study provide 
new insights in the inflammatory reactions associated with AD and CAA and, therefore, 
might provide interesting new targets for therapeutic intervention in the pathogenesis 
of AD and CAA.
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Abstract
Cerebral amyloid angiopathy (CAA) is a common pathological finding in Alzheimer's 
Disease and hereditary cerebral hemorrhage with amyloidosis of the Dutch type; in this 
latter condition it is caused by deposition of mutated amyloid p protein (Ap Glu22Gln; 
D-Api-40). Previously, we found a dependence of the Ap-mediated toxicity and 
apolipoprotein E (apoE) production by cultured pericytes on apoE genotype. Given their 
close association with the cerebrovascular wall both astrocytes and pericytes may be 
involved in CAA development, a process that includes Ap deposition and clearance and that 
may be affected by interaction with locally produced apolipoprotein E (apoE). Although 
astrocytes are regarded as the major source of apolipoprotein E (apoE) in the brain, also 
pericytes produce apoE. In this study we compared the apoE production capacity, the 
effects of apoE on D-Api-40 internalization, D-Api-40 cell surface accumulation and the 
vulnerability for D-Api-40-induced toxicity of either cell type in order to quantify the 
relative contributions of astrocytes and pericytes in the various processes that contribute 
to CAA formation. Strikingly, cultured astrocytes produced only 3-10% of the apoE 
amounts produced by pericytes. Furthermore, pericytes with the apoE £4 allele produced 
three times less apoE and were more vulnerable to D-Api-40 treatment than pericytes 
without an £4 allele. Such relations were not observed with astrocytes in vitro. Both 
pericytes and astrocytes, however, were protected from Ap-induced cytotoxicity by high 
levels of pericyte-derived apoE, but not recombinant apoE. In addition, pericyte-derived 
apoE dose-dependently decreased both internalization of Ap and Ap accumulation at the 
cell surface in either cell type. The present data suggest that apoE produced by pericytes, 
rather than astrocyte-produced apoE, modulates Ap cytotoxicity and Ap removal near 
the vasculature in the brain. Furthermore, since apoE production in pericytes is genotype 
dependent, this may contribute to the apoE genotype-dependent development of CAA 
in vivo.
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4.1 Introduction
Two neuropathological lesions characteristic for Alzheimer's disease (AD) are cerebral 
amyloid angiopathy (CAA) and senile plaques (SPs) [237], consisting of the amyloid-p 
protein (Ap). CAA is the major pathological lesion in hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (HCHWA-D), caused by a Glu to Gln mutation at position 22 
of AP, which results in a highly toxic form of AP [286]. AP is toxic towards various cultured 
cerebral cells including neurons [177;207;311], astrocytes [25], cerebrovascular smooth 
muscle cells (SMCs) and human brain pericytes (HBPs) [60;221;296].
In AD, several macromolecules colocalize with SPs and CAA, including apolipoprotein 
E (apoE) [8;193;197]. ApoE is the main lipoprotein present in the brain and is involved in 
transport of plasma lipids [173]. The apoE gene exists as three alleles, apoE e2, e3 and e4. 
The e4 allele is a major genetic risk factor for AD: carrying one or two copies of this allele 
is associated with higher prevalence of AD [234;260].
The mechanism by which the different isoforms of apoE mediate AD pathology has not 
been elucidated and is subject to much controversy. In vitro studies have demonstrated 
that apoE binds to Ap and forms stable complexes in an isoform-specific manner [177;261]. 
Binding of Ap to apoE, especially the apoE4 isoform, has been linked to increased Ap 
aggregation or fibrillization, ultimately leading to plaque formation [33;170]. ApoE may 
also increase Ap clearance from the brain, probably via the receptors of the low density 
lipoprotein receptor (LDLR) family [143;212].
Previously, we demonstrated in cultured cerobrovascular cells (HBPs and SMCs; i.e. 
cells that are degenerating in CAA) that cells carrying two copies of the apoE e4 allele 
(apoE 4/4 cells) were more vulnerable to Ab-induced cytotoxicity than apoE 3/4 or 3/3 
cells [302;317]. We also demonstrated that apoE purified from conditioned medium 
inhibited Ap-mediated cell death of these cells in a concentration-dependent manner 
[317]. Recent studies in transgenic mice have shown that apoE levels decreased in the 
following order £2/2>e3/3>e4/4 [13;224]. These findings could suggest that the increased 
vulnerability to Ap-mediated cytotoxicity observed in apoE4 cells might result from lower 
apoE production by these cells, rather than from differences in biological activity of the 
different apoE isoforms.
Astrocytes are in close contact with the vasculature in the brain and are regarded as 
the major source of apoE [20;209]. In AD, astrocytes also colocalize with senile plaques 
and mouse astrocytes were shown to internalize and degrade Ap deposits, possibly via 
an apoE-dependent mechanism [143;323]. Recently, adult human astrocytes were also 
shown to bind and internalize AP in vitro [195]. Due to their proximity with the vasculature 
and their capacity to produce apoE, astrocytes, just like other perivascular cells such as 
pericytes, may be involved in CAA development, a process that includes AP deposition 
and clearance and that may be affected by interaction with locally produced apoE. 
Therefore, in this study we compared the apoE production capacity, the effects of apoE on 
D-AP1-40 internalization, D-AP1-40 cell surface accumulation and the vulnerability for 
D-AP1-40-induced toxicity of either cell type in order to quantify the relative contributions 
of astrocytes and pericytes in the various processes that contribute to CAA formation.
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4.2 Methods
4.2.1 Reagents
Ap with the "Dutch" mutation (22 Glu^Gln, D-Api-40, 96% pure) was purchased from 
Quality Controlled Biochemicals (QCB; Hopkinton, Massachusetts, USA). D-Api-40 was 
used as a model Ap peptide, because of its enhanced aggregation properties. It causes 
a robust and reproducible degeneration of both HBPs and SMCs in previous studies. In 
addition, this peptide causes CAA in HCHWA-D [58;296;317]. Ap40-1 peptide (99% pure) 
was obtained from American Peptide Company (Sunnyvale, CA, USA). Both Ap40-1 and 
D-Api-40 were dissolved in i,i,i,3,3,3-hexafluoro-2 propanol (HFIP) (Sigma), air-dried and 
dissolved in DMSO at a concentration of 5 mM.
Human recombinant apoE produced in baculovirus in Sf insect cells was obtained from 
Invitrogen (Carlsbad, CA). Affinity-purified polyclonal anti-Ap antibodies were prepared 
as described [59].
4.2.2 Cells
HBPs and astrocytes were both isolated from human brain tissue obtained from a 
number of AD patients and neurologically unaffected individuals at autopsy, as described 
previously [6i;295;299] (Table i). Diagnosis and grading of AD patients was performed 
according to the criteria established by Braak & Braak [22]. Cultures were divided into two 
different groups according to their apoE genotype: non-£4 and £4 apoE genotype. HBPs 
were maintained in Eagle's modification of essential medium (EMEM), supplemented with 
i0% human serum (Lonza BioWhittaker Benelux BV, Breda, the Netherlands), 20% fetal 
bovine serum (Lonza BioWhittaker Benelux BV, Breda, the Netherlands), recombinant 
basic fibroblast growth factor (i ng/ml) and gentamycin (2.5 ^g/ml). Astrocytes were 
maintained in a mixture ( i: i vol/vol) of Dulbecco's modification of essential medium 
(DMEM) and HAMs Fi0 supplemented with i0% fetal bovine serum, 2 mM L-glutamine 
(Cambrex, Workingham, UK) and gentamycin (2.5 ^g/ml). All primary cell cultures were 
cultured at 37°C, 5% CO2 and 90% relative humidity. Although the cultured astrocytes and 
HBPs were derived from different clinical backgrounds (i.e. either AD or control patients), 
we did not observe differences between cultures with the same apoE genotype, but 
with different clinical background, with respect to their responses in the various types of 
experiments.
4.2.3 ApoE genotyping
DNA was isolated from small pieces of brain tissue from which also cell cultures were 
derived using a DNA isolation kit (Biozym, Landgraaf, The Netherlands). ApoE genotype 
was determined using PCR and HhaI restriction analysis according to previously described 
methods [ii6 ;3 i0 ].
4.2.4 ApoE secretion and quantification
ApoE secretion by cultured HBPs and astrocytes was measured by culturing cells in 
duplicate wells with serum free medium (medium with 0.i % BSA and antibiotics). After
6 days, medium was removed and apoE secretion was quantified using a sandwich ELISA 
[3i7]. Denaturation of the protein complexes in the media prior to ELISA measurements 
had no effect on the measured apoE content. To correct for differences in cell density,
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apoE levels in medium were normalized to protein content of the cell lysate in the wells 
using a BCA Protein Assay kit according to the manufacturer's description (Thermo Fisher 
Scientific Inc., Rockford, USA).
4.2.5 Apolipoprotein E depletion from conditioned media
Conditioned media were obtained by incubating cells with serum free medium for 6 days. 
Cells remained viable during this incubation period. Medium was harvested, aliquoted 
and stored at -20 °C until use. ApoE concentration was determined by sandwich ELISA.
In order to deplete apoE from conditioned medium, goat-a-apoE antibody (Biodesign 
International, Saco, ME, USA; 1 mg/ml) was incubated with 10% Immobilized protein 
G plus slurry (Thermo Fisher Scientific Inc.) in 10 mM NaAc pH 5.0 in a ratio of 1:50 
(antibody:slurry) at 4 °C for 16 hours. Subsequently, protein G beads were washed 3 times 
with phosphate buffered saline (PBS) pH 7.4 and dissolved in PBS pH 7.4 to a 10% slurry 
until further use. After removal of the supernatant of the slurry, conditioned medium of 
HBP £3/ e3 cell cultures was added to the protein G beads at a ratio of 1:10 (slurry:medium) 
at 4 °C for 16 hours. Supernatant was collected and was used for second round of depletion. 
Depleted conditioned medium was harvested and apoE concentration was determined 
by sandwich ELISA.
4.2.6 Degeneration experiments
Duplicate wells with cultured cells were preincubated with serum free medium for a 
minimum of 4 hours. Subsequently, cells were incubated with either fresh serum free 
medium, supplemented with synthetic 12.5 ^M D-AP1-40 peptide and/or 1.6 ^g/ml 
recombinant apoE protein (Invitrogen, Carlsbad, CA), or with (depleted) conditioned 
medium, supplemented with synthetic D-AP1-40, for 6 days. Cells were routinely 
inspected and photographed using an Olympus phase-contrast microscope. Cell 
viability was quantitated using a fluorescence live/dead cell assay according to the 
manufacturer's description (Live/Dead viability/cytotoxicity kit for mammalian cells; 
Molecular Probes - Invitrogen). Using this assay,live cells are distinguished by the presence 
of ubiquitous intracellular esterase activity, determined by the enzymatic conversion 
of the nonfluorescent cell-permeant calcein AM to the fluorescent calcein. Ethidium 
homodimer-1 enters cells with damaged membranes and undergoes enhancement of 
fluorescence upon binding to nucleic acids. Ethidium homodimer-1 is excluded by the 
intact plasma membrane of live cells. Cell cultures were analyzed using a Leica fluorescence 
microscope and the percentage of cell death was determined from countings in at least 
four microscopic fields per well.
4.2.7 Quantitative immunofluorescence staining
A quantitative immunofluorescence staining assay using the Odyssey infrared 
imaging system was performed as described previously [78;317]. In short, cells (in 
triplicate wells) were cultured in coated 96-well plates for 1-2 days until confluence. 
Additionally, cells were incubated with serum free medium for at least 4 hours. Next, 
either serum free medium or (depleted) conditioned medium with or without 5 
D-Ap 1-40 was added to the cells. A lower concentration of D-Ap 1-40 was used to avoid the 
toxic effect that high concentrations of D-Ap1-40 elicit. Upon incubation for a maximum of 
24 hours at 37°C, cells were rinsed twice with PBS and fixed with 4% paraformaldehyde for 
20 minutes at room temperature (RT). Cells were then washed with either PBS (to quantify
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cell surface immunoreactivity only) or PBS containing 0.i%  Triton X-i00 (to quantify 
overall cellular immunoreactivity) and rinsed again before blocking with i50 ^l LI-COR 
Odyssey blocking buffer ( i: i in PBS; LI-COR, Bad Homburg, Germany) for 90 minutes at 
RT. Primary rabbit polyclonal antibody against Ap (40-4, a generous gift from Dr. W.E. Van 
Nostrand, Stony Brook University, NY) was diluted (i:2000) in Odyssey blocking buffer 
and cells were incubated with the diluted antibody (50 ^l/well) overnight at 4°C. Cells 
were repeatedly washed with PBS and PBS-0.05% Tween-20 (PBS-T) and incubated with 
secondary antibodies diluted in Odyssey blocking buffer at RT for i hour; i.e. IRDye 
800CW-labelled Goat anti-rabbit (i:400, Rockland Immunochemicals). Cells were again 
rinsed with PBS or PBS-T and analysis was performed using the Odyssey infrared imaging 
system (LI-COR). Internalization of D-Api-40 in cultures treated with conditioned medium 
was calculated as percentage of internalization in cultures incubated with D-Api-40 in 
normal (serum free) medium, which was set at i00 percent.
4.2.8 Immunofluorescence staining
Duplicate wells on 8-well chamber slides (Nunc GmbH & Co. KG, Wiesbaden, Germany) 
with cultured cells were incubated with i2.5 ^M D-Api-40, either with or without 
recombinant apoE or (depleted) conditioned medium for 3 days. Cells were washed twice 
with PBS and then fixed with periodate-lysine-paraformaldehyde for i0  minutes. HBPs 
and astrocyte preparations were incubated with rabbit polyclonal anti-Ap antibody (40­
4; i:200). Subsequently, cells were simultaneously incubated with donkey-anti-rabbit 
Alexa 568 (Invitrogen Carlsbad, CA) and Topro-3 for nuclear staining (Vector) for i hour. 
Antibodies were diluted in PBS/0.i% BSA, which also served as a negative control. After 
each incubation, slides were extensively washed with PBS. Immunofluorescence staining 
was analyzed using a confocal-laser-scanning microscope (Leica, Wetzlar, Germany).
4.2.9 Western blot analysis
The presence of D-Api-40 in medium after incubation at the cells with or without 
apoE were evaluated by gel electrophoresis and Western blot. Ap samples containing i 
^g of protein, were diluted with sample buffer (25% (w/v) glycerol, 2% (w/v) SDS, 62.5 
mM Tris-HCl, pH 6.8 and 0.005% w/v Coomassie Brilliant Blue) and were separated by 
electrophoresis on a 4-20% Tris-Hepes precise protein gel (Thermo Fisher Scientific Inc.). 
Samples were not boiled to minimize disaggregation prior to electrophoresis. To facilitate 
the identification of proteins a Low-Range Rainbow prestained protein standard (GE 
Healthcare) and a precision plus prestained protein standard (Biorad) was used. Proteins 
were then transferred to PVDF membranes, which were subsequently blocked for i h at 
RT with LI-COR Odyssey blocking buffer ( i: i in PBS; LI-COR). The membranes were then 
incubated overnight at 4 °C with NAB228 (Sigma) mouse monoclonal primary antibody 
against Ap diluted (i:2000) in LI-COR Odyssey blocking buffer ( i: i in PBS; LI-COR). After 
washing with PBS-T, membranes were further incubated for i h at RT with goat-anti- 
mouse Alexa 680 (Invitrogen Carlsbad, CA). Immunofluorescent staining was analyzed 
using the Odyssey infrared imaging system (LI-COR).
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4.2.10 Statistical analysis
When analyzing more than 2 groups with each other, statistical analyses were performed 
using ANOVA with Bonferroni's post hoc analyses for multiple comparisons using SPSS 
14.0 for Windows (SPSS Inc., Chicago, Illinois USA). In addition, when analyzing only 2 
groups with each other, statistical analyses were performed using an independent sample 
t-test in SPSS 14.0.
4.3 Results
4.3.1 Effect of apoE genotype on Ab-mediated cell death
Using cultured HBPs and human astrocytes, we studied whether vulnerability to 
D-Api-40-mediated cell death could be related to the apoE genotype of these cells. Visual 
examination showed clear degeneration and cellular atrophy of both HBPs and astrocytes 
after 6 days of incubation with 12.5 ^M D-Api-40 (data not shown). A significant 
difference was observed in cell vulnerability between HBPs cultures with the non-£4 apoE 
genotype (25% cell death) and £4 apoE genotype (44% cell death; p<0.001; Figure 1A). No 
significant difference was observed in cell vulnerability between astrocyte cultures with 
the non-£4 apoE (42 % cell death) and £4 apoE genotype (40% cell death; p>0.05; Figure 
1B). Incubation with 25 ^M of the inverted sequence AP40-1 had no effect on cell death of 
HBPs [314;318] and astrocytes (data not shown), compared to control incubations.
Fig 1: Effects o f apoE genotype on the toxic effects of 12.5 pM D-Api-40 in HBPs and human astrocyte 
cultures. Cultured HBPs with non-£4 apoE genotype (n=6) demonstrated less cell death than £4 apoE 
genotype (n=5) cells after treatment with D- Api-40 for 6 days (A). Cultured astrocytes with non-£4 
apoE genotype (n=7) showed no difference compared to astrocytes with the apoE £4 genotype (n=4) 
after treatment with D- Api-40 for 6 days (B). Significance o f the observed difference (ANOVA with 
Bonferroni's post hoc test for multiple comparisons): ***, p<0.001. Mean +/- SD is shown; experiments 
were performed in duplicate.
4.3.2 ApoE production
We analyzed apoE production in HBPs and human astrocyte cultures with non-£4 apoE and 
£4 apoE genotypes. A significant difference was observed in apoE production between 
HBPs cultures with non-£4 apoE genotype (3.1 ng/^g protein/day) and apoE £4 genotypes 
(0.8 ng/pg protein/day; p<0.001; Figure 2A). A, much lower, mean production level of 0.08
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ng/pg protein/day was observed in astrocyte cultures. Furthermore, apoE production by 
astrocytes was not dependent on apoE genotype (p>0.05 for non-£4 apoE vs. £4 apoE; 
Figure 2B).
Fig 2: Quantification of apoE secretion by HBPs and human astrocytes in culture with non-£4 and £4 apoE 
genotypes by ELISA. Production of apoE by HBPs with non-£4 apoE genotype (n=6) was significantly 
higher compared to HBPs with £4 apoE genotype (n=5; A). Production of astrocytes with non-£4 and 
£4 apoE genotypes was comparable (B). Significance of the observed difference (ANOVA with 
Bonferroni's post hoc test for m ultiple comparisons): ***, p<0.001. Mean +/- SD is shown; experiments 
were performed in duplicate.
4.3.3 Effect of extracellular apoE on Ap-mediated cell death
We studied if the high susceptibility towards Ap-mediated cell death of human astrocyte 
cultures of different apoE genotypes was related to their low apoE production levels. We 
applied high concentrations of apoE to astrocyte cell cultures with apoE £3/£3 genotype 
(derived from AD and non-AD patients) to test if increasing the apoE concentration leads 
to a lower cellular vulnerability towards Ap. The addition of any of the three (£2, £3 or 
£4) recombinant apoE isoforms (1.6 pg/ml) produced by baculovirus in Sf insect cells had 
no significant effect on D-Api-40 induced cell death of cultured astrocytes. Exposure of 
astrocytes to recombinant apoE alone did not affect cell viability (data not shown). Cells 
derived from an AD or non-AD background responded similarly.
It is known, however, that semi-purified apoE, derived from conditioned medium, 
inhibited D-Api-40-induced cytotoxicity in HBP cultures [317]. Therefore, we studied 
the effect of apoE-containing conditioned medium on Ap-mediated cytotoxicity in 
astrocytes. Since purification of apoE from conditioned medium usually results in a low 
yield, conditioned medium from HBP £3/£3 cultures, containing 820 ng apoE/ml, was 
added to the cell cultures in order to investigate if HBP-derived apoE could counteract the 
toxic effects of Ap on the HBPs (n=2 cultures) and astrocyte cultures (n=4 cultures). Both 
cell types were of apoE £3/£3 genotype and were derived from AD and non-AD patients. 
To examine if possible effects could solely be attributed to apoE, conditioned medium, 
of which 95% of the apoE content was depleted, was applied to the cells as a control. 
Incubation of cells with (depleted) conditioned medium alone resulted in a degree of 
cell death comparable to control situation, for both HBPs and astrocytes (Figure 3 A, 
B). Conditioned medium reduced cell death from 30.9% to 3.6% (p<0.001) in HBPs and 
from 47.7% to 3.2% (p<0.001) in astrocyte cultures, whereas apoE-depleted conditioned
68
A p o lip op rotein  E p ro te cts  cu ltu red  p ericy te s  and  a s tro cy te s  from  D -A p-40 m ed iated  cell d e a th
medium had a partial effect, reducing Ap-mediated cell death to 10.5% (p<0.001) in HBPs 
and 15.7% (p<0.001) in astrocytes (Figure 3). Thus, depletion of apoE from conditioned 
medium significantly increased the vulnerability to D-AP1-40 in both HBPs (10.5% vs. 3.6% 
cell death; p<0.01) and in astrocytes (15.7% to 3.2% cell death, p<0.001) compared to 
conditioned medium.
¡Amount of apoE I - I + I I - + 1  I lAm ountof apoE I - I + I +++ I - I + I +++
Fig 3: Effects o f addition of conditioned medium (CM) obtained from HBPs (apoE £3/£3 genotype) or CM 
after depletion of apoE on cell death of HBPs (n=2; apoE £3/ e3 genotype) and human astrocytes (n=4; 
apoE £3/£3 genotype). Co-incubation with CM (+++, 820 ng apoE/ml) reduced D-Api-40-mediated 
cell death in HBPs (A) and in astrocytes (B) compared to incubation with D-Api-40 alone (both 
p<0.001). A partial, but still significant, effect (both p<0.001) was observed with apoE depleted CM (+,
40 ng apoE/ml). Depletion o f apoE from conditioned medium significantly increased the vulnerability 
to D-Api-40 in both HBPs (A, **, p<0.01) and in astrocytes (B, ***, p<0.001) compared to conditioned 
medium. Mean +/- SD is shown; experiments were performed in duplicate; -, 0 ng apoE/ml.
4.3.4 Ap accumulation at the cell surface
Cell surface accumulation of Ap has been reported to be the cytotoxic event in Ap-mediated 
cell death [220;293;296;318]. We therefore analyzed if the observed protective effects of 
conditioned medium on cell death could be explained by an effect on accumulation of the 
D-Api-40 peptide at the cell surface. Cell surface accumulation of Ap, as quantified by 
fluorescence, was completely abolished in both HBPs (p<0.05) and astrocytes (p<0.05; 
both cell types of apoE £3/£3 genotype; cells derived from an AD or non-AD background 
responded similarly) when D-Api-40 was administered together with conditioned 
medium from HBP £3/£3 cultures. D-Api-40 in combination with depleted conditioned 
medium resulted in a comparable Ap accumulation at the cell surface of both HBPs and 
astrocytes compared to control, which was set at i00% (Figure 4 A and B).
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Fig 4: Ap accumulation at the cell surface (A and B) and Ap internalization (C and D) of HBPs and human 
astrocytes cultures. HBPs (n=2; apoE £3/£3 genotype) and astrocytes (n=2; apoE £3/£3 genotype) 
were incubated with conditioned media obtained from HBP £3/e3 cultures before or after depletion 
of apoE and 5 pM D-Api-40 for 24 hours at 37 °C; experiments were performed in triplicate. Ap 
immunoreactivity was analyzed, as described in Methods. HBP £3/£3 conditioned medium (+++, 820 
ng/ml) decreased Ap accumulation at the cell surface with 100% in both HBP (A, *, p<0.05) and 
astrocyte cultures (B, *, p<0.05) compared to control (-, 0 ng apoE/ml). Incubation of Ap with depleted 
conditioned medium (+, 40 ng apoE/ml) resulted in a comparable Ap accumulation at the cell surface 
of both HBPs and astrocytes compared to control. Cell surface immunoreactivity was subtracted from 
overall immunoreactivity resulting in the percentage of Ap that is internalized. HBP conditioned 
medium (+++, 820 ng apoE/ml) inhibited D-Api-40 internalization in HBPs (C, #, p=0.09) and in 
astrocytes (D, *, p<0.05) relative to control (-, 0 ng apoE/ml), whereas this effect was partially restored 
by conditioned media after apoE depletion (+, 40 ng apoE/ml.
We confirmed these observations by confocal laser scanning microscopy. Incubation 
of cultured HBPs and astrocytes with D-Api-40 resulted in Ap accumulation at the cell 
surface (Figure 5 A, B and G, H). The degree of cell-surface accumulation was relative to 
the amount of HBP-derived apoE present in the culture medium. After co-incubation 
with conditioned medium far less D-Api-40 accumulated at the cell surface (Figure 5 C, 
D and I, J) than after co-incubation with depleted conditioned medium. Under the latter 
conditions, the cell surface area covered by immunoreactive Ap almost returned to levels 
achieved with D-Api-40 alone (Figure 5 E, F and K, L).
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Fig 5: Confocal laser scanning microscopy analysis of Ap at the surface of cultured HBPs (left; n=2; apoE £3/ 
£3 genotype) and human astrocytes (right; n=2; apoE £3/£3 genotype). Cells were incubated with 
12.5 |j M D-Api-40 (A, B, and G, H; B and H are cross sections) and co-incubated with HBP £3/£3 
conditioned media (C,D and I and J), or HBP £3/£3 conditioned media after apoE depletion (E,F and K, 
L) for 3 days. HBP £3/£3 conditioned medium decreased immunoreactivity of Ap compared to 
control, whereas conditioned medium after apoE depletion showed a partial reduction. 
Immunofluorescence staining of Ap (40-4, polyclonal, red). Magnification x 630. Nuclei are 
counterstained blue; experiments were performed in duplicate.
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4.3.5 Effect of apoE on Ab internalization
In addition to cell surface accumulation of Ap, we also analyzed if the observed 
protective effects of conditioned medium on cell death could be explained by an effect 
on internalization of the D-Api-40 peptide. Conditioned medium, containing 820 ng/ 
ml of apoE, showed a (near) significant decrease in D-Api-40 internalization in HBPs 
(p=0.09) and in astrocytes (p<0.05) compared to control, which was set at 100%. Depleted 
conditioned media, of which 95% of its apoE content is removed, decreased D-Api-40 
internalization only partially in HBPs and astrocytes compared to control (Figure 4 C and 
D). However, this decrease was not significant. In addition, it should be noted that the 
internalized fraction comprises only 2% of the total Ap accumulation at the cell surface.
4.3.6 Effect of apoE on aggregation state of Ap
We also analysed the presence of D-Api-40 in the supernatant of cells that were incubated 
with fresh medium or (depleted) conditioned media for 3 days by using Western blot 
analysis (Figure 6). These studies confirmed the above-described findings, since after 
incubation of the cells with D-Api-40 in medium containing either no apoE (i.e. fresh 
medium) or very low concentrations of apoE (i.e. depleted conditioned medium), little 
D-Api-40 with high molecular weight (75-250 kDa) was observed in the supernatant. In 
contrast, after co-incubation of the cells with D-Api-40 and conditioned medium (with 
high concentrations of apoE), both low molecular weight forms (4.5, i3,5 and i8 kDa) of 
D-Api-40 and high-molecular weight forms (75-250 kDa) of D-Api-40 were detected on 
Western blot (Figure 6).
In summary, these results suggest that high concentrations of apoE reduce Ap-mediated 
cell death by keeping Ap in a soluble form, thereby decreasing both accumulation of Ap 
at the cell surface and internalization of Ap by HBPs and astrocyte cultures.
4.4 Discussion
Since the first reports on the association of the apoE e4 allele with AD emerged, research 
has focused on unravelling the mechanism by which the different alleles and isoforms of 
apoE affect AD pathogenesis. Untill now, reports emphasized the differences in biological 
activity of the different apoE isoforms, such as Ap binding capability and subsequent 
promotion or inhibition of Ap aggregation, deposition and clearance [33;i43;i70;2i2;280]. 
Previously, we demonstrated that HBPs carrying two copies of the apoE e4 allele were 
more vulnerable to Ap-mediated cell death than HBPs carrying two copies of the apoE £3 
allele [302;3i7]. Recent studies in transgenic mice demonstrated apoE isoform-dependent 
effects on apoE levels, i.e. £2/2>£3/3>£4/4 [i3;224]. This could suggest that the increased 
vulnerability to Ap-mediated cytotoxicity observed in apoE £4 HBPs might result from 
lower apoE production by these cells, rather than from differences in biological activity of 
the different apoE isoforms. Thus, apoE production by HBPs near the vasculature might be 
relevant to the development of AD and CAA.
Astrocytes are in close contact with the vasculature in the brain and are regarded as 
the major source of apoE [20;209]. We therefore hypothesized that astrocytes, together 
with HBPs, may modulate the toxicity and removal of Ap at the cerebral vasculature. The 
major findings of this report are: i) Although HBPs with the apoE £4 allele produced three
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Fig 6: Western blot analysis of Ap after incubation with fresh or (depleted) conditioned medium at the cells 
for 3 days. Samples were subjected to a 4-20% Tris-Hepes precise protein gel (Thermo Fisher Scientific 
Inc.). Proteins were immunoblotted with an anti-Ap monoclonal antibody (NAB228; Sigma) and 
immunopositive bands were visualized by fluorescence. Lane i, incubation with D-Api-40 in fresh 
medium for 3 days ; Lane 2, incubation with D-Api-40 in conditioned medium for 3 days; lane 3, 
incubation with D-Api-40 in conditioned medium after apoE-depletion for 3 days.
times less apoE than HBPs without an £4 allele, the apoE production by astrocytes was not 
apoE genotype dependent. Furthermore, cultured astrocytes produced only 3-i0% of the 
apoE amounts produced by pericytes; 2) HBPs with the apoE £4 allele were more vulnerable 
to D-Api-40 treatment than HBPs without an £4 allele. Such a relation was not observed 
with astrocytes in vitro; 3) ApoE, derived from HBP £3/3 cultures, but not recombinant apoE, 
reduces Ap-mediated cell death of both cell types; 4) Ap accumulation at the cell surface 
of both astrocytes and HBPs depends on extracellular levels of apoE; 5) ApoE inhibits the 
interaction (and thus internalization) of Ap with cultured HBPs and astrocytes by keeping 
Ap in a soluble form.
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Surprisingly, in vitro apoE production by astrocytes was roughly tenfold lower than 
by HBPs (0.08 vs. 0.8-3.1 ng/pg protein/day). This is in apparent contradiction with earlier 
studies suggesting astrocytes as the main source of apoE in the brain [20;209]. However, 
astrocytes are a much more abundant cell type in the brain than HBPs, so their contribution 
to the entire local"apoE pool" might still be the largest. Furthermore, it cannot be excluded 
that the in vitro production of apoE does not perfectly reflect the natural situation, due 
to the absence of factors secreted by adjacent cells that may regulate apoE expression 
[65;106]. In addition, recent studies demonstrated that in vivo only a subpopulation of 
astrocytes express apoE, which may not be represented in cultures [326].
In this study we observed a correlation in HBPs between apoE production levels and 
the cellular susceptibility towards Ap-mediated cell degeneration. We also observed 
that astrocytes, although with different apoE genotype, produced similar low levels of 
apoE and the vulnerability of astrocyte cultures with different apoE genotype towards 
Ap-mediated cell death was comparable. Thus, in astrocytes, a clear correlation between 
apoE production and vulnerability to Ap does not exist. Interestingly, however, both 
astrocytes and HBPs were protected from Ap-induced cytotoxicity by HBP-derived 
apoE in a concentration-dependent manner. These results suggest that apoE levels, 
rather than apoE isoform, are important in Ap-mediated cytotoxicity [317]. A recently 
published study [224] describing that apoE levels in transgenic mice decreased in the 
following order £2/2>£3/3>£4/4, supports our data found in HBPs that apoE production is 
genotype dependent. The described differences in apoE levels were due to an enhanced 
degradation and reduced half-life of newly synthesized apoE4 compared to apoE3, 
mirroring the relative risk in developing AD. In addition, in another study a decrease 
of apoE levels in brain homogenates of apoE £4 transgenic mice was observed. It was 
suggested that post-translational mechanisms influence the levels of apoE in brain 
(£4/4<£3/3<<£2/2), resulting in apoE isoform-dependent effects on brain Ap levels (i.e. 
mice with the apoE £4/4 genotype showed more Ap deposition than mice with the apoE 
£3/3 genotype and apoE £2/2 genotype), suggesting a loss of protective capacity [13]. 
Furthermore, in another study it was stated that probucol, a cholesterol lowering drug 
that has been reported to stabilise cognitive symptoms in AD patients, increases apoE 
production in the hippocampus of aged rats [40]. Thus, these beneficial effects may also 
be explained by a reduction in Ap-cytotoxicity. In addition, reduction of apoE levels in the 
hippocampus of AD subjects proportional to the number of apoE £4 allele(s) has been 
reported [17]. Hence, individuals carrying either the apoE 3/4 or 4/4 genotype may have 
lower hippocampal levels of apoE than non-£4 carriers, which may thus contribute to 
enhanced vulnerability to Ap-cytotoxicity. Thus, genotype dependent differences in apoE 
levels seem to be important in the development of AD.
Accumulation of Ap at the cell surface has been reported as a key event in Ap- 
mediated cell degeneration [220;293;296;318]. Our present data are in line with these 
findings, since increasing the extracellular concentration of apoE decreases Ap cell surface 
accumulation, Ap-mediated cell death and Ap internalization in astrocytes and HBPs. It 
has been suggested that high apoE levels may be essential in clearance of Ab across the 
blood-brain barrier (BBB) via a member of the LDLR family, probably the LDLR-related 
protein (LRP-1 protein) [245;280;317;338]. Binding of Ap to apoE is thought to facilitate 
the uptake by LRP-1. It has also been suggested that at relatively high concentrations 
of Ap the cell's clearance machinery has insufficient capacity to remove Ap, and that Ap 
bound to LRP-1 may serve as an anchor for Ap accumulation at the cell surface [318].
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We now suggest that apoE may influence Ap-mediated degeneration of both HBPs and 
astrocytes in a concentration-dependent manner, possibly by preventing the formation 
of cell-surface bound aggregates and thereby keeping Ap soluble. In an earlier study it 
was found that apoE enhances soluble, but not aggregated, Api-40 uptake by LRP-i into 
synaptic terminals [i02]. However, we observed no increase of internalization of D-Api-40 
when coincubated with apoE. So, in our cell cultures, apoE may compete with D-Api-40 
for the binding to LRP-i (or another receptor), thereby decreasing both internalization of 
Ap by HBPs or astrocytes and its cell surface retention.
Studies in rodents indicated that astrocytes locally overexpress insulin-degrading 
enzyme [i53] and matrix metalloproteinases [33i] as a response to Ap. These enzymes 
contribute to the extracellular degradation of Ap, suggesting that astrocytes may also 
clear Ap by proteolytic degradation. Furthermore, in a recently published study it was 
shown that extracellular proteolytic degradation of soluble Ap is enhanced by increasing 
apoE levels [i29]. This could provide an additional explanation for the lower amounts of 
Ap at the cell surface, as well as the reduced levels of internalized Ap and Ap-mediated cell 
death of astrocytes, with increasing amounts of extracellular apoE.
Some limitations apply to our study, however. i) It should be noted, that the restoring 
effects of apoE-depleted medium were not complete when compared to incubation of 
the cells with Ap alone. This might suggest that other factors, e.g. growth factors [i80], Ap- 
degrading enzymes [i53;33i] or phospholipid complexes independently of apoE itself
[83] in the conditioned media may contribute to the protection of the cells against Ap- 
mediated cell death. 2) We cannot exclude that apoE has another effect on wild-type Ap40 
or Ap42 cytotoxicity, accumulation and clearance. 3) We observed remarkable differences 
in the effects of recombinant apoE vs. apoE produced by HBPs, which is in line with 
previous data [3i7]. However, several studies have shown that recombinant apoE could 
protect cells against Ap-mediated cytotoxicity [89;i90]. Interestingly, in another study it 
was shown that recombinant apoE solely protects against the toxicity of non-fibrillar wild­
type Ap, but not of fibrillar wild-type Ap [74]. This could explain the lack of protection 
of recombinant apoE in our experiment, since D-Api-40 is very prone to aggregation. 
In addition, the functional difference between apoE from either human or insect cell 
source is likely due to a different degree of lipidation of the protein [206]. It is, therefore, 
also possible that apoE produced by astrocytes has a different degree of lipidation and, 
consequently, biological activity, than apoE produced by HBPs [66;67;i55]. Future studies 
will have to reveal whether such a potentially cell-specific apoE lipidation can influence 
its interaction with Ap.
In conclusion, our present findings suggest that apoE has an important role in 
determining the degree of cellular Ap-toxicity. In both HBPs and astrocytes, high levels 
of extracellular apoE reduce Ap cell surface accumulation, Ap internalization and Ap 
cytotoxicity. This process might be relevant in clearance of Ap across the BBB and the 
development of CAA. However, cultured astrocytes produced only 3-i0% of the apoE 
amounts produced by pericytes. Furthermore, pericytes with the apoE £4 allele produced 
three times less apoE and were more vulnerable to D-Api-40 treatment than pericytes 
without an £4 allele. Such relations were not observed with astrocytes in vitro.The present 
data suggest that apoE produced by pericytes, rather than astrocyte-produced apoE, 
regulates Ap cytotoxicity and Ap removal near the vasculature in the brain. Furthermore, 
since apoE production in pericytes is genotype dependent, this may contribute to the 
apoE genotype-dependent development of CAA in vivo.
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Abstract
Alzheimer's disease (AD) is characterized by pathological lesions such as amyloid-p 
plaques and cerebral amyloid angiopathy. Both these lesions consist mainly of aggregated 
amyloid-p (Ap) protein and this aggregation is affected by macromolecules such as 
heparan sulfate (HS) proteoglycans. Previous studies demonstrated that HS enhances 
fibrillogenesis of Ap and that this enhancement is dependent on the degree of sulfation 
of HS. In addition, it has been reported that these sulfation epitopes do not occur 
randomly but have a defined tissue distribution. Until now, the distribution of sulfation 
epitopes of HS has not yet been studied in human brain. We investigated whether a 
specific HS epitope is associated with Ap plaques by performing immunohistochemistry 
on occipital neocortical and hippocampal tissue sections from AD patients using five HS 
epitope-specific phage display antibodies. Antibodies recognizing highly N-sulfated HS 
demonstrated the highest level of staining in both fibrillar Ap plaques and non-fibrillar 
Ap plaques, whereas antibodies recognizing HS regions with a lower degree of N-sulfate 
modifications were only immunoreactive with fibrillar Ap plaques. Thus, our results 
suggest that a larger variety of HS epitopes is associated with fibrillar Ap plaques, but 
the HS epitopes associated with non-fibrillar Ap plaques seem to be more restricted, 
selectively consisting of highly N-sulfated epitopes.
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5.1 Introduction
Aggregation of the amyloid-p protein (Ap) can be affected by many macromolecules, such 
as heat shock proteins [319], complement factors [183], apolipoprotein E (ApoE) [261] and 
proteoglycans [250]. Proteoglycans consist of a protein backbone to which one or more 
linear polysaccharides or glycosaminoglycan (GAG) chains are covalently linked [107]. 
The GAG chains consist of repeating disaccharide units which are often sulfated [123]. 
Seven major GAGs have been identified, amongst which heparan sulfate (HS). It has been 
demonstrated that HS is a potent enhancers of Ap fibril formation and stabilize Ap fibrils 
once formed [36;186]. Furthermore, this enhancement of fibril formation depends on the 
degree of sulfation of the HS [35].
We previously demonstrated that HS is found in all Ap plaques and in CAA in AD 
patients [287;288;298], suggesting a common role for HS in AD pathology. HS is mainly 
composed of repeating disaccharide units of glucuronic acid (GlcUA) and N-acetyl 
glucosamine (GlcNAc) and can have various biosynthetic modifications [37;80]. Some 
GlcNAc residues are N-deacetylated and subsequently N-sulfated (GlcNS), and this step 
serves as a trigger for further modifications such as epimerization of GlcUA to iduronic 
acid (IdoUA), 2-O-sulfation of either GlcUA or IdoUA, and 6-O-sulfation or 3-O-sulfation 
of GlcNS. The 3-O-sulfation of GlcNS is a rare modification of HS [103]. These biosynthetic 
modifications occur in specific regions of HS, leading to highly modified epitopes (N- 
and O-sulfate rich) interspaced by less modified regions [139;230]. All these different 
modifications of HS suggest a large structural diversity of HS, which was confirmed by 
chemical analysis of HS-derived disaccharides [169;171]. Previous research has shown that 
these different HS epitopes do not occur randomly, but have a defined distribution within 
a tissue as shown by immunohistochemistry and are tightly, topologically regulated [69]. 
This suggests that the arrangement of sulfate groups in HS is important for its interaction 
with other molecules. Since Ap fibril formation is enhanced by HS, and depends on the 
degree of sulfation of the GAG [35], it is possible that a specific sulfation pattern of HS is 
involved in the formation of Ap plaques.
To determine such an involvement, we have used unique HS epitope-specific 
phage display antibodies, which all recognize a specific degree of sulfation [69], in 
immunohistochemistry of AD brains. We studied the distribution of specific sulfation 
epitopes in both cerebral cortex and hippocampus, since both fibrillar Ap plaques and non- 
fibrillar Ap plaques are abundantly present throughout these brain areas. Understanding 
the role of (sulfated) HS in the pathogenesis of AD may provide new perspectives to 
develop therapies against this disease.
5.2 Methods
5.2.1 Autopsy material
Tissue samples from the occipital neocortex and hippocampus from 11 AD patients 
(age 76.5 ± 10.1 years; post mortem delay 4.5 ± 2.2 hours ) and 3 control cases without 
neurological disease (age 81.3 +/- 10.5 years; post mortem delay 5.0 +/- 1.7 hours) were 
obtained after rapid autopsy and immediately frozen in liquid nitrogen. Informed consent 
was obtained according to European guidelines. Table 1 provides an overview of the 
diagnosis, Braak stage, CERAD score, CAA grade, age, post mortem interval (PMI) and
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gender. Diagnosis and grading of AD patients and control cases were performed by a 
neuropathologist using antibodies 4G8 (Covance) and AT8 (Innogenetics) according to 
the criteria established by Braak & Braak and CERAD [22;189]. In addition, CAA grading 
was determined as described previously [319]. No significant differences were observed 
between the AD group and control group with respect to age and PMI.
Table 1: Overview of patients included in this study
Patient
number
Diagnosis Age PMI
(hours)
Gender NFT
stage
(Braak)
Plaque
score
(CERAD)
CAA
Grade
1 Alzheimer 83 5 Female VI B +++
2 Alzheimer 89 4 Female VI C ++
3 Alzheimer 67 7 Male VI C ++
4 Alzheimer 63 3 Female VI C ++
S Alzheimer 89 3 Female VI C ++
6 Alzheimer 85 4 Female VI B ++
7 Alzheimer 65 4 Female VI C +
8 Alzheimer 76 3 Female VI C ++
9 Alzheimer 65 10 Male VI C +
10 Alzheimer 75 2.5 Female VI C ++
11 Alzheimer 84 4 Female VI C +++
12 Control 81 3 Male I 0 -
13 Control 71 6 Female III C -
14 Control 92 6 Female III A +
PMI = post mortem interval. Grading of the Braak stage, CERAD score and CAA grade is described in materials 
and methods.
5.2.2 Phage display derived heparan sulfate epitope-specific antibodies
Antibodies against GAGs have been generated using a library of phage display derived 
single chain variable fragment antibodies as described previously [291;292] and contain 
a polyhistidine and VSV tag for detection [283]. Five HS epitope-specific antibodies were 
used in the present study; antibodies HS4E4, EV3C3, RB4EA12, A04B08 and HS4C3, each 
recognizing a different repertoire of HS modifications [69;150;246;270;312], although the 
exact epitope sequence that is recognized is currently not exactly known (Table 2).
5.2.3 Immunohistochemistry
In Table 3 the primary antibodies used in this study are listed. Phage display antibodies 
were detected by monoclonal mouse anti-VSV (P5D4; Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands) or polyclonal rabbit anti-VSV (MBL, Wobum, MA, USA). We 
used biotin-labeled horse anti-mouse antibodies (Vector Laboratories, Burlingame, CA, 
USA) as the detection antibody for mouse monoclonal antibodies, or goat-anti-rabbit 
antibodies (Vector) in case of rabbit polyclonal antibodies.
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Table 2 : Epitope specificity of anti-HS phage display antibodies
Antibody CDR3
sequence
Vh family DP number Modifications 
involved in 
binding
Modifications 
which may 
reduce 
binding
HS4C3a GRRLKD 3 38 N-sulfation
2-O-sulfation 
6-O-sulfation
3-O-sulfation
AO4B08b SLRMNGWRAHQ 3 47 N-sulfation
C5-epimerization
2-O-sulfation
6-O-sulfation
(high)
EV3C3c GYRPFR 3 42 N-sulfation
C5-epimerization
2-O-sulfation
6-O-sulfation
(possibly)
6-O-sulfation
(possibly)
HS4E4d HAPLRNTRTNT 3 38 N-sulfation
N-acetylation
C5-epimerization
2-O-sulfation
6-O-sulfation
2-O-sulfation
6-O-sulfation
RB4EA12e RRYALDY 3 32 N-sulfation
N-acetylation
6-O-sulfation
Amino acid sequence of the Vh complementary determining region 3, CDR3 sequence; Vh germ line gene 
family; donor patient number, DP number; and relevant modification reactions required for antibody binding 
are listed.
a [270], b Antibody AO4B08 requires an internal 2-O-sulfated iduronic acid residue [150], c unpublished data, 
d Antibody HS4E4 possibly requires as yet unspecified O-sulfated residues [150], e [312].
In case of phage display antibodies, serial cryo-sections (4 pm) were air-dried and fixed in 
4% paraformaldehyde diluted in PBS for 10 minutes. PBS containing 1% H2O2 was used for 
15 minutes to block endogenous peroxidase activity. At regular intervals, sections were 
stained with anti-Ap to allow for topographical alignment of Ap plaques with the phage 
display antibody staining. For anti-Ap staining, sections were air-dried and fixed in acetone 
for 5 minutes and endogenous peroxidase activity was blocked using acetone containing 
0.15% H2O2 for 5 minutes. Sections were pre-incubated for 30 minutes with 20% animal 
serum, the type of which was determined by the specific biotin-labelled antibody used. 
Subsequently, sections were incubated overnight at 4 °C with primary antibody (Table 3), 
with secondary and tertiary antibodies for 60 minutes at room temperature, and with the 
avidin-biotin complex according to the manufacturer's description. Between incubation 
steps, sections were extensively washed using PBS. 3-Amino-9-ethyl carbazole (AEC) was 
used as a chromogen. After a short rinse in tap water the preparations were incubated 
with hematoxylin for 1 minute and thoroughly washed with tap water for 10 minutes.
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Finally, sections were mounted with Imsol mount (Klinipath, Duiven, Netherlands). All 
antibodies were diluted in PBS and 1% Bovine Serum Albumin (BSA), which also served as 
a negative control.
Table 3: Primary antibodies used in this study
Primary
antibody
Antigen Species raised in Dilution Source (reference)
6C6
ca< Mouse 1:250 Dr. Schenk, Elan Pharmaceuticals, 
San Francisco, CA, USA
40-4
ca< Rabbit 1:200 Dr. Van Nostrand, Stony Brook, NY, 
USA
3G10 Pan-HSPG Mouse 1:200 Dr. David, [57]
HS4E4 Table 2 * 1:1 Dr. Van Kuppevelt, [150]
RB4EA12 Table 2 * 1:1 Dr. Van Kuppevelt, [312]
AO4B08 Table 2 * 1:1 Dr. Van Kuppevelt, [150]
EV3C3 Table 2 * 1:5 Dr. Van Kuppevelt, [247]
HS4C3 Table 2 * 1:2 Dr. Van Kuppevelt, [269]
* phage display antibodies
For double immunostaining, cryosections (4 pm) of the occipital neocortex and 
hippocampus of 3 AD patients were air-dried, and fixed in 4% paraformaldehyde for 10 
minutes. Then the sections were incubated overnight at 4 °C with primary antibodies. To 
detect total Ap plaques, polyclonal anti-Ap antibody 40-4 was used, because the phage 
antibodies were detected by incubation with monoclonal mouse anti-VSV P5D4 antibody. 
Subsequently, sections were incubated with Donkey-anti-rabbit 594 Alexa or Goat 
anti-mouse 594 Alexa (Invitrogen, Breda, the Netherlands), depending on the primary 
antibodies used. Antibodies were diluted in PBS/1% BSA, which also served as a negative 
control. After each incubation, slides were extensively washed with PBS. For the detection 
of fibrillar Ap plaques, sections were stained with Thioflavin S (1% w/v in distilled water) 
for 5 minutes at room temperature, in the dark. Then, sections were differentiated by 
incubation with 70% ethanol. Finally, sections were mounted in Vectashield (Vector 
Laboratories, Burlingame, CA, USA) and staining patterns were analyzed by fluorescence 
microscopy (Leica, Wetzlar, Germany).
5.2.4 Heparinase III treatment
Cryosections were pretreated with heparinase III (from Flavobacterium heparinum) twice 
for 1 hour at 37 °C to digest HS (40 mIU/ml; 10 mM Hepes, 2 mM CaCl2, pH 7.0 (Sigma- 
Aldrich Chemie BV, Zwijndrecht, the Netherlands). After rinsing with PBS, the sections 
were further processed as described above to determine that all HS is digested. The 
efficacy of heparinase III treatment was evaluated by incubating the sections with 3G10 
(table 3), an antibody directed against HS "stubs" [57], generated by heparinase treatment.
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5.2.5 Arixtra
Arixtra is a synthetic pentasaccharide with a known sulfation pattern [231], Figure 1, and is 
recognized very well by the phage-antibody HS4C3 [270]. There are 15 possible positions 
(N-, 2O-, 3O- and 6O-positions) where Arixtra could be sulphated, but only 8 positions are 
actually sulphated. In more detail, from Figure 1 it can be calculated that Arixtra is 100% 
N-sulfated, 50% 2O-sulfated, 20% 3O-sulfated and 60% 6O-sulfated. The 3-O-sulfation of 
HS is a rare modification and HS4C3 is able to recognize this modification. To examine if 
HS4C3 binds to a non-3O-sulfated structure in our tissue samples, the antibody was pre­
incubated with varying concentrations of Arixtra for 1 hour at room temperature, before 
immunohistochemistry was performed as described above. Pre-incubation of the other 
antibodies served as a control.
Position of 
sulfation
Number of possible 
sulfated positions
Num berof actually sulfated 
positions
NS 3 3
20 S 2 1
30 S 5 1
60S 5 3
Fig 1: Chemical structure of Arixtra
5.2.6 Quantification of immunohistochemical stainings
Staining of the different anti-HS phage display antibodies was evaluated by scoring 
the number of stained fibrillar and/or non-fibrillar Ap plaques, in both occipital cortex 
and hippocampus. For each AD patient, the number of HS-positive plaques in 8-13 
microscopical fields (magnification 100x) per serial section were analyzed. The anti-Ap 
antibodies used in this study identify both non-fibrillar and fibrillar Ap plaques, while 
thioflavin S identifies only fibrillar Ap plaques. The percentage Ap plaques stained by a 
specific anti-HS phage display antibody compared with the anti-Ap (n=11) or thioflavin
S (n=3) staining was scored by two of the authors (IBB and LtR) and presented as the 
average of these two scores.
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5.3 Results
5.3.1 Ap staining in AD brains
Antibodies 6C6 and 40-4 both recognize fibrillar and non-fibrillar Ap plaques, but cannot 
distinguish between these two types of plaques. Using these antibodies numerous fibrillar 
and non-fibrillar Ap plaques were observed in all AD patients (Fig. 2, only 6C6 staining is 
shown). Ap plaques were mainly observed throughout the grey matter, but sporadically 
a plaque was observed in the white matter. Thioflavin S strongly stained only fibrillar Ap 
plaques in both hippocampus and occipital cortex (Fig. 3); approximately 50% of the anti- 
Ap positive plaques were stained by thioflavin S.
5.3.2 Heparan sulfate epitopes in AD brains
All HS epitope-specific antibodies stained the extracellular matrix of cortical vessels and 
capillaries (see Fig. 2 for some examples), albeit with different intensities, indicating that 
the antibodies were reactive. Antibody RB4EA12 showed an overall weaker staining 
compared to antibodies EV3C3 and HS4C3 in the hippocampus, but the staining was 
still visible. Staining of all HS-antibodies was abolished when sections were pretreated 
with heparinase III (data not shown). In addition, the stubs generated by heparinase III 
treatment could be detected by antibody 3G10, identifying all HS present in the tissue 
(data not shown).
The five anti-HS antibodies showed different staining patterns of HS in Ap plaques. 
Representative staining results are shown in Figures 2 and 3 and a summary of the 
immunohistochemical results in AD brains is shown in Figure 4. Antibody EV3C3 
abundantly stained Ap plaques (fibrillar and non-fibrillar) in both the occipital cortex 
and hippocampus. Approximately 46% of the hippocampal Ap plaques and 34% of the 
occipital Ap plaques were stained by EV3C3. Furthermore, virtually all thioflavin S positive 
plaques, both in hippocampus and occipital cortex, were stained with this antibody, but 
EV3C3 staining was clearly not limited to these fibrillar Ap plaques.
Antibody HS4C3 stained approximately 25% of the Ap plaques (fibrillar and non- 
fibrillar) in the occipital cortex and approximately 36% of the Ap plaques in the 
hippocampus. Furthermore, virtually all thioflavin S positive plaques in the occipital 
cortex and approximately 85% of the thioflavin S positive plaques in the hippocampus 
were stained with this antibody, but HS4C3 staining was not limited to these fibrillar Ap 
plaques.
Antibody AO4B08 weakly stained Ap plaques (fibrillar and non-fibrillar). Approximately 
15% of the Ap plaques in the occipital cortex and 5% of the Ap plaques in the 
hippocampus were stained by AO4B08. No thioflavin S positive plaques were stained in 
the hippocampus, whereas approximately 93% of the thioflavin S positive plaques were 
stained in the occipital cortex with this antibody. However, often only a part of the plaque 
was stained.
Antibody HS4E4 also weakly stained Ap plaques (fibrillar and non-fibrillar). Only 15% 
of the Ap plaques in the hippocampus were stained by HS4E4, with little staining (3%) 
of the occipital cortex. Approximately 48% of the thioflavin S positive plaques in the 
hippocampus and 82% of the thioflavin S positive plaques in the occipital cortex were 
stained with this antibody.
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Fig 2: Immunohistochemical staining of Ap plaques (fibrillar and non-fibrillar) in occipital neocortex and 
hippocampus of AD brains for Ap (6C6;a and b; arrows) and for specific HS epitopes with EV3C3 (c and 
d; arrows), HS4C3 (e and f; arrows), AO4B08 (g and h; arrow), HS4E4 (i and j; arrows) and RB4EA12 (k 
and l). Antibody RB4EA12 (l) showed a weaker staining compared to antibodies EV3C3 and HS4C3 in 
the hippocampus, but the staining was still visible. Panels a, c, e, g, i, and k are from serial sections and 
panels b, d, f, h, j, and l are from serial sections. Original magnification 200x
Only in the hippocampus RB4EA12 stained Ap plaques (fibrillar and non-fibrillar; 
33%). Almost all thioflavin S positive plaques in both the occipital cortex (100%) and 
hippocampus (77%) were stained by antibody RB4EA12. However, often only a part of the 
plaque area was stained, similar as observed with antibody AO4B08.
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Fig 3: Colocalization of fibrillar Ap plaques in occipital cortex and hippocampus of AD brains using thioflavin 
S (staining green) and nonfibrillar Ap plaques (40-4;a and g, staining red) or specific HS epitopes 
using EV3C3 (b and h), HS4C3 (c and i), AO4B08 (d and j), HS4E4 (e and k) and RB4EA12 (f and l; 
staining red). Original magnification 630x
In summary, the percentage of Ap plaques (fibrillar and non-fibrillar) in the 
hippocampus that were immunopositive decreased in the following order: EV3C3 > HS4C3 
> RB4EA12 > HS4E4 > AO4B08. In the occipital cortex this order was: EV3C3 > HS4C3 > 
AO4B08 > HS4E4> RB4EA12. Staining for fibrillar Ap plaques in both hippocampus and 
occipital cortex descended in the following order: EV3C3 > HS4C3 > RB4EA12 > HS4E4 > 
AO4B08.
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Fig 4: Summary of the immunohistochemical results. The individual (n=11) percentage of total Ap plaque 
staining (dots; fibrillar and non-fibrillar plaques together) and overall average (horizontal line) per 
anti-HS antibody in the cortex (A) and hippocampus (B) is shown. Also, the individual (n=3) percentage 
of fibrillar Ap plaque staining (dots) and overall average (horizontal line) per anti-HS antibody in the 
cortex (C) and hippocampus is shown. Antibody RB4EA12 showed a weaker staining compared to 
antibodies EV3C3 and HS4C3 in the hippocampus, but the staining was still visible (B).
5.3.3 Arixtra inhibits HS4C3 staining of amyloid plaques
At a high concentration (100 pg/ml) Arixtra inhibited HS4C3 staining of both cerebral 
vasculature and Ap plaques (Fig. 5a and b). At lower doses (1-10 pg/ml), HS4C3 staining 
of Ap plaques became more prominent (Fig. 5c-h). Similar results were obtained with 
antibody EV3C3.
Staining of the other three antibodies was not affected by pre-incubation with Arixtra 
(data not shown).
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Fig 5: Immunohistochemical staining of hippocampus of AD patient with phage-display antibodies 
preincubated with different doses of Arixtra. A dose-dependent effect of Arixtra was observed in 
combination with antibodies HS4C3 and EV3C3. Antibodies were preincubated with 100 pg/ml (a 
and b), 10 pg/ml (c and d), 1 pg/ml (e and f) and 0 pg/ml (g and h) of Arixtra. Panels a, c, e and g are 
from serial sections and panels b, d, f and h are also from serial sections. Original magnification 200x
5.4 Discussion
Evidence for an important role of HS in the pathogenesis of AD is accumulating. HS is able 
to enhance fibrillogenesis of Ap in vitro [54] and in rat brains in vivo [249]. Furthermore, it 
has been demonstrated that HS colocalizes with Ap-containing deposits in non-fibrillar 
and fibrillar plaques [99;248]. Previous studies demonstrated that the degree of sulfation 
of HS is critical for enhancement of fibrillogenesis of Ap [35] or other amyloidogenic 
peptides [34]. It has been reported that the large variety of sulfation patterns of HS do 
not occur randomly but have defined tissue distribution [69]. The present study is to our 
knowledge the first to investigate the topology of specific HS epitopes associated with 
Ap plaques in AD patients. To address this issue, we used five anti-HS antibodies obtained 
by phage display technology. All antibodies recognize a unique epitope structure, the 
position of sulfate groups being of major importance [69;150;269;270;312], Table 2.
All HS epitope-specific antibodies stained the extracellular matrix of cortical vessels 
and capillaries, although with different intensity. This was expected, because HS are 
usually found in the basement membranes of all vessels throughout the body [108]. Most 
HS epitope-specific antibodies used in this study also stained the vasculature of other 
organs [69;150;291].
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We demonstrated differences in expression of specific HS epitopes associated with Ap 
plaques in AD patients. Overall, the epitopes recognized by the antibodies EV3C3 and 
HS4C3 demonstrated the highest degree of expression and those by antibodies HS4E4, 
RB4EA12 and A04B08 the lowest, both in occipital cortex and hippocampus. Staining of 
fibrillar Ap plaques approached 100% in the occipital cortex with almost all five antibodies, 
whereas in the hippocampus antibodies EV3C3 and HS4C3 showed the highest level of 
staining with less prominent results using the antibodies HS4E4, RB4EA12 and A04B08. 
Staining of non-fibrillar Ap plaques was most frequent with antibodies EV3C3 and 
HS4C3 both in the occipital cortex and hippocampus and less frequent with antibodies 
HS4E4, RB4EA12 and A04B08. Recently, it was shown that antibody HS4E4 recognizes 
HS which preferentially accumulates around Ap40 dense cores of fibrillar plaques, but 
was largely absent from nonfibrillar Ap42 plaques [198]. Although we did not make a 
distinction between Ap40 and Ap42, this essentially confirms our data that only fibrillar 
Ap plaques showed antibody HS4E4 staining of colocalizing HS. Previously, we have 
demonstrated expression of core protein of the HSPGs agrin and glypican-1 in virtually all 
Ap plaques (fibrillar and non-fibrillar) in both cerebrum and cerebellum as well as in CAA 
[287;288;298] of AD brains. In addition, HSPGs of the syndecan family and collagen XVIII 
were only observed in fibrillar Ap plaques [287;290]. Together with our current data, this 
could suggest that the large variety of HS epitopes observed in fibrillar Ap plaques may 
be associated with many different protein backbones, whereas in non-fibrillar Ap plaques, 
the more restricted HS repertoire could be associated with a limited number of protein 
backbones. However, these parallel observations are not necessarily linked to each other 
since one protein backbone may also contain different types of HS side chains and are 
thus strictly hypothetical.
It has been hypothesized that nonfibrillar Ap plaques are immature Ap plaques 
eventually developing into fibrillar Ap plaques [237]. Indeed, in a transgenic mouse 
model expressing mutant APP, non-fibrillar plaques develop before fibrillar plaques 
become visible. On the other hand, however, other transgenic mouse models show that 
both fibrillar and non-fibrillar Ap plaques appear simultaneously, suggesting that fibrillar 
and non-fibrillar plaques may develop independently [120]. Previous studies of our group 
suggested that GAG chains may play an important role in the formation and persistence 
of both types of Ap plaques [288;298]. By using thioflavin S staining to distinguish non­
fibrillar from fibrillar Ap plaques, showed that all HS epitopes are present in fibrillar plaques 
in the occipital cortex. In the hippocampus, however, expression of HS epitopes in fibrillar 
Ap plaques is more restricted. In an earlier study it was found that HS protect fibrillar Ap 
better against proteolysis [101] than nonfibrillar Ap. This observation could also be related 
to the present finding that more HS epitopes are present in fibrillar Ap plaques compared 
to non-fibrillar Ap plaques.
HS is mainly composed of repeating disaccharide units of glucuronic acid and 
N-acetyl glucosamine. Some N-acetyl glucoasamine residues can be N-deacetylated and 
subsequently N-sulfated, thus both modifications are mutually exclusive. It has been 
found that antibodies EV3C3 and HS4C3 recognize only N-sulfated epitopes in HS, but not 
N-acetylated epitopes [247;270]. In contrast, antibodies RB4EA12 and HS4E4 not only 
require N-sulfated epitopes, but also need N-acetylated epitopes in HS for recognition 
[150;312]. In addition to staining of fibrillar plaques, antibodies EV3C3 and HS4C3 also 
stained non-fibrillar plaques. Antibodies RB4EA12 and HS4E4, however, only stained 
fibrillar Ap plaques. Thus, there seems to be a transition from non-fibrillar Ap plaques
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containing only fully N-sulfated HS (recognized by EV3C3 and HS4C3) to fibrillar Ap plaques 
with both fully N-sulfated, but also partially N-sulfated HS (recognized by RB4EA12 and 
HS4E4). In addition, N-sulfation of HS serves as a trigger for further modifications such as
2-O-sulfation, 6-O-sulfation and 3-O-sulfation [139;230]. Therefore, it might be possible 
that other positions in HS (2O-, 3O- and 6O-positions) are also more frequently sulfated 
in HS found in non-fibrillar plaques compared to HS found in fibrillar plaques [150;312]. 
Highly N-sulfated (and O-sulfated) HS may therefore be involved in the initiation of the 
aggregation process of Ap, e.g. by increasing the aggregation process [35] or by stabilizing 
the formed aggregates [117].
Pre-incubation of the antibodies HS4C3 and EV3C3, but not the three other anti-HS 
antibodies, with Arixtra abolished their detection of specific HS epitopes in Ap plaques. 
These data support earlier findings that Arixtra exposes epitopes that can be recognized 
by some, but not all, phage display antibodies [312]. Moreover, these data confirm that 
different types of HS modifications may be observed in Ap plaques. From our studies it 
seems likely that HS modified by 2-O and 6-O sulfation are more frequently represented 
in non-fibrillar Ap plaques. In addition, the 3-O sulfation modification of HS, although 
being a relatively rare HS modification, recognized by HS4C3, is possibly also ubiquitously 
present. Although the specific HS modification that is considered inhibitory or essential 
for binding of a phage display antibody to HS is only known to some extent (Table 2), our 
study suggests lesion-specific association of these modified HS structures in AD brains. 
Using HS sequencing technology [277], the exact epitopes which the antibodies, used in 
this study, recognize may be characterized at the monosaccharide level in the near future. 
Well-defined anti-HS antibodies will make it possible to pinpoint defined structural HS 
modifications, and perhaps even monosaccharide sequences, to plaque formation and 
stabilization in AD.
In summary, HS epitope-specific antibodies made it possible to investigate the 
expression of different HS epitopes in fibrillar and non-fibrillar Ap plaques in the occipital 
cortex and hippocampus. We found that the specific HS epitopes associated with Ap 
plaques in both brain areas were largely comparable. In contrast, however, only two out 
of five antibodies, each with their specific HS recognition pattern, stained fibrillar Ap 
plaques and the specific epitopes are likely highly sulfated. All five antibodies stained 
fibrillar Ap plaques, and therefore a larger variety of HS epitopes seems to be associated 
with fibrillar plaques. Future studies, however, will have to reveal the precise structure of 
the HS epitopes in Ap plaques.
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Abstract
Alzheimer's disease is characterized by deposits of the amyloid p protein (Ap) in the 
form of senile plaques and cerebral amyloid angiopathy. Deposition of Ap into these 
pathological lesions is directed by step-wise aggregation of Ap into oligomers, protofibrils 
and mature fibrils. Currently, all therapies are purely symptom-relieving, and an actual 
treatment or prevention of AD is still lacking. Since aggregated forms of Ap are particularly 
neurotoxic, interference with the process of Ap aggregation is a long-envisioned target 
for therapy. Based on the knowledge that both sulfated (macro)molecules and small 
synthetic peptides interfere with Ap aggregation, we developed hybrid ligands to target 
Ap fibrillization by a combination of peptide-peptide and sulfate-peptide interactions. 
A series of peptides, modified at the N-terminus with sulfated linkers, was successfully 
prepared by solid phase synthesis. The hybrid ligands were tested using a viability assay 
and an aggregation assay. Molecular modeling was applied to explain the binding of the 
hybrid ligands to Ap42. The hybrid ligands that we designed, synthesized and evaluated 
were found to be non-toxic to cells but displayed negligible inhibition of Ap fibrillization 
and Ap-mediated cytotoxicity compared to the beta-sheet breaker peptides known 
today. Further molecular modeling simulations suggested that the hybrid ligands were 
incorporated into the p-sheet structure of Ap aggregates, indicating that the hybrid 
ligands may bind to Ap but are unable to inhibit further aggregation. Optimization of 
the hybrid ligands by reducing hydrogen bond interactions of the ligand with following 
Ap proteins might result in ligands, with improved binding to one Ap protein, that could 
potentially disrupt further p-sheet formation. This in turn may reduce toxicity of Ap.
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6.1 Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder that is characterized by a 
progression from episodic memory problems to a slow global decline of cognitive 
function that leaves patients with end-stage AD bed-ridden and dependent on custodial 
care. It affects 10% of the people over the age of 65, and accounts for approximately 50% 
of all patients with dementia [40]. The current standard of care for mild to moderate AD 
includes treatment with acetylcholinesterase inhibitors to improve cognitive function. In 
addition, the common non-cognitive neuropsychiatric symptoms of AD (such as mood 
disorder, agitation, and psychosis) often require extra medication [46]. However, these 
treatments are purely symptom-relieving, and an actual treatment or prevention of AD is 
still lacking.
Histopathological features of AD are extensive deposition of the amyloid p protein (Ap) 
in senile plaques (SPs) in the cerebral cortex as well as in the cerebrovascular wall (cerebral 
amyloid angiopathy, CAA). This deposition is a result from the conversion of a-helical or 
random coil Ap to p-sheet, which facilitates self-aggregation of normally soluble Ap into 
dimers, trimers, oligomers, protofibrils and eventually mature insoluble fibrils [237]. In 
addition, the formation of p-sheet-rich aggregates has been reported to be toxic towards 
various cultured cerebral cells, including neurons, cerebrovascular smooth muscle cells 
and human brain pericytes [25;207;221;296]. Taken together, this suggests that Ap might 
be involved in the pathogenesis of AD.
An attractive therapeutic strategy for AD is to block the early steps of misfolding and 
aggregation of the soluble Ap by using small molecule drugs. If the peptide interactions 
are the same in oligomers and in larger fibrils, then such molecules could inhibit both 
the formation of toxic oligomers and of fibrils. To this end, several research groups have 
designed "p-sheet breakers" (BSB) [254;276]. BSB are based on peptide sequences that 
specifically interfere with p-sheets within Ap. Two sets of peptides were effective BSB, 
namely the peptides LPFFD (or its analogues LVFFA or LPYFD) and KLVFF that bind to 
a region between amino acids 16 and 22 of Ap [88;255;276]. These compounds inhibit 
Ap-mediated neurotoxicity [2;255] and Ap deposition in vivo and improve behavioral 
deficiency induced by Ap deposition [2;38;255]. However, a reasonable molar excess 
compared to the Ap protein is needed to achieve such a result [204;254;255].
It is known that small sulfated and sulfonated molecules have high binding affinity 
with Ap, since they are designed to interfere with glycosaminoglycan/Ap interaction
[137]. The binding site on Ap for GAGs likely resides within the cluster of basic amino acids 
13-16 of Ap [187], although it remains possible that other domains within Ap interact with 
GAGs as well [210]. Thus, this might indicate that the binding site on Ap for the small 
anionic sulfates and sulfonates also resides within the same cluster of amino acids.
Covalent linking of two separate ligands to give so-called hybrid ligands is a powerful 
general concept to enhance binding affinity and improve the biological activity compared 
to the separate molecules, a strategy that has successfully been used in medicinal 
chemistry in the past years [100;104;156]. Increasing the binding affinity of a BSB peptide 
to Ap might decrease the molar excess needed to affect Ap aggregation, toxicity and 
deposition. Considering the relative positions of BSB peptides and GAG binding to Ap 
(amino acids 16-22 and 13-16 respectively) [114;187;254;255;276], it occurred to us 
that the covalent attachment of (poly)sulfates with the BSB peptide by a certain linker 
would possibly lead to a hybrid with improved binding characteristics and, thereby, 
possibly improved characteristics with respect to inhibition of Ap fibrillization and Ap-
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mediated cytotoxicity. Hence, we synthesized Ap ligands that combine pentapeptide-Ap 
interaction and sulfate-Ap interaction and evaluated their effects on Ap aggregation and 
Ap-mediated cytotoxicity relative to the separate ligands.
6.2 Methods
Since BSB peptide KLVFF contains the basic amino acid lysine (K), which would result in a 
zwitterionic structure upon monosulfonylation, BSB peptide LPFFD, lacking a basic amino 
acid, was chosen as starting point of our hybrid ligands. The synthetic route towards several 
hybrid ligands (3, 4, 5a-5d and 6a-6d) is shown in Fig. 1, and is based on standard Fmoc- 
based solid phase synthesis and introduction of a variety of alcohols at the N-terminus 
of the pentapeptide, via carbamate or urea functionality. Because cleavage of C5H10O4- 
LPFFD-OH (5d (L-Pro) and 5d' (D-Pro)) from the Breipohl resin did not result in the desired 
compound, likely caused by the harsh cleavage conditions, a 2-chlorotrityl resin was 
used instead. The milder conditions for cleavage from the 2-chlorotrityl resin successfully 
afforded C5H10O4-LPFFD-OH (5d and 5d'). After cleavage from the resin, sulfate groups 
were introduced by sulfonylation of the alcohol groups under the action of sulfurtrioxide- 
amine complex. Using HPLC, a purity of > 95% was achieved for all synthetic sequences. In 
addition to the hybrid ligands shown in Fig. 1, as a control peptide Ac-LPFFD-NH2 (7) was 
also synthesized. Ac-LPFFD-NH2 (7) is known in literature as iAp5p and is shown to reduce 
amyloid plaque formation in a transgenic mouse model [204]. In our study, it served as a 
control to our hybrid ligands in the biological assays.
Two kinds of assays were used to determine the biological activity of the hybrid 
ligands. First of all, hybrid ligands were screened for in vitro activity in inhibition of amyloid 
fibril formation. Fibril formation was quantified with a fluorescence assay based on the 
specific binding of thioflavin T (Th-T) to p-sheet amyloid aggregates [157]. By binding to 
the p-sheets in Ap aggregates, a fluorescent signal is produced which is proportional to 
the amount of fibrils formed. The effect of the hybrid ligands on p-sheet formation of 
Ap42 in the first 48 hours of incubation was analyzed and compared to the inhibitory 
effect of Ac-LPFFD-NH2 (7) alone. In earlier studies (unpublished data) it became apparent 
that co-incubation of (monomeric) Ap with Ac-LPFFD-NH2 (7) in a molar ratio of 1:20 
resulted in approximately 50% inhibition of the aggregation of Ap. Therefore, we have 
used this molar ratio to study the hybrid ligands in the aggregation assay. Secondly, 
toxicity of Ap in cell culture has been reported to be related to the formation of p-sheet- 
rich aggregates [207] and has been used in several studies to screen diverse compounds 
to prevent amyloid neurotoxicity. Degeneration of smooth muscle cells (SMCs) and 
pericytes by Ap (aggregation) is a prominent feature of CAA. We, therefore, developed a 
model of Ap-mediated degeneration of cultured human brain pericytes (HBPs) and SMCs 
[299;303]. These cells were isolated from human brain capillaries and leptomeningeal 
vessels, respectively, from control and AD brains obtained at autopsy. In this model 
the aggregation of wild-type Ap1-42, is cytotoxic for HBP and SMC cultures [296]. The 
effect of the hybrid ligands on Ap42-mediated cell death after 6 days of incubation was 
analyzed and compared to the inhibitory effect of Ac-LPFFD-NH2 (7) alone. In earlier 
studies (unpublished data) it became apparent that co-incubation of (monomeric) Ap 
with Ac-LPFFD-NH2 (7) in a molar ratio of 1:5 resulted in approximately 50% inhibition of 
the cytotoxicity of Ap. Therefore, we have used this molar ratio to study the hybrid ligands 
in the viability assay.
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Fig 1: Synthetic route towards hybrid ligands. Reaction conditions: (a) p-nitrophenylchloroformate and 
DIPEA in dichloromethane, r.t., 1 h; (b) HO-X-NH2, N,N-diisopropylethylamine in DMF, r.t., 18 h; TFA/ 
H2O/1,2-ethanedithiol/triisopropylsilan (92.5/2.5/2.5/2.5), r.t., 2h (3a-3d); (d) HO-X-OH, 
1,8-diazabicycloundec-7-ene (DBU) in DMF, r.t., 18 h; TFA/H2O/1,2-ethanedithiol/triisopropylsilan 
(92.5/2.5/2.5/2.5), r.t., 2 h (5a-5c) or 2-hydroxymethyl-1,3-propanediol, DBU in DMF, r.t., 18 h; 
dichloromethane/TFA/acetic acid (3/1/1), r.t., 1h (5d); (c,e) sulfur trioxide-trimethylamine in DMF, 50 
°C, 18 h; sat. aq. NaHCO3, r.t.,18 h (4a-4d and 6a-6d).
6.3 Results and discussion
Co-incubation of A042 with Ac-LPFFD-NH2 (7) resulted in an inhibition of the toxicity and 
aggregation of A042 (Fig. 2), which confirms earlier research [255]. However, no significant 
effect was found of either hybrid ligand both on toxicity and aggregation of A042. In table
1 an overview of the hybrid ligands and their effects on aggregation and toxicity of A042 
is given. Fig. 2 shows a representative figure for all hybrid ligands. Co-incubation of A042 
with Ac-LPFFD-NH2 (7) in a molar ratio of 1:20 results in 66% decrease in fluorescent signal 
(p < 0.01; Fig. 2A), i.e. Ac-LPFFD-NH2 (7) seems to inhibit the fibril formation of A042, which 
confirms earlier research [121]. However, co-incubation of A042 with C5H10O4-LPFFD- 
OH (5d) or the bissulfonylated analogue C5H8Na2O10S2-LPFFD-OH (6d) in a molar ratio 
of 1:20 resulted in a fluorescent signal comparable to the signal of A042 alone (Fig. 2A). 
Incubation of buffer alone or the compounds themselves did not result in a fluorescent
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signal. In addition, a significant difference was observed in cell death between HBPs 
treated with 10 pM AP42 either alone (25% cell death) or with Ac-LPFFD-NH2 (7; 11.3% 
cell death; p < 0.001; Fig. 2B) in a molar ratio of 1:5 for 6 days, which also confirms earlier 
research [2;255]. However, again no significant effect was observed when co-incubating 
AP42 with 5d or 6d in a molar ratio of 1:5 for 6 days compared to incubation with AP42 
alone (Fig. 2B). Incubation of the compounds alone resulted in cell death comparable 
to control levels. Thus, N-terminal chain extension of peptide LPFFD with an aliphatic 
alcohol or sulfonylated alcohols, via urea or carbamate functionality, consequently leads 
to derivatives with reduced activity with respect to Ac-LPFFD-NH2 (7) itself.
Fig 2: Analysis of the effect of Ac-LPFFD-NH2 (7), C5H,0O4-LPFFD-OH (5d) and C5H8Na2O,0S2-LPFFD-OH (6d) 
on AP-induced cytotoxicity towards human brain pericytes (HBPs). Effects on aggregation of 50 pM 
AP42 for 48 hours (A) and cell death in HBP cultures after incubation with 10 pM Ap42 for 6 days (B) is 
shown. The concentration of hybrid ligand is shown as the molar ratio of AP42: hybrid ligand. Co­
incubation of AP42 with Ac-LPFFD-NH2 (7) in a ratio of 1:20 results in 66% decrease in fluorescent 
signal (p < 0.01; A). However, co-incubation of AP42 with C5H10O4-LPFFD-OH or C5H8Na2O10S2-LPFFD- 
OH in a ratio of 1:20 resulted in a fluorescent signal comparable to the signal of AP42 alone (A). 
Incubation of buffer alone or the compounds themselves did not result in a fluorescent signal. In 
addition, a significant difference was observed in cell death between HBPs treated with 10 pM AP42 
alone (25% cell death) or with Ac-LPFFD-NH2 (7; 11.3% cell death; p < 0.001; B) in a ratio of 1:5 for 6 
days. However, no significant effect was observed when co-incubating AP42 with C5H10O4-LPFFD-OH 
or C5H8Na2O10S2-LPFFD-OH in a ratio of 1:5 for 6 days compared to incubation with AP42 alone (B). 
Incubation of the compounds alone resulted in a cell death comparable to control levels.
To find a possible explanation for these results, a molecular modeling approach was 
applied to the hybrid ligands (3, 4, 5a-5c and 6a-6c) and the NMR structure deposed in 
RCSB Protein Data Bank under the ID number 2BEG [167] as a model for the AP42 fibrils 
(see 6.4. supporting materials). In earlier studies the binding site of LPFFD on AP42 was 
determined [44;114] and we used this binding site to align our hybrid ligands to the AP42 
protein. As can be seen in Fig. 3, a nice p-pleated sheet was observed when aligning several 
AP42 proteins. According to the obtained model, it was rationalized that a spacer of three 
carbon atoms should be sufficient to target His13 and/or His14 in the AP42 protein with a 
sulfate group of the hybrid ligand, Fig. 3. Based on this insight, our synthetic compounds 
could simultaneously target the binding domains of GAGs (binding to Ab amino acids 13­
16) and of pentapeptides (binding to Ab amino acids 16-22).
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Fig 3: Alignment of 4a to the AP42 protein. A nice p-pleated sheet can be observed when aligning several 
AP42 proteins. According to the obtained model a spacer of three carbon atoms should be sufficient 
to target His13 and/or His14 in the AP42 protein with a sulfate group of the hybrid ligand. Therefore, 
our synthetic compounds could simultaneously target the binding domains of GAGs (binding to Ap 
amino acids 13-16; green) and of pentapeptides (binding to Ap amino acids 16-22; dark blue).
After alignment, molecular dynamics was performed with the assumption that the 
phenylalanine (amino acid 3) of the hybrid ligand adopts the same orientation as the 
phenylalanine (amino acid 18) of the AP42 protein. Thus, from this initial conformation 
for molecular dynamics simulations in water, the energetically most favorable "docking" 
conformation was sought. It should be mentioned that during these calculations the 
starting configuration will not be the most sampled configuration if it is not energetically 
favorable, certainly if the simulation time is long enough. From these calculations it 
became apparent that, although both phenylalanines of the hybrid ligand adopt the 
same orientation as the phenylalanines of the AP42 protein, it is difficult to target the 
histidines in the AP42 protein with a non-peptide side-chain in the hybrid ligand. Rather, 
the side-chain bends away such that the sulfate groups interact with Lys15 of the AP42 
protein backbone, rather than with His13 or His14 (Fig. 4). Interestingly, during further 
molecular modeling simulations it became apparent that the hybrid ligands could be 
fully incorporated into the P-sheet structure of aggregated AP (Fig. 5), explaining why our 
hybrid ligands exerted no effect on AP aggregation and toxicity.
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Fig 4: Snapshot of molecular dynamics simulations of 6b aligned to the AP42 protein. Although both 
phenylalanines of the hybrid ligand adopt the same orientation as the phenylalanines of the AP42 
protein, it is difficult to target the histidines in the AP42 protein with a non-peptide side-chain of the 
hybrid ligand. The side-chain bends in such a way that the sulfate groups rather interact with Lys15 of 
the AP42 protein backbone than with His13 or His14.
It is thought that BSB peptides, such as Ac-LPFFD-NH2 (7), interfere with electrostatic 
interactions during aggregation or destabilize the AP-fibril internal hydrogen bond 
network, necessary to maintain the P-sheet structure, by forming strong hydrogen 
bonds with the AP subunits [43]. During the calculations we were solely focused at the 
optimization of the affinity of the sulfonylated hybrid ligands to the AP protein. The 
disadvantage of these compounds, however, is that because of this high quality binding, 
it is very likely that we have designed compounds that incorporate into the P-sheet 
structure of AP42 aggregates, rather than inhibiting aggregation of the protein, due to 
restoring the AP fibril internal hydrogen bond network (Fig. 5). Thus, to be an effective BSB 
ligand, hybrid ligands should not only have a higher binding affinity to the AP42 protein, 
but should also disrupt the P-sheet structure. Therefore, to optimize the ligands, a "bulky" 
sidechain/group could be introduced to optimize our hybrid ligands, thereby preventing 
its incorporation into the P-sheet structure of AP42. An alternative strategy involves 
changing the amino acid sequence by replacing, for instance, one of the phenylalanines 
by a polar amino acid and/or reducing hydrogen bond interactions of the hybrid ligand 
with a next AP protein.
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Fig 5: Snapshot of molecular dynamics simulations of 6d' (yellow) aligned into the P-sheet structure of 
aggregated AP42 protein. The ligands can be incorporated into the P-sheet structure of aggregated 
AP, as was observed during these molecular dynamics calculations. The ligand connects/binds the 
two parts of the lower sheet (green) with on overage six hydrogen bonds and the two parts of the 
upper sheet (red) with on average two hydrogen bonds.
In conclusion, a hybrid ligand with improved characteristics with respect to inhibition 
of AP fibrillization and AP-mediated cytotoxicity compared to Ac-LPFFD-NH2 (7) [204;255] 
was not found. However, as our molecular modeling experiments suggest, the designed 
hybrid ligands likely have a higher binding affinity for AP, but cannot avoid further 
aggregation of the AP protein. Changing the amino acid sequence by replacing, for 
instance, one of the phenylalanines by a polar amino acid and/or reducing hydrogen 
bond interactions of the hybrid ligand with a next AP protein could be a variable for 
optimization of the hybrid ligands in future studies to validate the hypothesis that hybrid 
ligands targeting AP fibrillization by a combination of peptide-peptide and sulfate­
peptide interactions have enhanced properties.
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Table 1: Overview biological effects of the hybrid ligands on AP aggregation and AP- 
mediated cytotoxicity
Effect on A042 Aggregation 
(average ± standard deviation)*
Effect on A042 Toxicity (average ± 
standard deviation)*
3a 82.7 ± 5.8 96.1 ± 12.6
4a 83.0 ± 4.9 95.9 ± 12.6
3b 98.7 ±14.7 92.5 ± 11.4
4b 127.3 ± 3.7 92.0 ± 10.3
3c 98.7 ± 14.7 96.6 ± 12.0
4c 119.5 ± 7.3 92.0 ± 10.3
3d 100.0 ± 12.7 99.6 ± 9.9
4d 100.5 ± 8.0 96.5 ± 8.6
5a 92.9 ± 6.9 93.0 ± 14.7
6a 107.1 ± 21.5 106.7 ± 19.2
5b 100.0 ± 28.8 91.6 ± 9.2
6b 96.3 ± 13.1 95.9 ± 9.6
5c 97.0 ± 12.6 89.7 ± 17.3
6c 95.1 ± 3.6 91.4 ± 17.9
5d 76.4 ± 23.3 81.1 ± 28.3
6d 90.1 ± 28.6 86.3 ± 23.2
5d' 87.9 ± 10.4 94.8 ± 19.4
6d' 94.7 ± 6.7 93.8 ± 13.0
7 51.9 ± 16.3 51.8 ± 15.3
* AP42 aggregation and toxicity is set to 100%; molar ratio 1:20 (AP42:hybrid ligand) in aggregation assay 
and 1:5 in viability assay
6.4 Supporting information
6.4.1 General experimental
Unless stated otherwise all chemicals were obtained from commercial sources and used 
without further purification. If no further details are given the reaction was performed 
under ambient atmosphere and temperature. Dichloromethane was dried over an 
activated alumina column using an MBraun SPS800 solvent purification system. The water 
used was deionised using a Labconco Water Pro PS purification system. If no further details 
are given, purification of peptide was carried out on a Gilson semipreparative RP-HPLC 
system at a flow rate of 4 mL/min, using a Dr. A. Maisch C18 column, with a linear gradient 
of 5% to 100% acetonitrile (0.1% TFA) in 60 minutes. The peptides were characterized 
by electrospray MS and analytical RP-HPLC (flow rate 0.4 ml/min; same gradient as 
semipreparative RP-HPLC). The solvent system used both for analytical and preparative 
HPLC was: deionised water and acetonitrile.
100
A rational design to create hybrid p-sheet breaker peptides to inhibit aggregation and toxicity of amyloid-p
6.4.2 Mass spectrometry (MS)
Mass analyses were performed using electrospray ionization on a LCQ Advantage Max 
from Thermo Finnigan.
6.4.3 Synthesis
6.4.3.1 General procedure for pentapeptide 4-nitrobenzoate formation (2) by solid 
phase synthesis
The LPFFD peptide (1) was synthesized using standard 9-fluorenylmethyl carbamate 
(Fmoc) peptide synthesis on a Breipohl resin [24;262]. Peptide coupling was achieved 
using 3 equiv of Fmoc amino acid and dicyclohexylcarbodiimide (DCC, 3.3 equiv) with 
N-hydroxy benzotriazole (HOBt, 3.6 equiv) in DMF. The resin was swollen in DMF for 20 min 
prior to use. The Fmoc group was removed using piperidine in DMF (20% v/v, three times, 
6 min). After coupling of the final amino acid, the Fmoc-protected peptide on the resin 
was washed thoroughly with DMF, dichloromethane and methanol. The resin was dried in 
vacuum and was divided in batches.
The dry resin was swollen for 30 min in DMF. Subsequently, the Fmoc-protecting group 
was removed using piperidine in DMF (20% v/v). The resin was washed well with DMF 
and dichloromethane. Three equivalents of p-nitrophenylchloroformate was dissolved in 
dichloromethane and 3 equivalents of N,N-diisopropylethylamine (DIPEA) was added. The 
solution was added to the resin and the resin was agitated for 1 h. The resin was washed 
with dichloromethane and DMF and used for further synthesis.
6.4.3.2 General procedure for alcohol addition by urea functionality (3a-3d)
After washing pentapeptide 4-nitrobenzoate (2) with dichloromethane and DMF, 5 
equivalents of 3-amino-1-propanol, 3-amino-1,2-propanediol or 4-amino-1-butanol 
was dissolved in DMF together with 3 equivalents of N,N-diisopropylethylamine 
(DIPEA) and added to the resin. The resin was agitated for 18 h. The resin was washed 
thoroughly with DMF and methanol and dried in vacuo. The peptides were cleaved from 
the resin by treatment with trifluoroacetic acid/water/1,2-ethanedithiol/triisopropylsilan 
(92.5/2.5/2.5/2.5, v/v) for 2 h. After co-evaporation with heptane, the peptides were 
lyophilized from acetic acid. The peptides were purified using HPLC and characterized by 
HPLC and electrospray MS. The main peak of 3a eluted at Rt of 28.2 minutes of the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
C37H51N7O9 [M+H+] 738.8, found 738.3. The main peak of 3b eluted at Rt of 27.2 minutes 
of the analytical chromatogram, was confirmed by electrospray mass spectrometry: m/z 
calculated for C37H51N7O10 [M+H+] 754.8, found 754.5. The main peak of 3c eluted at Rt 
of 27.2 minutes of the analytical chromatogram, was confirmed by electrospray mass 
spectrometry: m/z calculated for C37H51N7O10 [M+H+] 754.8, found 754.5. The main peak 
of 3d eluted at Rt of 29.1 minutes of the analytical chromatogram, was confirmed by 
electrospray mass spectrometry: m/z calculated for C38H53N7O9 [M+H+] 752.9, found 752.5.
6.4.3.3 General procedure for alcohol addition by carbamate functionality (5a-5c)
After washing compound 2 with dichloromethane and DMF, 5 equivalents of 
1,3-propanediol or glycerol was dissolved in DMF together with 1.3 equivalents of 
1,8-diazabicycloundec-7-ene (DBU) and added to the resin. The resin was agitated for 18 h. 
The peptides were cleaved from the resin by treatment with trifluoroacetic acid/water/1,2- 
ethanedithiol/triisopropylsilan (92.5/2.5/2.5/2.5, v/v) for 2 h. After co-evaporation with
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heptane, the peptides were lyophilized from acetic acid. The peptides were purified 
using HPLC and characterized by HPLC and electrospray mass spectrometry. The main 
peak of 5a eluted at Rt of 29.8 minutes of the analytical chromatogram, was confirmed 
by electrospray mass spectrometry: m/z calculated for C37H50N6O10 [M+H+] 739.8, found 
739.4. The main peak of 5b eluted at Rt of 27.8 minutes of the analytical chromatogram, 
was confirmed by electrospray mass spectrometry: m/z calculated for C37H50N6O11 [M+H+]
755.8, found 755.5. The main peak of 5c eluted at Rt of 27.8 minutes of the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
C„H5nNA, [M+H+] 755.8, found 755.5.37 50  6  11 L J ’
6.4.3.4 Preparation of C5H10O4-LPFFD-OH (5d)
The LPFFD peptide was synthesized using standard 9-fluorenylmethyl carbamate 
(Fmoc) peptide synthesis on a 2-chlorotrityl chloride resin [251]. The resin was swollen 
in dichloromethane for 20 min and 5 equivalents of DIPEA and 3 equivalents of Fmoc- 
protected aspartic acid (OBz protected) were added and the mixture was agitated for 30 
minutes. After washing with dichloromethane, 5 equivalents of DIPEA and 3 equivalents 
of methanol were added and the mixture was agitated for 30 minutes to cap possible 
unreacted sites on the resin. The resin was washed thoroughly with dichloromethane 
and DMF. The Fmoc group was removed using piperidine in DMF (20% v/v, three times,
6 min). Further peptide coupling was achieved using 3 equiv of Fmoc amino acid and 
dicyclohexylcarbodiimide (DCC, 3.3 equiv) with N-hydroxybenzotriazole (HOBt, 3.6 equiv) 
in DMF. After coupling of the final amino acid, the Fmoc-protected peptide on the resin 
was washed thoroughly with DMF and methanol. The resin was dried in vacuum and was 
divided in batches.
The dry resin was swollen for 30 min in DMF. Subsequently, the Fmoc-protecting group 
was removed using piperidine in DMF (20% v/v). The resin was washed well with DMF 
and dichloromethane. Three equivalents of p-nitrophenylchloroformate was dissolved in 
dichloromethane and 3 equivalents of DIPEA was added. The solution was added to the 
resin and the resin was agitated for 1 h. After washing the resin with dichloromethane 
and DMF, 5 equivalents of 2-hydroxymethyl-1,3-propanediol was dissolved in DMF 
together with 1.3 equivalents of DBU and added to the resin. The resin was agitated for 
18 h. The peptides were cleaved from the resin by treatment with dichloromethane/1,1,1- 
trifluoroethane/acetic acid (3/1/1, v/v) for 1 h. After removal of the solvents under reduced 
pressure, the peptides were lyophilized from acetic acid.
The peptides were dissolved in methanol until a concentration of 0.1 N was reached. 
After removal of air from the solution, 5% Pd/C was a added to the stirred mixture and 
the benzylester of the peptides was hydrogenated at ordinary pressure (balloon) and 
temperature for 18 h. The reaction mixture was filtered using Celite and the filtrate 
was concentrated under reduced pressure. The peptides were lyophilized from acetic 
acid. The peptides were purified using HPLC and characterized by electrospray mass 
spectrometry. The main peak of 5d (L-proline) eluted at Rt of 25.7 minutes of the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
[M+H+] 770.8, found 770.4. The main peak of 5d' (D-proline) eluted at Rt of 26.4 minutes 
of the analytical chromatogram, was confirmed by electrospray mass spectrometry: m/z 
calculated for [M+H+] 770.8, found 770.5.
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6.4.4 General procedure for sulfonation of alcohols (4a-4d and 6a-6d)
The alcohol groups of the peptides were sulfonated according to a modified procedure 
from Lee et al. [154]. In short, the peptides were dissolved in DMF (1,0 ml) and 10 equivalents 
of sulfur trioxide-trimethylamine complex was added to the solvent in 5 steps in 3 h. The 
mixture was stirred at 50 °C under nitrogen overnight. The reaction flask was cooled down 
to room temperature, the reaction was quenched with saturated aqueous NaHCO3 (2 ml) 
and the mixture was kept stirring for another 16 h. The solvent was coevaporated with 
ethanol under reduced pressure, and a mixed solvent of dichloromethane and methanol 
(1/1, 10 ml) was added to the residue. The mixture was filtered over Celite and the filtrate 
was concentrated under reduced pressure to give a syrup. After desalting the residue 
by column chromatography on Sephadex G-15 using deionised water, the sulfonated 
peptides were purified and analysed using C18 RP-HPLC. The solvent system used both 
for analytical and preparative HPLC was: deionised water 0.1 M AcONH4 and acetonitrile 
[138;333], linear gradient from 5% to 75% acetonitril in 30 minutes.
The main peak of 4a eluted at Rt of 23.0 minutes of the analytical chromatogram, was 
confirmed by electrospray mass spectrometry: m/z calculated for C37H50N7O12SNa [M-Na+]
816.9, found 816.5. The main peak of 4b eluted at Rt of 19.5 minutes of the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
C37H50N7O12S2Na2 [M-2.Na+ + H+] 913.0, found 912.9. The main peak of 4c eluted at Rt 
of 20.5 minutes of the analytical chromatogram, was confirmed by electrospray mass 
spectrometry: m/z calculated for C37H50N7O12S2Na2 [M-2.Na+ + H+] 913.0, found 912.9. 
The main peak of 4d eluted at Rt of 23.3 minutes of the analytical chromatogram, was 
confirmed by electrospray mass spectrometry: m/z calculated for C38H52N7O12SNa [M-Na+]
830.9, found 830.5.
The main peak of 6a eluted at Rt of 23.6 minutes of the analytical chromatogram, was 
confirmed by electrospray mass spectrometry: m/z calculated for C37H49N6O13SNa 
[M-Na+] 817.9, found 817.5.The main peak of 6b eluted at Rt of 19.6 minutesof the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
C^H^NA^Na [M-2.Na+ + H+] 913.9, found 913.3. The main peak of 6c eluted at Rt37 48  6  17 2 2
of 20.6 minutes of the analytical chromatogram, was confirmed by electrospray mass 
spectrometry: m/z calculated for C37H48N6O17S2Na2 [M-2.Na+ + H+] 913.9, found 913.3. The 
main peak of 6d (L-proline) eluted at Rt of 18.5 minutes of the analytical chromatogram, 
was confirmed by electrospray mass spectrometry: m/z calculated for [(M-2.Na+)/2] 463.9, 
found 463.5. The main peak of 6d' (D-proline) eluted at Rt of 18.5 minutes of the analytical 
chromatogram, was confirmed by electrospray mass spectrometry: m/z calculated for 
[(M-2.Na+)/2] 463.9, found 463.5.
6.4.5 Aggregation assay
To study the effect of the hybrid ligands on P-sheet formation of AP in the first 48 hours 
of incubation, we analyzed the formation of P-pleated sheets using thioflavin T (Th-T). 
The assay is based on the fluorescence emission of Th-T. Th-t binds to AP, producing 
a fluorescent signal that is proportional to the amount of fibrils formed [157]. AP1-42 
was incubated either with or without hybrid ligand in a molar ratio of 1:20 (AP42:hybrid 
ligand) in 50 mM Tris-HCl buffer with 150 mM NaCl (pH 7.4) at a concentration of 50 pM for 
48 hours. At different time points, 20 pl samples were taken and mixed with 50 mM glycine
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(pH 9.2), 3 pM Th-T in a final volume of 1 ml. Fluorescence was measured in duplicate 
with excitation at 450 nm and emission at 482 nm using a Perkin-Elmer luminescence 
spectrometer.
6.4.6 Cell culture
Human brain pericytes (HBP) and human leptomeningeal smooth muscle cells (HLSMC) 
were isolated and characterized as described previously [219;296]. Cells were maintained 
in Eagle's minimal essential medium (EMEM; Bio Whittaker Europe, Verviers, Belgium) 
supplemented with 10% human serum (Gemini Bio-Products, Calabasas, CA, USA), 20% 
fetal calf serum (Life Technologies, Rockville, USA), 0.1% basic fibroblast growth factor and 
2% gentamycin at 37°C and 5%-CO2. Cell passages 3-15 were used for the experiments. 
For degeneration studies, cells were incubated in an eight-well chamber slide (Nunc, 
Roskilde, Denmark) with EMEM and 0.1% BSA (serum-free medium) supplemented with 
10.0 pM wild-type AP1-42 for 6 days [314;317]. Control cells incubated with the serum­
free medium alone demonstrated normal morphology. Cells were co-incubated with the 
hybrid ligands in a molar ratio of 1:5 (AP42:hybrid ligand) for 6 days. Cell viability was 
quantified using a fluorescent Live/Dead® Viability/Cytotoxicity Kit according to the 
manufacturer's instructions (Molecular Probes, Eugene, OR, USA) and analyzed using a 
Leica fluorescence microscope. The percentage of dead cells was determined from at 
least four counts per well (approximately 800 cells per count), and the experiments were 
performed in duplicate. Each experiment was repeated at least two times.
6.4.7 Statistical analysis
Statistical analysis was performed using ANOVA with Bonferroni's post hoc analyses for 
multiple comparisons using SPSS 14.0 for Windows (SPSS inc., Chicago, IL).
6.4.8 Calculations
The structure of the AP42 fibrils used for the molecular modeling experiment was based 
on the NMR structure deposed in RCSB Protein Data Bank under the ID number 2BEG 
[167]. The missing residues 1-16 were modelled using YASARA module LOOP MODELLING 
(www.yasara.com). Atoms of these flexible residues were never constrained. Two kinds of 
molecular modeling experiments were performed. First, to determine the alignment of 
the hybrid ligands with the AP fibrils, the synthesized peptides were superimposed on 
residues LVFF of the chain E. In the next step the chain E was deleted and the interactions 
of a peptide with A-D molecules of AP42 were further optimized using geometry 
minimization procedure as implemented in Yasara software. During the optimization and 
molecular dynamics simulations the positions of the backbone atoms of AP (residues 
17-42) were constrained. The energy minimization and the molecular dynamics were 
performed using Amber99 force field. The molecular dynamics simulations carried for 2.5 
ns in water at 300K gave an insight into the nature of interaction between the AP protein 
and proposed ligands as well as the flexibility of the ligands.
Second, to determine if the hybrid ligands could be incorporated into the P-sheet 
structure of aggregated AP, synthesized peptides were superimposed on residues LVFF 
of the chain C. After deletion of chain C were the molecular modeling experiments 
performed as described above.
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Chapter 7
7.1 Introduction
Neurodegenerative conformational diseases are characterized by cerebral 
accumulation of fibrillar protein (referred to as amyloids), due to misfolding and 
aggregation of a natively unfolded protein [22;23;90]. Examples of these disorders are 
Alzheimer's disease (AD) and Parkinson's disease (PD). AD is the most common progressive 
and age-related neurodegenerative disorder. It is characterized by extracellular deposition 
of the amyloid p (AP) protein in the parenchyma, but also in the cerebrovascular wall, 
respectively referred to as plaques and cerebral amyloid angiopathy (CAA) [22;237]. 
In addition, hyperphosphorylated tau protein also accumulates as intraneuronal 
neurofibrillary tangles [237]. PD is the most common neurodegenerative movement 
disorder and is characterized by intraneuronal inclusions of a-synuclein in the substantia 
nigra and cerebral cortex [256;257]. Both Ap and a-synuclein are proteins capable of 
self-aggregation, forming dimers, trimers, oligomers, protofibrils and eventually mature 
fibrils (Fig. 2; introduction), of which the last three are rich in p-sheet structure [242]. 
Although protofibrils and mature fibrils are found in the pathological lesions in AD and 
PD, they are assumed to be less toxic than oligomers, which are directly held responsible 
for neurotoxicity [121;168;200]. In addition, point mutations in the encoding genes of Ap 
and a-synuclein increase the propensity of these proteins to aggregate, thereby raising 
the odds that the disease will have an early onset [58;92;147;158;239;286]. Although it is 
generally accepted that fibrillization of Ap and a-synuclein is the pathological basis for the 
development of AD and PD, still many questions regarding the underlying mechanisms 
for their misfolding and accumulation remain unanswered.
The studies reported in this thesis aimed to provide more insight into these underlying 
mechanisms. More specifically, Ap and a-synuclein do not only associate with themselves, 
but also interact with various other factors, such as sHsps, apoE, HSPGs and inflammatory 
agents. It is not entirely understood whether these factors contribute to the pathogenesis 
of AD and PD, or rather fail in their effort to rescue the amyloidogenic proteins from 
aggregating. Understanding the intra- and extracellular assembly of normally soluble 
proteins into amyloid aggregates might provide new clues to develop therapies for these 
diseases.
This chapter is structured as follows. First, the main findings of this thesis will be 
summarized and discussed. After that, this chapter will end with a conclusion.
7.2 Summary
Chapter 2 - We previously demonstrated that sHsps have affinity for Ap [314], and that 
a few of these proteins are co-deposited with Ap deposits [315;319] (Chapter 3). Since 
sHsps function as molecular chaperones that prevent proteins from adopting an incorrect 
conformation [131], they might affect misfolding and aggregation of other proteins 
involved in neurodegeneration as well. In chapter 2, we demonstrated that several sHsps 
bind to wild-type and mutant a-synuclein and inhibit mature fibril formation, suggesting 
that sHsps can indeed affect (mis)folding and aggregation of amyloidogenic proteins.
Chapter 3 - Since a strong link has been established between Ap accumulation in the 
brain of AD patients and cerebral inflammation, it is suggested that this Ap accumulation 
triggers inflammation in AD [111]. However, in a previous study of our group we 
demonstrated that Hsp20, HspB8 and HspB2B3 could induce a more pronounced cytokine
108
Summary and General Discussion
production in cultured cerebrovascular cells and astrocytes than Ap itself [313]. In chapter 
3 we confirmed these findings and additionally showed that Hsp20, HspB8 and HspB2 
co-localized with intracellular adhesion molecule 1 (ICAM-1) in dyshoric angiopathy near 
(cap)CAA. Furthermore, we found that Hsp20, HspB8 and HspB2B3 induced production 
of IL-8, ICAM-1 and MCP-1 by cerebrovascular cells and astrocytes and, on the other 
hand, that Hsp27 inhibited production of TGF-p1 and CD40 ligand. Taken together, our 
data suggest that those sHsps that co-localize with Ap in plaques and (cap)CAA might be 
involved in the induction of a local inflammatory reaction to a much larger extend than Ap 
itself.
Chapter 4 - Besides sHsps, several other proteins, including apolipoprotein E (apoE) 
and heparan sulfate proteoglycans (HSPGs) are also found in or near Ap deposits. Ever 
since the apoE £4 genotype was identified as a risk factor for AD, many research groups 
have tried to come up with a biological explanation for this epidemiological observation. 
ApoE binds to Ap and affects its fibril formation, possibly in an isoform-specific manner 
(£2<£3<<£4) [151;260]. Previously, we found a dependence on apoE genotype of Ap- 
mediated cell death and apoE production by cultured cerebrovascular cells [317], 
suggesting that the increased vulnerability to Ap-mediated cell death observed in 
apoE £4 cells might result from lower apoE production by these cells, rather than from 
differences in biological activity of the different apoE isoforms. Due to their proximity to 
the vasculature in the brain and their capacity to produce apoE, astrocytes, just like other 
cerebrovascular cells may be involved in CAA development, a process that includes Ap 
deposition and clearance and that may be affected by interaction with locally produced 
apoE. In chapter 4 we observed that cultured astrocytes produced only 3-10% of the 
apoE amounts produced by cerebrovascular cells. Furthermore, cerebrovascular cells with 
the apoE £4 allele produced three times less apoE and were more vulnerable to Ap than 
cerebrovascular cells without an £4 allele, confirming our earlier results [317]. This latter 
relation with apoE genotype was not observed with astrocytes in vitro. Both cerebrovascular 
cells and astrocytes, however, were protected from Ap-induced cytotoxicity by high 
levels of extracellular apoE. In addition, extracellular apoE dose-dependently decreased 
both internalization of Ap and Ap accumulation at the cell surface in either cell type. Our 
results suggest that apoE produced by cerebrovascular cells, rather than astrocytic apoE, 
modulates Ap cytotoxicity and Ap removal near the vasculature in the brain. Furthermore, 
since the levels of apoE production by cerebrovascular cells is apoE genotype dependent, 
this may provide a explanation for the widely observed dependence of the development 
of CAA in vivo on apoE genotype.
Chapter 5 - In vitro studies have demonstrated that HSPGs affect Ap deposition at 
many levels, such as regulation of Ap cleavage [16;235], triggering Ap aggregation and 
protecting Ap deposits from proteolytic breakdown [36;54]. Previous studies have shown 
that HSPGs enhances aggregation of Ap and that this enhancement is dependent on 
the degree of sulfation of HS [275]. In addition, it has been reported that these sulfation 
epitopes do not occur randomly but have a defined tissue distribution. In chapter 5 
we investigated whether a specific HSPGs epitope is associated with Ap plaques in the 
occipital neocortical and hippocampal tissue using heparan sulfate epitope specific phage 
display antibodies on tissue sections from AD patients. We observed that antibodies 
recognizing highly N-sulfated HSPGs stained the largest population of both fibrillar Ap 
plaques and non-fibrillar Ap plaques, whereas antibodies recognizing heparan sulfate 
regions with a lower degree of N-sulfate modifications were only immunoreactive with
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fibrillar Ap plaques. Our results suggest that a large variety of heparan sulfate epitopes is 
associated with fibrillar Ap plaques, but that the heparan sulfate epitopes associated with 
non-fibrillar Ap plaques are more restricted, selectively consisting of highly N-sulfated 
epitopes.
Chapter 6 - The current standard of care for patients with mild to moderate AD 
includes treatment with acetylcholinesterase inhibitors to improve cognitive functions
[46]. However, these treatments are purely symptom-relieving, and an actual treatment 
or prevention of AD is still lacking. An attractive therapeutic strategy for AD is to block 
the early steps of misfolding and aggregation of the Ap by using small molecule drugs. 
To this end, several research groups have designed "p-sheet breakers" [254;255;276]. 
These compounds inhibit aggregation and toxicity of Ap, but a molar excess of these 
compounds compared to the Ap protein is needed to achieve such a result. Since certain 
sulfation epitopes of HSPGs were found to be associated with Ap plaques (chapter 5), we 
investigated in chapter 6 if sulfation of p-sheet breakers may increase the propensity of 
these peptides to inhibit aggregation and toxicity of Ap. The resulting hybrid ligands that 
we designed, synthesized and evaluated were non-toxic to cells, but displayed negligible 
inhibition of Ap fibrillization and toxicity compared to the p-sheet breakers known today. 
Molecular modeling simulations suggested that the hybrid ligands were incorporated 
into the p-sheet structure of Ap aggregates, indicating that the hybrid ligands may bind to 
Ap, but are unable to inhibit further aggregation. Reducing hydrogen bond interactions 
of the hybrid ligand with a following Ap protein could be a variable of optimization of the 
hybrid ligands in future studies.
7.3 Discussion
7.3.1 Introduction
Accumulation of Ap and a-synuclein in brain tissue seems to be a key event in the 
pathogenesis of AD and PD, respectively. Despite the differences in disease progression 
and clinical symptoms, these disorders share some common features. First, accumulation 
of amyloidogenic proteins seems to be triggered by self-aggregation, forming neurotoxic 
oligomers and protofibrils, and eventually insoluble fibrils. Second, several factors can 
modulate aggregation and toxicity of misfolding proteins, such as sHsps, apoE and HSPGs. 
Third, neuro-inflammation could play an role in early disease development. Previously, our 
group discovered that sHsps could modulate aggregation of Ap, but also that sHsps could 
induce IL-6 production in cultured cerebrovascular cells and astrocytes. The aim of this 
thesis was to investigate if sHsps are also able to modulate the aggregation of a-synuclein 
(chapter 2), and in addition, if the induction of inflammatory factors by sHsps was limited 
to IL-6 or not (chapter 3). Since sHsps function as molecular chaperones that can prevent 
proteins from adopting an incorrect conformation [131;316], we also studied "amateur" 
chaperones like apoE and HSPGs. We, therefore, examined the effects of apoE on Ap 
internalization, Ap cell surface accumulation and vulnerability for Ap-induced toxicity of 
cultured cerebrovascular cells and astrocytes (chapter 4). Furthermore, since a specific 
sulfation epitope of HSPGs was found to be associated with Ap plaques (chapter 5), we 
studied if sulfation of synthetic peptides, known as beta-sheet breakers, might increase 
the propensity of these peptides to inhibit aggregation and toxicity of Ap (chapter 6).
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7.3.2 Chaperones in aggregation of amyloidogenic proteins in neurodegenerative 
conformational diseases
HSPGs consist of a protein backbone to which one or more glycosaminoglycan (GAG) 
chains are linked [107]. The GAG chains are composed of repeating disaccharide units of 
glucuronic acid and N-acetyl glucosamine and can have various biosynthetic modifications, 
including sulfation [37;80]. These biosynthetic modifications occur in specific regions of 
HSPGs, resulting in highly modified epitopes (N- and O-sulfate rich) interspaced by less 
modified regions [139;230]. The different HSPG epitopes do not occur randomly but have 
a defined tissue distribution, suggesting that the arrangement of sulfate groups of HSPGs 
is important for interaction with other molecules. Evidence for an important role of HSPGs 
in the pathogenesis of AD and PD is accumulating. HSPGs are associated with Ap and 
a-synuclein deposits in AD and PD respectively, and are able to enhance fibrillization 
of these amyloidogenic proteins [54;160;248;250]. Furthermore, in AD tissue, a specific 
association of low N-sulfated HSPGs was found with fibrillar Ap plaques (chapter 5). In 
addition, highly N-sulfated HSPGs were co-deposited in both fibrillar and non-fibrillar Ap 
plaques (chapter 5). It has been hypothesized that non-fibrillar Ap plaques are immature 
Ap plaques eventually developing into fibrillar Ap plaques [237]. Taken together, this 
suggest that highly sulfated HSPGs could be involved in Ap plaque development in AD. 
Since HSPGs are also associated with other amyloid deposits, it would be interesting to 
study the distribution of sulfation epitopes of HSPGs in or near these amyloid deposits, 
for instance a-synuclein deposits in PD. If the HSPGs epitope distribution is comparable to 
the distribution in Ap deposits, it could indicate a common role of specific sulfate epitopes 
of HSPGs in the formation of amyloid deposits.
Several studies already stressed the importance of sHsps, such as aB-crystallin or 
Hsp27 in the accumulation of a-synuclein [199;215;216] and Ap [149]. In addition, other 
sHsps, such as Hsp20, HspB8 and HspB2 can also be found in or near Ap deposits [315;319] 
(Chapter 3) and can inhibit Ap fibrillization [314]. Interestingly, sHsps can also bind to 
wild-type and mutant a-synuclein and modulate their mature fibril formation (Chapter 
2). This could suggest that sHsps might be important in modulating fibrillization of 
amyloidogenic and misfolding proteins in general. Indeed, HspB8 can inhibit aggregation 
and toxicity of mutated superoxide dismutase 1 [56] and prevent formation of inclusion 
bodies by Htt43Q (mutated huntingtin fragment containing 43 glutamines) [31]. It might, 
therefore, be interesting to investigate if HspB8 and other sHsps affect other misfolding 
and amyloidogenic proteins as well.
Ever since the first reports on the association of the apoE £4 allele with AD emerged, 
research has focused on unraveling the mechanism by which the different alleles and 
isoforms of apoE affect AD pathogenesis. Most reports emphasized the differences 
in biological activity of the different apoE isoforms, such as Ap binding capability and 
subsequent modulation of Ap aggregation, deposition and clearance [33;170;212]. 
However, the absolute levels of apoE are also important, since high levels of apoE 
contribute to the protection from Ap-mediated cell death of cerebrovascular cells and 
astrocytes (chapter 4), Furthermore, a correlation between apoE genotype and apoE 
production by cerebrovascular cells is found, but not in astrocytes (chapter 4). A previous 
study [224], describing that apoE levels in transgenic mice decreased in the following 
order: £2/ £2>£3/ £3>£4/ £4 supports the data found in cerebrovascular cells. The described 
differences in apoE levels were due to an enhanced degradation and reduced half-life of 
newly synthesized apoE4 compared to apoE3, mirroring the relative risk in developing AD.
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In addition, reduction of apoE levels in the hippocampus of AD subjects proportional to 
the number of apoE £4 allele(s) has been reported [17]. Thus, not only the apoE isoform, 
but also the apoE levels contribute to the biological function of apoE in vivo and thus, its 
role in the pathogenesis of AD.
7.3.3 Role of sHsps in inflammation in neurodegenerative conformational diseases
A common feature of neurodegenerative conformational diseases is chronic inflammation, 
characterized by accumulation of activated microglia and astrocytes in damaged areas 
in the brain and around aggregated protein deposits [182;183]. It has been suggested 
that both Ap and a-synuclein can induce inflammatory factor production by microglia 
[111;313;336]. Some of these factors have neuroprotective activities and aid in brain 
repair processes, while others enhance oxidative stress and trigger apoptotic cascades in 
neurons. Therefore, pro- and anti-inflammatory responses must be in balance to prevent 
the potential detrimental effects of prolonged or unregulated inflammation-induced 
oxidative stress acting on vulnerable neuronal populations. It has been shown that Ap 
had no effect on the production of inflammatory factors by human leptomeningeal 
smooth muscle cells and human brain astrocytes (chapter 3). However, these cells were 
stimulated to do so by sHsps that accumulate in or near Ap deposits, such as Hsp20, 
HspB8 and HspB2B3 (chapter 3). This might indicate that sHsps that co-localize with 
Ap in plaques and CAA contribute to the inflammatory reactions observed in AD. Since 
co-localization of sHsps has also been observed in association with the pathological 
hallmarks of PD [128], sHsps might also contribute to the inflammation observed near 
fibrillar protein depositions in PD. However, this remains to be elucidated. In addition, 
it would be interesting to investigate if other cell types, such as microglial and neuronal 
cells, are also triggered by sHsps to secrete inflammatory agents.
7.3.4 Chaperones as common therapeutic agents in neurodegenerative 
conformational diseases?
Since accumulation of an amyloidogenic protein is one of the hallmarks of 
neurodegenerative conformational diseases, a therapeutic approach for one disease 
might also work for another. Interestingly, there are several examples where a compound 
was initially developed as a potential drug for one conformational disease, and was found 
to posses activity against another disorder too. For example, amyloidophilic substance 
cpd-B was originally designed as therapeutic compound for the treatment of AD. At the 
same time, this compound also displayed therapeutic efficacy against prion disease, 
another conformational neurodegenerative disorder, and is currently a therapeutic drug 
candidate for both these diseases [133].
A promising candidate for common interference of fibrillization of amyloidogenic 
proteins might be the functional unit(s) of sHsps. Recently, the functional unit of the 
chaperone aA-crystallin was identified - a 19 amino acid hydrophobic peptide fragment 
responsible for the chaperone function of the protein [232]. This peptide might be used 
as a universal chaperone for controlling protein aggregation. In addition, it would be 
interesting to study the functional unit(s) of other sHsps and investigate if these functional 
unit(s) could also be used in the same manner. However, one should be aware of their 
ability to bind misfolded proteins and keep them in an intermediate conformation. Such a 
conformation might even be more toxic than the aggregated state [258]. Another class of 
promising candidates for interference of fibrillization of amyloidogenic proteins in general
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includes sulfonated compounds, for example GAG mimetics, small anionic molecules or 
molecules based on sulfonated dyes like congo red and thioflavin S, of which the latter 
two both bind amyloid fibrils [137;163]. The bioavailability of these compounds in human 
patients remains to be improved, however.
7.3.5 Specific therapeutics agents in neurodegenerative conformational disease?
Although there are mechanistic commonalities between the different neurodegenerative 
diseases, there are also differences. For example, in AD Ap accumulates extracellularly 
whereas in PD a-synuclein accumulates intracellularly. In addition, the area of the brain 
affected and thus the cell type affected by the amyloidogenic protein is also different 
between the two diseases. Taken together, this might indicate that the local environment 
(i.e. proteins and other factors) determines where the amyloidogenic protein will 
accumulate and that, therefore, this could be different between different diseases. 
Furthermore, inheritance of one or two copies of the apoE £4 allele is associated with an 
increased risk of AD [234] and such an association was not that obvious in PD [134;148]. 
These differences could be used to develop specific therapies, aimed at either increasing 
the turnover of the accumulated protein, or blocking the formation of aggregates. For 
example, increasing the clearance of the amyloidogenic protein by pharmacological 
upregulation of certain degrading proteases [240;244] could be a therapeutic strategy. 
However, since the proteases are involved in a number of regulatory pathways [278], it is 
possible that other biological relevant pathways will also be affected.
Another approach to develop specific therapies is by targeting the amyloidogenic 
peptides of the different diseases, using a short peptide fragment homologous to 
a segment of the full-length peptide. Of particular interest are those peptide-based 
compounds that, by binding to the self-assembling peptide, interfere with its assembly 
into toxic aggregates, like p-sheet breakers [254;255;276]. An advantage of such 
compounds is that they specifically target the abnormal conformation of a protein and 
will not disrupt any possible normal function of the soluble protein. However, there is 
concern about the ability of p-sheet breakers to destabilize the abnormal conformation 
of protein aggregates and to "dissolve" fibrillar aggregates, since this can lead to the 
formation of toxic intermediates.
In chapter 6, we designed hybrid ligands by combining peptide-based (specific) and 
sulfonation-based (common) compounds to target Ap fibrillization. Covalent linking 
of these two different kind of compounds was used to improve binding affinity and 
enhance the biological activity compared to the separate molecules, a strategy that has 
successfully been used in pharmacochemistry in the past [100;156]. Unfortunately, the 
hybrid ligands that we designed displayed negligible inhibition of Ap fibrillization and 
Ap-mediated toxicity. Further molecular modeling simulations indicated that the hybrid 
ligands were incorporated into the p-sheet structure of Ap aggregates. This highlights the 
pitfall of increasing binding affinity to amyloidogenic proteins. When increasing binding 
affinity to aggregating proteins, one should take into account that the compound should 
not only have optimal binding affinity but should also avoid further aggregation of the 
target protein. If a hybrid ligand can be identified that combines peptide-based (specific) 
and sulfonation-based (common) compounds and also disrupts p-sheet formation, this 
approach might also be useful for other neurodegenerative conformational diseases, like 
PD.
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Both AD and PD are multifactorial diseases in which both genetic [84;239] (studied in 
chapter 4) and non-genetic factors [36;160;186;287;288;319] (studied in chapter 2, 3 
and 5) are involved in its pathogenesis. In addition, there are mechanistic commonalities 
among these two neurodegenerative conformational diseases, suggesting that a common 
therapy against these diseases is possible. However, there are also some differences 
between AD and PD, offering other opportunities to develop specific therapies against 
these diseases. Understanding the earliest events of intra- and extracellular assembly 
of normally soluble proteins and how they disrupt normal cellular functions should be 
key objectives for future research. Studying the role of chaperones in the development 
of neurodegenerative conformational diseases could yield specific and/or common 
approaches for therapy.
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Chapter 8
8.1 Neurodegeneratieve ziekten
Onze hersencellen staan permanent met elkaar in verbinding. Daardoor kunnen we 
bewegen, denken, voelen en onthouden. Lichaam en geest functioneren prima, zolang 
die onderlinge verbindingen tussen alle hersencellen optimaal werken. Jammer genoeg 
neemt met het ouder worden het aantal en de geleidingssnelheid van deze minuscule 
vezels af. Dat verklaart waarom mensen dingen gaan vergeten en trager worden in 
denken en doen als ze ouder worden.
Neurodegeneratie is de term voor verlies van structuur en functie en uiteindelijk 
de dood van cellen in het centrale zenuwstelsel (de hersenen en het ruggenmerg). In 
tegenstelling tot de meeste cellen in de rest van ons lichaam, kunnen de cellen in ons 
centrale zenuwstelsel moeilijk opnieuw aangroeien. Dit betekent dat als een cel eenmaal 
verloren is gegaan, deze slechts bij uitzondering vervangen kan worden. Afhankelijk van 
het soort cel en het gebied in onze hersenen, kan het verlies van cellen leiden tot een divers 
spectrum aan neurologische ziektebeelden. De meest voorkomende daarvan zijn dementie 
en bewegingsstoornissen. Neurodegeneratie kan verschillende oorzaken hebben, maar 
het lijkt er op dat er een paar overeenkomsten zijn tussen de verschillende ziekten.
Een groeiend aantal neurodegeneratieve ziekten lijkt veroorzaakt te worden door het 
ophopen van eiwitten, hetzij in de cel, hetzij buiten de cel. Deze eiwitten vouwen zich 
(om een tot nu toe onbekende reden) verkeerd en hebben hierdoor een sterke neiging 
om te gaan samenklonteren (aggregeren). De ziekten die gekenmerkt worden door deze 
ophopingen van eiwitten heten neurodegeneratieve conformationele ziekten of eiwit 
conformationele ziekten. Tot deze groep van ziekten behoren: de ziekte van Alzheimer, 
Parkinson en Huntington, multiple systeem atrofie en prion ziekten. Hoewel de ziekten 
verschillen in ziekteverloop, klinische symptomen en het eiwit dat ophoopt in de 
hersenen, hebben ze toch vergelijkbare kenmerken. De ophopingen lijken namelijk sterk 
op elkaar in uiterlijk en hoe ze gevormd worden. In dit proefschrift is er gekeken naar de 
eiwitten die ophopen bij de ziekte van Alzheimer en de ziekte van Parkinson, namelijk het 
amyloïd-p (AP) eiwit (Hoofdstuk 3-6) en het a-synucleïne eiwit (Hoofdstuk 2).
8.1.1 Ziekte van Alzheimer
Bij de ziekte van Alzheimer is er sprake van gestage aantasting van de hersencellen 
(zenuwcellen). In eerste instantie zijn er alleen denk- en geheugenstoornissen 
(dementie), maar na verloop van tijd worden de symptomen erger (rusteloosheid, 
hallucinaties en depressie). Deze aandoening werd voor het eerst beschreven in 
1906 door de Duitse psychiater Aloïs Alzheimer. Op dit moment is de ziekte van 
Alzheimer de meest voorkomende vorm van dementie: in Nederland kennen we 
ongeveer 130.000 patiënten. Daarnaast is de ziekte ouderdomsgerelateerd, ongeveer 
10% van de bevolking ouder dan 65 jaar krijgt deze ziekte. Er wordt geschat dat 
met de vergrijzing het aantal patiënten zal groeien naar 400.000 in 2030.
Ondanks de stijging van het aantal testen die de ziekte van Alzheimer mogelijk 
kunnen detecteren, zoals neuropsychologische testen, neuroimaging (MRI) en 
biochemische analyse van de hersenvloeistof, is de uiteindelijke diagnose alleen 
mogelijk met behulp van histologisch onderzoek van de hersenen van de patiënt. In de 
hersenen van patiënten met de ziekte van Alzheimer ziet men krimp (atrofie) van een 
aantal hersengebieden. Daarnaast zijn er ophopingen van het amyloid-p (AP) eiwit 
en het tau eiwit aanwezig. Beiden zorgen voor de sterfte van zenuwcellen en zijn dus
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uiteindelijk verantwoordelijk voor de atrofie van de hersenen van patiënten met de ziekte 
van Alzheimer. De AP ophopingen bevinden zich niet alleen tussen de zenuwcellen, 
zogenaamde plaques, maar zitten ook rondom bloedvaten als zogenaamde cerebrale 
amyloïd angiopathie (CAA). Dit proces is de oorzaak van de sterfte van cellen die 
onderdeel uitmaken van de hersenbloedvaten, zoals pericyten en gladde spiercellen, wat 
bijdraagt aan het ziekteproces. De ophopingen van het tau eiwit zijn terug te vinden in de 
zenuwcellen. Vaak zie je in hersenen van patiënten met de ziekte van Alzheimer ook een 
ontstekingsreactie rond de ophopingen van Ap. Een kenmerk van deze ontstekingsreactie 
is het verschijnen van specifieke cellen, zoals astrocyten en microglia.
Het Ap eiwit wordt gevormd uit het amyloïd precursor eiwit (APP). Door middel van 
twee enzymen worden voornamelijk twee vormen van Ap uit APP geknipt, AP40 en AP42 
(fig. 5A, hoofdstuk 1). Mutaties in het APP eiwit, zowel binnen als buiten het AP gebied 
(fig. 5B, hoofdstuk 1), kunnen ertoe leiden dat er sneller en meer AP ophopingen worden 
gevormd, waardoor de ziekte van Alzheimer zich eerder (<65 jaar) kan openbaren. Een 
voorbeeld hiervan is de "Dutch" mutatie in AP. Patiënten met deze mutatie krijgen op een 
relatief jonge leeftijd fatale hersenbloedingen als gevolg van uitgebreide CAA vorming.
8.1.2 Ziekte van Parkinson
Bij de ziekte van Parkinson is er vooral sprake van het afsterven van zenuwcellen 
in de zogenaamde substantia nigra. Deze cellen maken de stof dopamine aan. 
Dopamine is noodzakelijk voor de controle van lichaamsbewegingen. De ziekte 
van Parkinson is de meest voorkomende neurodegeneratieve bewegingsstoornis 
en werd voor het eerst beschreven in 1817 door de Britse chirurg James Parkinson. 
Deze ziekte wordt gekenmerkt door motorische problemen, zoals het trillen van 
ledematen en stijfheid van spieren. Er zijn echter ook niet-motorische symptomen, 
zoals problemen met cognitie/geheugen en slaapproblemen. In Nederland wordt 
geschat dat ongeveer 1% van de bevolking ouder dan 55 jaar deze ziekte zal krijgen.
Bij patiënten die lijden aan de ziekte van Parkinson worden zogenaamde Lewy 
bodies (ingekapselde ophopingen van eiwit) gevonden in de zenuwcellen van de 
substantia nigra, maar ook vaak in andere gebieden als thalamus en neocortex. 
Lewy bodies bestaan voornamelijk uit ophopingen van het eiwit a-synucleïne en 
worden verantwoordelijk gehouden voor de sterfte van cellen in de aangetaste 
hersengebieden. Dit eiwit speelt ook een grote rol in de pathologie van ziektes als 
dementie met Lewy Bodies, en multiple systeem atrofie. Om deze reden is de naam 
synucleinopathieën geïntroduceerd om neurodegeneratieve ziekten gekenmerkt 
door ophopingen van a-synucleïne te benoemen. Naast het ontstaan van Lewy bodies 
vindt hier omheen ook een ontstekingsreactie plaats die, net zoals bij de ziekte van 
Alzheimer, wordt gekenmerkt door het verschijnen van astrocyten en microglia.
In tegenstelling tot AP, wordt a-synucleïne niet geknipt uit een ander voorloper-eiwit. 
De biologische functie van het a-synucleïne eiwit is nog niet helemaal duidelijk, maar er 
wordt gesuggereerd dat het een beschermende functie heeft in de synaps (contactplaats 
tussen twee zenuwcellen). Tot nu toe zijn er 3 mutaties bekend die een familiaire vorm 
van de ziekte van Parkinson veroorzaken, namelijk de mutaties A53T, A20P en E46K (fig. 6, 
hoofdstuk 1). Het hebben van één van deze mutaties zorgt voor een vroeg ontstaan van 
de ziekte van Parkinson (<50 jaar).
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8.2 Het misvouwen van eiwitten
Het verkeerd vouwen van eiwitten kan leiden tot de formatie van ongestructureerde 
(amorfe neerslagen) of gestructureerde (amyloïd fibrillen) ophopingen van eiwitten. 
Hierbij aggregeren afzonderlijke eiwitten samen tot steeds langere ketens van het eiwit. 
De aggregatie begint met het vormen van zogenaamde dimeren en trimeren van het 
eiwit, om vervolgens oligomeren, protofibrillen en uiteindelijk fibrillen te vormen (zie 
figuur 2, hoofdstuk 1). Een kenmerk van alle gestructureerde ophopingen van eiwitten is 
dat deze voornamelijk bestaan uit P-sheet structuren (fig. 1, hoofdstuk 1). Daarnaast is er 
aangetoond dat een hydrofoob (water-afstotend) gebied nodig is voor het samenklonteren 
van eiwitten. Het AP eiwit heeft bijvoorbeeld 2 hydrofobe gebieden en het a-synucleïne 
eiwit heeft er één. Hoewel in de kenmerkende ophopingen van neurodegeneratieve 
conformationele ziekten voornamelijk de(proto)fibrillenworden gevonden, is de algemene 
gedachte dat de oligomeren zorgen voor de toxiciteit en dus de sterfte van zenuwcellen.
Ook al is het inmiddels algemeen geaccepteerd dat het ophopen van AP en a-synucleïne 
de pathologische basis is voor de ziekte van Alzheimer en de ziekte van Parkinson, veel 
vragen zijn toch nog steeds onbeantwoord. Bijvoorbeeld, wat zijn de onderliggende 
mechanismen voor het misvouwen dat voorafgaat aan het ophopen van de eiwitten? 
Welke factoren/eiwitten hebben invloed op het aggregeren? Zijn er overeenkomsten 
in de aggregatie van AP en a-synucleïne? En zijn deze overeenkomsten misschien 
te gebruiken als algemene therapie tegen de gehele groep van neurodegeneratieve 
conformationele ziekten? In dit proefschrift proberen we meer inzicht te krijgen in de 
onderliggende mechanismen van het aggregeren van deze twee amyloïdogene eiwitten. 
Er is met name gekeken naar andere eiwitten/factoren die in de ophopingen van AP en 
a-synucleïne te vinden zijn, zoals kleine heat shock eiwitten, apolipoproteïne E, heparan 
sulfaat proteoglycanen en ontstekingsfactoren. Meer begrip over het aggregatieproces 
kan eventueel leiden tot nieuwe medicijnen tegen deze ziekten.
8.3 Chaperones in de aggregatie van amyloïdogene eiwitten in 
neurodegeneratieve conformationele ziekten
8.3.1 Kleine heat shock eiwitten
In eerdere studies van onze groep hebben we gevonden dat kleine heat shock eiwitten 
(sHsps) co-lokaliseren met de ophopingen van AP in de ziekte van Alzheimer. Daarnaast 
is ook gevonden dat de aggregatie van AP beïnvloedt kan worden door sHsps. Omdat 
sHsps eiwitten zijn die in het algemeen andere eiwitten kunnen terugvouwen naar de 
juiste conformatie, zou het dus kunnen dat sHsps ook de aggregatie van a-synucleïne 
kunnen beïnvloeden. In hoofdstuk 2 werd de binding van sHsps met a-synucleïne 
bestudeerd. We hebben laten zien dat de verschillende sHsps kunnen binden aan 
a-synucleïne en dat ze ook de aggregatie van a-synucleïne kunnen beïnvloeden. Of 
dit betekent dat sHsps het misvouwen en aggregeren van nog andere amyloïdogene 
eiwitten zouden kunnen beïnvloeden, zal onderzocht moeten worden.
In de hersenen van patiënten met de ziekte van Alzheimer worden vaak 
ontstekingsreacties gezien. Omdat deze ontstekingsreacties meestal worden gevonden 
in de buurt van de ophopingen van AP, wordt er wel eens gedacht dat AP zelf deze 
reactie veroorzaakt. In een eerdere studie van onze groep hebben we echter gevonden
118
Nederlandse Samenvatting
dat juist sHsps, en niet AP, een hele sterke ontstekingsreactie kunnen veroorzaken in een 
celkweekmodel. In hoofdstuk 3 bevestigen we deze bevindingen en bestuderen we het 
effect van sHsps op de ontstekingsreacties in meer detail. We hebben gevonden dat drie 
sHsps, Hsp20, HspB8 en HspB2B3 co-lokaliseren met de ontstekingsfactor intracellular 
adhesion molecule 1 (ICAM-1) rond bloedvaten met CAA. Verder hebben we laten zien dat 
dezelfde sHsps de productie stimuleren van de ontstekingsfactoren Interleukine 8 (IL-8), 
ICAM-1 en Monocyte chemoattractant protein 1 (MCP-1). Deze data geven aan dat sHsps 
die co-lokaliseren met AP in plaques en CAA een belangrijke rol bij het oproepen van 
ontstekingsreacties in de hersenen van patiënten met de ziekte van Alzheimer kunnen 
hebben. In de ziekte van Parkinson wordt ook colokalisatie van sHsps met a-synucleïne 
gevonden. Of sHsps ook een rol spelen in het ontstekingsproces, wat vaak wordt gevonden 
bij de ziekte van Parkinson, zal uitgezocht moeten worden.
8.3.2 Apolipoproteïne E
NaastsHspswordenerookandere eiwittengevondenin (deomgeving) vanAP ophopingen, 
waaronder apolipoproteïne E (apoE). De mens kan drie verschillende genotypes hebben 
van het apoE gen (£2, £3, £4), en kan dus 3 verschillende isovormen van het apoE eiwit 
hebben: apoE2, apoE3 of apoE4. Vanaf het moment dat werd aangetoond dat het hebben 
van het apoE £4 genotype een risicofactor is voor het krijgen van de ziekte van Alzheimer, 
is door veel onderzoeksgroepen geprobeerd om een verklaring te vinden voor deze 
observatie. Inmiddels is bekend dat apoE aan AP bindt en het samenklonteren van AP kan 
beïnvloeden. In een eerdere studie hebben we gevonden dat gekweekte bloedvatcellen 
(cerebrovasculaire cellen) met verschillend apoE genotype verschillen toonden in de 
vatbaarheid voor celdood door AP. Cerebrovasculaire cellen met een apoE £4 genotype 
waren vatbaarder voor AP dan cerebrovasculaire cellen met een ander apoE genotype. 
Daarnaast is in dezelfde studie gevonden dat cerebrovasculaire cellen met het apoE £4 
genotype minder apoE maakten dan cerebrovasculaire cellen met een apoE £3 genotype. 
Dit zou kunnen betekenen dat de gevoeligheid voor AP van de cerebrovasculaire cellen 
met een apoE £4 genotype veroorzaakt wordt door de lage productie van apoE en niet 
omdat deze cellen een andere isovorm van het apoE eiwit maken. In hoofdstuk 4 zijn 
we dit verder gaan onderzoeken door ook naar andere cellen te gaan kijken die ook in 
aanraking kunnen komen met AP in onze hersenen. Volgens een aantal studies zouden 
namelijk astrocyten de grootste bron van apoE in onze hersenen zijn. Astrocyten zitten 
ook in de buurt van de bloedvaten in onze hersenen en zouden daarom ook betrokken 
kunnen zijn in de ontwikkeling van CAA. De ophoping van AP in de hersenvaten zou 
dus beïnvloed kunnen worden door lokaal geproduceerd apoE van astrocyten en 
cerebrovasculaire cellen. In hoofdstuk 4 zagen we dat gekweekte astrocyten aanzienlijk 
minder apoE produceerden dan cerebrovasculaire cellen (maar 3-10%). Daarnaast 
vonden we in astrocyten geen relatie tussen de hoeveelheden geproduceerd apoE en de 
gevoeligheid voor celdood door AP. Opvallend was dat beide celtypen, cerebrovasculaire 
cellen en astrocyten, beschermd werden tegen de celdood door AP als we apoE 
toevoegden aan het kweekmedium. Ook de opname van AP door beide celtypen en het 
stapelen van AP op het celoppervlak van beide celtypen werd verlaagd als er extra apoE 
was toegevoegd aan het kweekmedium van de cellen. Analyse van het AP in het medium 
na deze experimenten liet zien dat het lijkt dat AP geremd wordt in het samenklonteren 
als er meer apoE in het medium zit. Deze data suggereert dat hoge hoeveelheden van 
apoE kunnen beschermen tegen de effecten van AP. Daarnaast suggereert deze studie
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ook dat cerebrovasculaire cellen (lokaal) meer apoE maken dan astrocyten. Het lijkt er 
dus op dat apoE geproduceerd door cerebrovasculaire cellen een belangrijkere rol heeft 
dan apoE gemaakt door astrocyten in de bescherming tegen de effecten van AP op de 
hersenvaten. Aangezien de productie van apoE in cerebrovasculaire cellen afhankelijk is 
van het ApoE genotype, suggereert dit dat mensen met het apoE £4 genotype te weinig 
apoE maken en daardoor een verhoogd risico hebben op het krijgen van de CAA en de 
ziekte van Alzheimer.
8.3.3 Heparan sulfaat proteoglycanen
Een andere groep eiwitten die veel wordt gevonden in (de omgeving) van AP ophopingen 
zijn de heparan sulfaat proteoglycanen (HSPGs). Proteoglycanen bestaan uit een eiwit 
met daaraan lange suikerketens. Deze suikerketens bestaan uit repeterende disaccharides 
die vaak gesulfateerd kunnen zijn. Eerdere studies hebben aangetoond dat HSPGs de 
ophoping van AP op meerdere manieren kunnen beïnvloeden, zoals het reguleren van 
het knippen van AP uit APP, het in werking zetten van de samenklontering van AP of de 
AP ophopingen beschermen tegen afbraak. De invloed die HSPGs kunnen hebben op de 
samenklontering van AP is afhankelijk van de mate van sulfatering van de suikerketens 
van de HSPGs. Het is aangetoond dat de mate van sulfatering weer afhankelijk is van het 
weefsel waarin de HSPGs voorkomen. In hoofdstuk 5 hebben we gekeken of een specifiek 
patroon van sulfatering geassocieerd is met AP plaques in the occipitale cortex en de 
hippocampus van patiënten met de ziekte van Alzheimer. We zagen dat antilichamen 
(antistoffen die specifieke eiwitten herkennen en binden) die hoog N-gesulfateerde 
HSPGs herkennen fibrillaire AP plaques, maar ook niet-fibrillaire AP plaques aankleurden. 
De antilichamen die laag N-gesulfateerd HSPGs herkennen, kleurden daarentegen alleen 
de fibrillaire AP plaques. Dit kan mogelijk betekenen dat een grote groep HSPGs met een 
verschillend sulfateringspatroon gevonden kunnen worden in fibrillaire AP plaques, maar 
dat in non-fibrillaire AP plaques voornamelijk HSPGs gevonden worden met een hoog 
N-gesulfateerd patroon. Deze laatste groep van HSPGs zou dus betrokken kunnen zijn bij 
het in werking zetten van de ophoping van AP. Omdat HSPGs ook gevonden worden in 
andere amyloïd ophopingen, is het interessant om de verdeling van sulfateringspatronen 
te bestuderen in deze opeenhopingen, zoals bijvoorbeeld a-synucleïne aggregaten in 
de ziekte van Parkinson. Als de verdeling van de sulfateringspatronen van de HSPGs bij 
deze ziekte vergelijkbaar is met de patronen die we gevonden hebben in de ziekte van 
Alzheimer, zou dit kunnen wijzen op een algemene rol van specifieke sulfateringspatronen 
van HSPGs bij de vorming van amyloïd aggregaten. Dit zal echter nog nader bekeken 
moeten worden.
8.3.4 p-sheet breakers
Momenteel zijn er slechts 5 goedgekeurde medicijnen tegen de ziekte van Alzheimer. 
De meeste van deze medicijnen zijn gericht op het verminderen van de afbraak van 
de neurotransmitter (boodschapperstof, nodig om signalen door te geven van de 
ene zenuwcel naar de andere) acetylcholine. Deze medicijnen geven een (tijdelijke) 
verbetering van cognitie (geheugen e.d.), maar dit is slechts symptoombestrijding van 
de ziekte. De oorzaak wordt hiermee niet behandeld. Een manier om de oorzaak van 
de ziekte van Alzheimer te behandelen is om in de eerste fase van het misvouwen en 
ophopen van AP in te grijpen. Hiervoor zijn al door meerdere onderzoeksgroepen 
zogenaamde "P-sheet breakers" ontwikkeld. Deze stoffen remmen de ophoping en de
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toxiciteit van AP, maar hiervoor is een grote hoeveelheid van de P-sheet breakers nodig, 
waardoor ze minder geschikt zijn als medicijn. Omdat we in hoofdstuk 5 hebben ontdekt 
dat sulfatering van eiwitten belangrijk kan zijn in het aggregatieproces van AP, hebben 
we in hoofdstuk 6 onderzocht of het sulfateren van P-sheet breakers de potentie van deze 
stoffen verhoogd om de ophoping en toxiciteit van AP te remmen. De hybride liganden 
die we hebben ontworpen waren niet toxisch in celweek, maar lieten geen remming 
van de samenklontering en/of toxiciteit van AP zien. Computersimulaties toonden aan 
dat dit zou kunnen komen doordat de hybride liganden zo goed binden aan AP dat ze 
ingebouwd worden tijdens het aggregeren van AP, en dus geen kans krijgen om de 
samenklontering te remmen. Het zal moeten worden onderzocht of het verminderen van 
waterstofbruggen van het hybride ligand met een volgend AP eiwit de ophoping van AP 
wel kan remmen.
8.4 Conclusie
Zowel de ziekte van Alzheimer als de ziekte van Parkinson zijn multifactoriële ziekten 
waarbij genetische en niet-genetische factoren een rol spelen in de pathogenese. Tot nu 
toe zijn er nog geen medicijnen gevonden die beide ziekteprocessen kunnen stoppen. 
De huidige medicijnen kunnen alleen de symptomen van de ziekten behandelen en 
niet de oorzaken ervan. Daarom blijft het van groot belang meer inzicht te krijgen in de 
pathologie van de ziekte van Alzheimer en de ziekte van Parkinson en gaat de zoektocht 
naar nieuwe medicijnen nog altijd voort. In dit proefschrift is gekeken naar de aggregatie 
van twee eiwitten, namelijk AP (betrokken bij de ziekte van Alzheimer) en a-synucleïne 
(betrokken bij de ziekte van Parkinson). Er zijn overeenkomsten in het mechanisme 
waarmee de twee verschillende ziekten lijken te ontstaan, wat suggereert dat een 
algemene therapie, gericht op aggregaten, tegen deze ziekten mogelijk is. De kleine heat 
shock eiwitten zijn bijvoorbeeld chaperones die de aggregatie van beide eiwitten kunnen 
beïnvloeden. Maar er zijn ook verschillen tussen de ziekte van Alzheimer en de ziekte van 
Parkinson, wat weer mogelijkheden biedt om specifieke therapieën tegen deze ziekten te 
ontwikkelen. Het bestuderen en begrijpen van de eerste fasen van het samenklonteren 
van eiwitten en hoe dit de celfuncties kan verstoren is van groot belang om specifieke 
en/of algemene therapieën tegen deze neurodegeneratieve conformationele ziekten te 
kunnen ontwikkelen.
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List of Abbreviations
AD Alzheimer's disease
ApoE Apolipoprotein E
APP Amyloid precursor protein
Aß Amyloid-beta
BSA Bovine serum albumin
CAA Cerebral amyloid angiopathy
CSLM Confocal laser scanning microscopy
CNS Central Nervous system
D40 or D-Aß40 Amyloid-beta with Dutch mutation
DMEM Dulbecco's modified Eagle medium
DMSO Dimethyl sulfoxide
EMEM Eagle's modification of essential medium
GAG Glycosaminoglycan
HBP Human brain pericyte
HCHWA-D Herditary Cerebral Hemorrhages with amyloidosis of the Dutch type
(HL)SMC (Human leptomeningeal) smooth muscle cells
Hsp Heat shock protein
HSPG Heparan sulfate proteoglycan
ICAM Intercellular adhesion molecule
IL Interleukin
Kd dissociation constant in equilibrium
k d dissociation rate
LDLR low-density lipoprotein receptor
LPS lipopolysaccharide
LRP low-density lipoprotein receptor- related protein
MCP-1 monocyte chemoattractant protein 1
NFTs Neurofibrillary tangles
PBS Phosphate-buffered saline
PD Parkinsons's disease
PLP Periodate-lysine-paraformaldehyde
PMI Post mortem interval
SDS Sodium dodecyl sulfate
sHsp small heat shock protein
SMC smooth muscle cells
SPR surface Plasmon resonance
SPs senile plaques
TGF-ß1 transforming growth factor ß1
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Dankwoord
Eindelijk, het is klaar! Een mijlpaal is bereikt! Er zullen altijd nieuwe dingen te ontdekken 
en te leren zijn, waardoor je als wetenschapper nooit bent uitgeleerd, maar wat ben ik 
blij dat ik nu kan zeggen dat mijn promotie-onderzoek is afgerond. Gelukkig heb ik het 
"leren en ontdekken" de afgelopen 5 jaar niet alleen hoeven doen. Veel mensen hebben 
hun bijdrage geleverd aan het in dit proefschrift beschreven onderzoek, ofwel hebben 
gezorgd voor de morele ondersteuning en afleiding. Iedereen ontzettend bedankt 
daarvoor, maar natuurlijk wil ik een aantal mensen in het bijzonder bedanken.
Allereerst wil ik mijn co-promotoren Marcel Verbeek en Rob de Waal bedanken voor het feit 
dat zij mij de mogelijkheid hebben geboden om dit promotie-onderzoek te doen. Beste 
Marcel, ik weet nog goed dat je me belde tijdens mijn bijbaantje in de supermarkt om me 
te vertellen dat ik de baan bij jullie had gekregen. Wie had destijds kunnen weten dat ik 
mijn huidige baan ook weer via jou zou krijgen. Ik wil je bedanken voor je begeleiding en 
adviezen. Je deur stond altijd open en hoe druk je het ook had, er was altijd wel tijd voor 
overleg. Bovendien was je altijd supersnel met nakijken van manuscripten, ook als ik even 
geen zin meer had in schrijven. Bedankt voor de fijne samenwerking en ik hoop dit de 
komende jaren verder voort te kunnen zetten.
Beste Rob, werkbesprekingen met jou op de maandagochtend waren altijd leuk om de 
week mee te starten. Zoals Nienke in haar dankwoord schreef, waren deze besprekingen 
altijd net wat interessanter door je enthousiasme over wetenschappelijke, maar ook niet- 
wetenschappelijke onderwerpen. Daarnaast wist je altijd voor mij wat twijfelachtige 
resultaten om te zetten naar iets uitzonderlijks positiefs. Dank daarvoor!
Mijn promotoren wil ik ook graag bedanken. Beste Ron Wevers en George Padberg, jullie 
werden in de allerlaatste fase bij mijn promotie betrokken als promotoren. Als hoofden 
van respectievelijk LGEM en Neurologie zijn jullie wat minder nauw betrokken geweest bij 
mijn promotieonderzoek. Ik waardeer het daarom zeer dat jullie mij samen hebben willen 
begeleiden in deze fase.
Tijdens mijn promotie-onderzoek ben ik verschillende keren bij organische chemie 
geweest om daar verbindingen te synthetiseren. Ik wil graag iedereen bedanken voor 
hun hulp en uitleg gedurende deze periodes. In het bijzonder wil ik Floris van Delft 
bedanken. Beste Floris, ik moet toegeven dat ik in het begin niet zat te springen om bij 
organische chemie te beginnen. De frustraties van de synthese tijdens mijn stage bij 
jullie op de afdeling zaten nog vers in mijn geheugen. Je beloofde dat je me zou laten 
zien dat chemie ook leuk kon zijn en dat is je gelukt! Helaas hadden de verbindingen die 
we hebben gemaakt niet het effect wat we hoopten, maar toch hebben we er nog een 
artikel uit kunnen persen. Bedankt voor je morele ondersteuning, je enthousiasme en de 
prettige gesprekken.
Nienke, mijn "partner in crime". Samen hebben we de afgelopen jaren ontzettend 
veel gedeeld, variërend van heel serieus (overleggen over het opzetten van nieuwe 
experimenten), tot vervelend (missen van het vliegtuig na een congres) of heel lollig (ik wil 
toch nog steeds die race in de kantoortuin proberen ©). Ook buiten het werk om hebben
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we veel contact en ik hoop dat ik nog lang mag genieten van je Groningse nuchterheid. 
Nu is het inderdaad mijn beurt en als het mogelijk was om meer dan twee paranimfen te 
vragen, dan was jij zeker nummer 3!
Bea, twee jaar nadat ik was begonnen met mijn promotie-onderzoek kwam jij de 
"Alzheimer groep" als postdoc versterken. Vele malen heb ik gebruik mogen maken van 
je "encyclopedische kennis', waardoor experimenten net iets beter of sneller uitgevoerd 
konden worden. Daarnaast heb je me door menig promotiedipje heen geholpen door te 
luisteren en te relativeren. Dank daarvoor en stiekem ben je nummer 4.
Alle collega's van de neurogroep: bedankt voor de gezelligheid en jullie interesse in mijn 
onderzoek. Mareike, Kim, Megan en Elisanne, heel veel succes met het afronden van 
jullie promotie. Het gaat jullie zeker lukken! Inge, jammer dat je bent weggegaan, veel 
succes en plezier in Wageningen. Alexandra, je hebt me niet alleen wegwijs gemaakt in de 
wereld van de bacteriën, maar ook ontzettend veel meegeholpen met het zuiveren van 
de kleine heat shock eiwitten. Dit heeft ertoe geleid dat je als co-auteur staat op twee van 
mijn artikelen. En terecht! Daarnaast heb ik enorm met je gelachen op het lab. Bedankt 
voor alles! Herman, Marijke en Ria, bedankt voor jullie hulp bij de vele Elisa's en blotjes en 
vooral bedankt voor de gezelligheid!
OokFokjewil ikevennoemen. Beste Fokje,je hebt me geholpen metdecholesterolmetingen 
voor een van mijn studies. Ondanks de inzet van jou, Judith en Sanne is er (nog) niets 
uitgekomen. Maar wat niet is, kan nog komen! Bedankt voor je hulp en de fijne gesprekken 
tijdens de pauzes er tussen.
De dames van het secretariaat van het LGEM lab mag ik zeker niet vergeten. Zonder jullie 
zou alles minder soepel zijn verlopen. Bedankt voor alle hulp bij het verzenden van de vele 
pakketjes in binnen- en buitenland tot het regelen van stagepapieren voor studenten. Als 
ik een nieuwe hobby zoek, kom ik advies vragen bij jullie ©.
Alle andere collega's van het LGEM: bedankt voor o.a. de gezelligheid, de uitjes, de vele 
verjaardagstaarten, "sinterkerst" en de "keek van de week". Ik ben altijd met veel plezier 
naar mijn werk gegaan en daarvoor wil ik jullie bedanken!
Mijn onderzoek is deels uitgevoerd bij LGEM, maar ook deels bij de afdeling Pathologie. 
Ik wil daarom ook een aantal mensen bij pathologie bedanken voor al hun hulp. Ik wil 
graag beginnen met Irene. Beste Irene, hoe vaak heb ik wel niet bij jou aangeklopt om 
uitleg van een experiment, of om oude coupes ,die weer eens afgestoft konden worden, 
voor een bepaalde studie. Ook al hoor je al een tijdje niet meer bij de "Alzheimergroep" we 
mogen nog steeds gebruik maken van je kennis, waar ik je erg dankbaar voor ben! Beste 
Riki, bedankt voor het regelen van al het papierwerk, zodat "mijn" stagiaires bij pathologie 
konden werken. Beste Ine en Melissa, bedankt voor jullie hulp in de celkweek, waardoor 
ik lekker kon experimenteren met mijn celletjes. Beste Cathy en Kiek, bedankt voor jullie 
hulp bij de immunohistochemische experimenten, zonder jullie waren de kleuringen 
nooit zo mooi geworden!
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Sinds november 2010 werk ik als postdoc bij Brigit de Jong. Van begin af aan liet zij mij vrij 
om, wanneer mogelijk, te werken aan het afronden van mijn promotie-onderzoek. Beste 
Brigit, bedankt voor de mogelijkheid om aan mijn boekje te mogen werken tijdens mijn 
eerste maanden bij jou. Ik vind het een ontzettend leuke uitdaging om nu samen met jou 
"ons" onderzoek op te zetten en ik hoop dat we daarvan veel vruchten/papers mogen 
plukken!
Carlijn en Ivi, jullie hoorden weliswaar niet bij de "Alzheimergroep" van onze afdeling, 
maar doordat we elkaar zo vaak zagen tijdens congressen, leek het er soms wel op ©. 
Bedankt voor de gezelligheid en de kritische discussies over het onderzoek.
Ik heb ook verschillende studenten mogen begeleiden tijdens hun stages. Samen hebben 
zij veel meer werk verzet dan ik ooit alleen had kunnen doen en zonder deze mensen 
zou mijn boekje er niet zijn! Heel erg bedankt! Miel, nadat Micha naar Amsterdam was 
vertrokken, mocht ik de begeleiding van jouw stage overnemen. Inmiddels ben je alweer 
een aantal jaren zelf bezig met je eigen promotie-onderzoek, succes met het afronden 
van je proefschrift! Rick, als student kon je al kritische vragen stellen. Het verbaast me dus 
niet dat je inmiddels ook zelf bent begonnen aan een promotie-onderzoek, succes! Tom 
en Luuk, jullie stageverslagen hebben geleid tot een mooi artikel, en inmiddels zijn jullie 
ook in de volgende fase van jullie "leerproces", succes hiermee! Ramon, Kim (inmiddels 
mijn collega) en Karsten, ook jullie stageverslagen hebben geleid tot een mooi artikel. 
Bij het drukken van dit proefschrift is deze nog niet geaccepteerd, maar dat gaat zeker 
goedkomen! Mieke, wat een mailtje al niet kan doen, veel succes en ik weet zeker dat je 
er een mooi boekje van gaat maken. Judith en Sanne, jullie gezamenlijke werk staat niet 
in het boekje, maar het is niet voor niets gedaan, ik wil jullie bij deze bedanken voor jullie 
inzet tijdens jullie stage.
Ook wil ik mijn mede-auteurs bedanken voor hun bijdrage: Micha Wilhelmus, Matthijs 
Kox, Wilbert Boelens, Toin van Kuppevelt, Gerdy ten Dam, Guido David, Benno Küsters, 
Rob Veerhuis, Gijs Schaftenaar, Anna Karawajczyk, Anna Carrano, Annemieke Rozemuller, 
Ine Segers-Nolten en Vinod Subramaniam. Bedankt voor het meedenken en jullie kritische 
blik in de verschillende onderzoeken.
Bij het maken van de voorkant van mijn boekje heb ik wat hulp gehad. Beste Coraliene: 
wat een vrijgezellenfeest al niet voor effect kan hebben. Je hebt, naar mijn idee, een 
goede weergave gemaakt van mijn onderzoek! Bedankt hiervoor! Doordat we ruim op 
tijd zijn begonnen met ontwerpen, hebben we er rustig aan kunnen werken en ik vind dat 
het geweldig is geworden!
Ik wil mijn vrienden bedanken voor hun interesse in mijn onderzoek en hun steun, maar 
vooral ook voor alle gezellige middagen en avonden waardoor ik het onderzoek even kon 
vergeten. Floor en Sander, Esther en Jurrian, Angela en Hilbert, Wendy en Martin, Tom en 
Suus, Saskia, Iris en Leendert, bedankt!
Dan wil ik graag nog een aantal families bedanken die hun interesse toonden voor mijn 
onderzoek en mij de nodige afleiding hebben gegeven. Families Kuijt en Blom, voor jullie 
is dit hele "promotie-gebeuren" nieuw. Toch hebben jullie altijd geprobeerd te begrijpen
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wat het inhoudt en wat het voor mij betekent, dank daarvoor! Familie Bambacht, en in het 
bijzonder Jan en Toos, wat jullie voor mij hebben gedaan is absoluut niet vanzelfsprekend 
en ik kan jullie daarvoor nooit genoeg bedanken! Familie Formijn, Familie(s) van Driel en 
Familie Visser, jullie accepteerden mij zonder problemen en ik voel me altijd erg welkom 
bij jullie, mijn dank!
Ma, ik ben heel erg blij dat je bij mijn promotie kan zijn. Ik hoop dat je er net zo van kunt 
genieten als ik!
Carmen en Jerney, vanaf het moment dat ik wist dat ik zou gaan promoveren heb ik 
gezegd dat het me super leek om daar met jullie te staan. Ik vind het dus ook geweldig 
dat jullie mijn paranimpfen willen zijn. Ik hoop dat jullie het ook bijzonder vinden om dit 
samen met mij te mogen meemaken.
Als laatste wil ik graag WP bedanken. Het klinkt cliché, maar woorden schieten te kort. De 
laatste tijd zijn we samen veel bezig geweest met het lay-outen van dit boekje (alsnog 
mijn excuses voor de vele momenten dat ik de laptop bijna door het raam wilde gooien 
©). Nu deze dan eindelijk klaar is kunnen we weer wat meer tijd besteden aan o.a. onze 
gezamenlijke hobby's, dansen en motorrijden. Ik hoop dat we dit nog lang samen mogen 
blijven doen. Lieve WP, bij jou voel ik me thuis. Dit boekje is dan ook voor jou!
A
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Colour Figures
Chapter 2
Fig. 2: Comparison of the surface plasmon resonance sensorgrams of the different sHsps (binding to wild­
type a-synuclein) at the highest concentration (50 pM). Although the sensorgrams of the different 
sHsps appear very different, the dissociation rate of the different sHsps from wild-type a-synuclein is 
comparable.
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WTa-syn alone + aB-crystallin
B WTa-syn alone +sHsp27
WT a-syn alone + sHspB2B3
163
Chapter 10
Fig. 3: Analysis of the effects of sHsps on WT a-syn fibril formation using thioflavin T assay and atomic 
force microscopy (AFM). Quantitative changes in p-sheet formation of 100 pM WT a-syn (red lines) 
incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 (B), Hsp20 
(C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the sHsps 
alone and purple lines represent aggregation curves of WT a-syn co-incubated with the different 
sHsps. Arrows indicate the time point in the aggregation process (steady state) where a sample was 
taken to study the morphology of the WT a-syn aggregates by AFM. Significant differences in the 
kinetic aggregation curves of WT a-syn co-incubated with or without sHsps are shown. The level of 
significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The reference curves and AFM 
images of (b) and (e) were measured in the same assay. Size of atomic force microscopy images is 2.5 
x 2.5 pm2.
Fig. 4: Analysis of the effects of sHsps on mutant E46K a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant E46K a-syn 
(red lines) incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves of E46K a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology of the mutant E46K a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves of mutant E46K a-syn co-incubated with or without 
sHsps are shown. The level of significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The 
reference curves and AFM images of (a) and (c), and (b) and (e) were measured in the same assay. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2.
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Fig. 5: Analysis of the effects of sHsps on mutant A30P a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant A30P a-syn 
(red lines) incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves of A30P a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology of the mutant A30P a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves of mutant A30P a-syn co-incubated with or without 
sHsps are shown. The level of significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2
Fig. 6: Analysis of the effects of sHsps on mutant A53T a-syn fibril formation using thioflavin T assay and 
atomic force microscopy. Quantitative changes in p-sheet formation of 100 pM mutant A53T a-syn 
(red lines) incubated at 37 °C, either in the presence or absence of 100 pM aB-crystallin (A), Hsp27 
(B), Hsp20 (C), HspB8 (D) or HspB2B3 (E) were studied. Blue lines represent aggregation curve of the 
sHsps alone and purple lines represent aggregation curves of A53T a-syn co-incubated with the 
different sHsps. Arrows indicate the time point in the aggregation process (steady state) where a 
sample was taken to study the morphology of the mutant A53T a-syn aggregates by AFM. Significant 
differences in the kinetic aggregation curves of mutant A53T a-syn co-incubated with or without 
sHsps are shown. The level of significance is indicated as follows: * p<0.05, ** p<0.01, *** p<0.001. The 
reference curves and AFM images of (a) and (c), and (b) and (e) were measured in the same assay. Size 
of atomic force microscopy images is 2.5 x 2.5 pm2.
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Chapter 3
CAA capCAA CAA capCAA
Fig 3: Immunohistochemical staining of sHsps and inflammatory factors in or near CAA vessels (A, C, E, G, I, 
K, M, O, Q; serial sections) and capCAA (B, D, F, H, J, L, N, P, R; serial sections; arrows indicate the same 
capillary in each panel to serve as a reference to allow optimal comparison with other panels) in the 
occipital cortex of AD brains. The anti-AP antibody 6C6 stained CAA, capCAA and dyshoric angiopathy 
in AD brains (A, B; to allow optimal comparison with other stains, these panels are shown twice). Both 
anti-aB-crystallin (C, D) and anti-Hsp27 (E, F) antibody staining was absent in AP deposits. No anti- 
Hsp20 and anti-HspB8 staining was observed in CAA and capCAA, however, colocalization of Hsp20 
and HspB8 (G, H, and I, J) with dyshoric angiopathy (AP surrounding CAA) was observed. Presence of 
HspB2 in CAA (K) and capCAA (L) of AD brains with severe CAA was observed, but also colocalization 
of HspB2 with dyshoric angiopathy (K) was observed. The anti-aB-crystallin (C), anti-Hsp20 (G) and 
anti-HspB8 antibodies (I) stained reactive astrocytes and microglia associated with CAA. Occasionally, 
immunoreactivity of HspB2 with reactive astrocytes and microglia was observed. Furthermore, anti- 
IL-8 (M, N, arrow) and anti-MCP-1 (Q, R, arrow) staining was absent from CAA and capCAA vessels. In 
addition, ICAM-1 was associated with dyshoric angiopathy, but not with the AP deposits in the vessel 
wall (O, P, arrow; insert ICAM-1 staining (left) and AP staining (right) of another capCAA vessel). 
Original magnification 200x
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Staining
Anti-Aß Anti-Aß
HBPs Astrocytes
Fig 5: Confocal laser scanning microscopy analysis of Ap at the surface of cultured HBPs (left; n=2; apoE £3/ 
£3 genotype) and human astrocytes (right; n=2; apoE £3/£3 genotype). Cells were incubated with 
12.5 |j M D-Api-40 (A, B, and G, H; B and H are cross sections) and co-incubated with HBP £3/£3 
conditioned media (C,D and I and J), or HBP £3/£3 conditioned media after apoE depletion (E,F and K, 
L) for 3 days. HBP £3/£3 conditioned medium decreased immunoreactivity of Ap compared to 
control, whereas conditioned medium after apoE depletion showed a partial reduction. 
Immunofluorescence staining of Ap (40-4, polyclonal, red). Magnification x 630. Nuclei are 
counterstained blue; experiments were performed in duplicate.
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Fig 2: Immunohistochemical staining of Ap plaques (fibrillar and non-fibrillar) in occipital neocortex and 
hippocampus of AD brains for Ap (6C6;a and b; arrows) and for specific HS epitopes with EV3C3 (c and 
d; arrows), HS4C3 (e and f; arrows), AO4B08 (g and h; arrow), HS4E4 (i and j; arrows) and RB4EA12 (k 
and l). Antibody RB4EA12 (l) showed a weaker staining compared to antibodies EV3C3 and HS4C3 in 
the hippocampus, but the staining was still visible. Panels a, c, e, g, i, and k are from serial sections and 
panels b, d, f, h, j, and l are from serial sections. Original magnification 200x
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Fig 3: Colocalization of fibrillar Ap plaques in occipital cortex and hippocampus of AD brains using thioflavin 
S (staining green) and nonfibrillar Ap plaques (40-4;a and g, staining red) or specific HS epitopes 
using EV3C3 (b and h), HS4C3 (c and i), AO4B08 (d and j), HS4E4 (e and k) and RB4EA12 (f and l; 
staining red). Original magnification 630x
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Fig 3: Alignment of 4a to the AP42 protein. A nice p-pleated sheet can be observed when aligning several 
AP42 proteins. According to the obtained model a spacer of three carbon atoms should be sufficient 
to target His13 and/or His14 in the AP42 protein with a sulfate group of the hybrid ligand. Therefore, 
our synthetic compounds could simultaneously target the binding domains of GAGs (binding to Ap 
amino acids 13-16; green) and of pentapeptides (binding to Ap amino acids 16-22; dark blue).
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Fig 4: Snapshot of molecular dynamics simulations of 6b aligned to the AP42 protein. Although both 
phenylalanines of the hybrid ligand adopt the same orientation as the phenylalanines of the AP42 
protein, it is difficult to target the histidines in the AP42 protein with a non-peptide side-chain of the 
hybrid ligand. The side-chain bends in such a way that the sulfate groups rather interact with Lys15 of 
the AP42 protein backbone than with His13 or His14.
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Fig 5: Snapshot of molecular dynamics simulations of 6d' (yellow) aligned into the P-sheet structure of 
aggregated AP42 protein. The ligands can be incorporated into the P-sheet structure of aggregated 
AP, as was observed during these molecular dynamics calculations. The ligand connects/binds the 
two parts of the lower sheet (green) with on overage six hydrogen bonds and the two parts of the 
upper sheet (red) with on average two hydrogen bonds.
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Notes
